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ABSTRACT OF THE DISSERTATION
Synthetic Gene Circuits for Self-Regulating and Temporal Delivery of Anti-Inflammatory
Biologic Drugs in Engineered Tissues
by
Lara Pferdehirt
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2021
Professor Farshid Guilak, Chair
The recent advances in the fields of synthetic biology and genome engineering open up
new possibilities for creating cell-based therapies. We combined these tools to target repair of
articular cartilage, a tissue that lacks a natural ability to regenerate, in the presence of arthritic
diseases. To this end, we developed cell-based therapies that harness disease pathways and the
unique properties of articular cartilage for prescribed, localized, and controlled delivery of
biologics, creating the next generation of cell therapies and new classes of synthetic circuits.
We created tissue engineered cartilage from murine induced pluripotent stem cells that
had the ability to sense inflammatory stimuli to produce an anti-cytokine biologic to self-regulate
and inhibit inflammation. To create this gene circuit, we developed a synthetic promoter
activated by NF-κB signaling, a key inflammatory pathway activated within chondrocytes in
arthritis. This lentiviral system was capable of producing an anti-cytokine therapeutic, IL-1Ra,
and protecting tissue engineered cartilage from inflammation-mediated degradation.
Chondrocytes within articular cartilage respond to mechanobiologic signals through ion
channels, such as the TRPV4 ion channel, involved in mechanotransduction. We developed
synthetic cell-based therapies that could sense mechanical stimuli, such as activation of TRPV4,
xiii

and produce prescribed biologic drugs in response to mechanical stimuli. With this approach, we
created two novel mechanogenetic circuits activated by TRPV4 that produced our therapeutic
transgene with different drug release kinetics.
The cartilage circadian clock plays a key role in maintaining cartilage homeostasis and
integrity. When the circadian clock is desynchronized, such as in the presence of inflammation,
articular cartilage begins to degrade. Therefore, we created clock-preserving synthetic circuits
that are capable of preserving circadian rhythms even in the presence of inflammation. In
addition to creating these circuits, we also characterized the circadian clock throughout
chondrogenic differentiation and uncovered interesting characteristics between circadian
disruption and extracellular matrix (ECM) degradation that can be further examined to better
understand the relationship between inflammation and circadian rhythm disruption.
Finally, we developed the newest generation of cell-based therapies by creating
chronogenetic therapies. Expanding beyond preserving circadian rhythms, we developed
synthetic chronogenetic circuits driven by the circadian clock for temporal delivery of biologic
drugs at specific times of day. This approach was motivated by the field of chronotherapy and
the increase in efficacy of drugs when administered at specific times of day. We developed the
first cell-based chronotherapy capable of producing an anti-inflammatory biologic at a specific
time to combat the peak of inflammatory flares exhibited by patients with chronic inflammation.
Overall, the work in this dissertation builds upon existing synthetic biology and genome
engineering tools to create smart cell therapies that are activated by a prescribed input and can
produce a therapeutic transgene in a controlled manner. These synthetic circuits provide novel
strategies to target inflammation in an arthritic joint and can be expanded for other applications
to create better and more effective therapeutics to treat disease.
xiv

Chapter 1: Synthetic Biology and the Next
Generation of Cell Therapies for
Musculoskeletal Disease Treatment and
Beyond
1.1 Genome engineering and cell therapies
A biological revolution is currently occurring with the invention and discovery of
synthetic biology and genome engineering tools. These tools, such as the development of
synthetic gene circuits delivered through viruses and genome engineering tools such as CRISPRCas9, provide new approaches in developing cells programmed for specific cellular behavior in
response to environmental signals. With the ability to engineer cells for controlled behaviors, the
field of cell therapies is gaining popularity over the use of small molecule drugs and systemic
delivery of biologics. This new era of therapeutics is driven by the need for a more targeted,
controlled, and long-lasting effect that systemic oral delivery of drugs cannot provide. In this
context, the use of personalized cell therapies and harnessing cells as drug delivery vehicles is
increasing and will change the way diseases are treated. Therefore, we have decided to apply
these revolutionary tools to our areas of interest: articular cartilage repair and the treatment of
osteoarthritis (OA) and rheumatoid arthritis (RA).

1.2 Articular cartilage
Articular cartilage is the soft connective tissue that covers articulating bone surfaces in
diarthrodial joints. It is a highly hydrated tissue with a dense extracellular matrix (ECM)
1

composed primarily of type II collagen and aggrecan. Type II collagen comprises 90-95% of the
collagen in the ECM, with other collagens, such as types I, III, IV, V, VI, IX, and XI helping to
form the type II collagen network, providing essential structure and organization (1-3).
Proteoglycans are the second most abundant component in articular cartilage and consist
predominantly of negatively charged sulfated glycosaminoglycan (sGAG) chains. Chondrocytes
are the only resident cell type within articular cartilage and constitute only 1-2% of the total
cartilage volume. Chondrocytes respond to a variety of stimuli, including mechanical loads,
hydrostatic pressure, and growth factors to maintain the structure and function of articular
cartilage. All these components come together to create the zonal structure of articular cartilage,
contributing to its unique compressive, tensile, and viscoelastic properties that allow it to bear
loads, dissipate energy, and provide joint lubrication (3, 4). Together, this structure allows for a
near-frictionless and wear-resistant surface. Articular cartilage is avascular and aneural and is
maintained through a balance between anabolic and catabolic activities; two important
components of articular cartilage that maintain this balance are its mechanobiologic response and
its circadian clock.

1.2.1 Mechanobiologic response of articular cartilage
As mentioned, articular cartilage contains unique mechanical properties, and
chondrocytes respond to mechanical stimuli. Chondrocytes respond to mechanobiologic signals
through specialized molecular components, such as mechanically sensitive ion channels and
receptors that transduce specific stimuli from the physical environment (5, 6). In articular
cartilage, the transient receptor potential vanilloid 4 (TRPV4) ion channel is activated by osmotic
stress and plays an important role in the mechanosensitivity of chondrocytes (7-11). TRPV4 in
articular cartilage has been shown to regulate the anabolic biosynthesis of chondrocytes in
2

response to physiologic mechanical strain (12). Therefore, the response of chondrocytes to
TRPV4 mediated mechanical loading is an important characteristic of articular cartilage and is
important in maintaining tissue homeostasis.

1.2.2 Articular cartilage circadian clock
In addition to mechanical loading, articular cartilage contains a tissue specific circadian
clock that contributes to maintenance of tissue homeostasis. Circadian clocks are internal genetic
timing mechanisms that exist in the brain and nearly all cells in peripheral tissues and operate on
a roughly 24-hour period (13-15). These rhythms coordinate tissue-specific physiology with
different cycles such as light and darkness, body temperature, and rest and activity (13). Core
clock genes, comprised of transcriptional activators Bmal1 and Clock and transcriptional
repressors Per1/2 and Cry1/2 and output genes, such as Rev-erbs, Dbp, and Nfil3, create an autoregulatory negative feedback loop that drives this oscillatory behavior of the clock (14, 15).
These clocks genes drive expression of many other genes referred to as clock-controlled genes
that are tissue-specific and play important roles in maintaining tissue homeostasis through their
temporal expression (16). It has been shown that many anabolic and catabolic pathways in
articular cartilage have different daily dynamics, driven by the cartilage circadian clock, to help
maintain cartilage homeostasis (16-22). Pathways that have different activity at different times
include metabolic, ECM remodeling, and catabolic pathways (16, 21). Serum levels of
biomarkers related to cartilage metabolism that show day/night variations include aggrecan,
collagen II, cartilage oligomeric matrix protein, hyaluronic acid, keratin sulfate, and
transforming growth factor β (TGF-β) (17, 20). Bmal1 has been implicated in controlling this
cartilage homeostasis and integrity. In a Bmal1 cartilage-specific knockout mouse model, the
clock disruption showed dysregulation of TGF-β and NFATc2 pathways, which resulted in a
3

shift in homeostasis to an increased catabolic response (19). Therefore, preservation and
synchrony of the cartilage circadian clock is also important in maintaining cartilage homeostasis.

1.3 Inflammation and articular cartilage
Inflammation plays an important role in wound healing and tissue repair; however,
dysregulated and chronic inflammation is involved in the pathogenesis of any musculoskeletal
diseases. Inflammation is a main regulator of the pression and severity of rheumatoid arthritis
(RA), an auto-immune disorder affecting joints. In osteoarthritis (OA), inflammation directly
contributes to the degradation of articular cartilage. Additionally, inflammation prevents stem
cell chondrogenesis in engineered cartilage (23-26). OA is characterized by degradation of
articular cartilage, subchondral bone thickening, and osteophyte formation, while both OA and
RA are characterized by the modification of synovial fluid, leading to pain, inflammation, and
stiffness, limiting mobility in affected individuals (27, 28).
Inflammatory signaling pathways are activated in chondrocytes by a variety of stimuli,
such as traumatic injury through abnormal mechanical loading and biochemical mediators such
as inflammatory cytokines, chemokines, and adipokines (29). In arthritis, pro-inflammatory
cytokines from both the synovium and chondrocytes induce aberrant expression of catabolic and
inflammation-related genes. The two primary pro-inflammatory cytokines present within an
arthritic joint are tumor necrosis factor-⍺ (TNF⍺) and interleukin-1 (IL-1) (24). These cytokines
suppress synthesis of cartilage matrix components, such as type II collagen and aggrecan, and
activate signaling pathways including nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) and mitogen activated protein kinases (MAPK) that causes the expression of
catabolic and degradative enzymes and inflammatory cytokines (24, 26, 29-31). Matrix
metalloproteinases (MMPs) and disintegrin and metalloproteinase with thrombospondin motifs
4

(ADAMTS) family members are the main cartilage ECM degrading enzymes in OA and
upregulated by TNF⍺ and IL-1 (32). Additionally, these inflammatory cytokines, especially IL-1,
induce expression of other inflammatory mediators such as IL-6, monocyte chemoattractant
protein-1/C-C motif chemokine ligand 2 (MCP-1/CCL2), and nitric oxide (NO), and the
upregulation of these inflammatory mediators creates a positive feedback loop that further
amplifies and progresses cartilage degradation (32).
Additionally, inflammation has been shown to disrupt the circadian clock in cartilage
(33). As previously mentioned, desynchronization of the circadian clock in articular cartilage led
to a catabolic response and contributed to OA-like cartilage degradation (19). The addition of IL1 to cartilage explants showed loss in circadian rhythms that was only rescued with the
administration of dexamethasone, an anti-inflammatory agent (33). Therefore, the disruption of
the circadian clock through stimuli such as inflammation, could be an important contributor to
the pathogenesis of OA (34).

1.4 Current strategies for treatment of arthritis
For OA, where the degradation of articular cartilage is a primary characteristic, there are
currently no disease modifying drugs available. Articular cartilage is avascular and aneural and
lacks an intrinsic ability to repair itself (23). Additionally, the harsh inflammatory environment
within an OA joint provides a challenging environment for cartilage repair. Non-steroidal antiinflammatory drugs (NSAIDs), analgesic drugs, and local administration of corticosteroids are
commonly prescribed for OA pain; however, these do not inhibit disease progression (24, 35).
For patients with RA, NSAIDs as well as disease-modifying anti-rheumatic drugs are prescribed
and have shown some efficacy in alleviating symptoms of RA.
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A number of therapies targeting IL-1 and TNF⍺ have been explored, including delivery
of anti-cytokines. IL-1 receptor antagonist (IL-1Ra, anakinra), a competitive antagonist of IL-1,
has been shown to alleviate symptoms of RA and post-traumatic OA (36-38). TNF⍺ targeting
therapies include monoclonal antibodies (infliximab, adalimumab, golimumab) and the soluble
TNF receptor-2-IgG-Fc fusion protein (sTNFR1, etanercept). These drugs have some efficacy in
patients with RA and have been shown to relieve pain and reduce synovitis (39, 40). Clinical
trials of IL-1Ra therapy to patients with established OA have not shown efficacy, suggesting that
controlled long-term delivery in a localized manner may be necessary for disease modification
(38, 41, 42). Additionally, anti-cytokine therapies are often delivered at high doses, which may
have significant off-target effects, including an increased susceptibility to infection and certain
autoimmune diseases (43) as well as increased resistance to anti-cytokine therapies in RA
patients, reducing the effect of the drug (44).
Gene therapy, a technique that includes the delivery or modification of a gene for the
treatment or prevention of disease, has been used to delivery IL-1Ra to the joints of patients with
RA and OA (25, 45, 46). However, despite the therapeutic potential of anti-cytokine drugs and
gene therapy approaches, there are currently no effective disease-modifying treatments to
address both the symptoms and structural changes of OA (45-47).

1.5 Cartilage tissue engineering, gene therapy, and synthetic
biology
To address these limitations, tissue engineering and gene therapy approaches can be
combined to create a cartilaginous tissue that is capable of replacing damaged tissue while
delivering therapeutic drugs to diseased joints (48). Murine induced pluripotent stem cells
(miPSCs) are an attractive option for tissue engineering because they are a source of large
6

numbers of precisely defined, patient-matched cells and are capable of chondrogenic
differentiation and disease modeling (49, 50). Additionally, by using both gene therapy and
synthetic biology, cells can be transduced ex vivo with expression vectors designed to produce a
desired gene through specific stimuli (51, 52). Furthermore, by using genome engineering
techniques, cells can be generated to be resistant to specific stimuli (53). The creation and
implantation of tissue-engineered constructs allows for localized delivery of biologic drugs to
specific sites in the body. Applying synthetic biology approaches allows for the engineering of
new biological systems that do not exist in nature. Previously, miPSCs were edited using
CRISPR-Cas9 to lack a functional IL-1 receptor 1 (IL1R1). These IL1R1 knock-out cells were
then grown into tissue engineered cartilage that was protected from IL-1 induced degradation
(53). While this and other gene therapy approaches to target inflammation (54-58) are significant
advances, there are still limitations in methods to have localized and prescribed delivery of
effective biologic therapeutics.

1.6 Creation of the next generation of cell therapies for
arthritis
We sought to create cell therapies that were able to deliver biologic therapeutics to target
inflammation in OA and RA in a localized and prescribed manner (59). To this end, we have
focused on creating the next generation of cell therapies for arthritis applications. This involves
using genome engineering, gene therapy, and synthetic biology tools to create cells capable of
sensing specific stimuli and producing a prescribed therapeutic in an auto-regulating manner.
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1.6.1 Engineering of inflammation driven circuits
Due to the tremendous role inflammation plays in both OA and RA, we first sought to
create cell therapies capable of sensing inflammatory stimuli and producing an antiinflammatory biologic. To this end, CRSIPR-Cas9 gene editing was used to incorporate
sTNFR1, the TNF⍺ inhibitor, or IL-1Ra, the IL-1 inhibitor, downstream of the Ccl2 promoter, a
promoter activated by inflammatory cytokines, in miPSCs (60). These cells were grown into
tissue-engineered cartilage, and this cell therapy was able to autonomously produce antiinflammatory mediators in the presence of inflammatory stimuli, protecting tissue engineered
cartilage from degradation and mitigating the effects of RA in an in vivo model (57, 61).
However, transgene production is limited to the level of endogenous promoter activation.
Therefore, we sought to expand further in creating self-regulating systems to sense and
inhibit inflammation and developed a lentiviral gene therapy approach by creating a synthetic
promoter activated by NF-κB signaling to drive production of a prescribed therapeutic transgene,
in this case IL-1Ra (62). This system is explained in detail in Chapter 2 of this dissertation.
Briefly, this lentiviral system was capable of sensing and responding to inflammatory stimuli by
producing therapeutic levels of IL-1Ra capable of protecting tissue-engineered cartilage (62).
Additionally, the synthetic promoter can be modified to change the sensitivity of the system, and
the transgene can be easily replaced with another therapeutic drug.

1.6.2 Engineering mechanically responsive circuits
Inflammation, however, is not the only important stimuli that articular cartilage
experiences. As mentioned earlier, mechanical input is a key component of chondrocytes.
Therefore, we sought to create gene circuits capable of sensing mechanobiologic stimuli and
using mechanical input to drive production of a prescribed transgene. To this end, we created
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two mechanogenetic lentiviral gene circuits that respond to TRPV4 activation, which are
described in detail in Chapter 3 (63). The first circuit was our NF-κB responsive synthetic
promoter driving IL-1Ra (62), as we found that NF-κB is activated in response to mechanical
loading and subsequent TRPV4 activation. The second circuit was driven by prostaglandinendoperoxide synthase 2 (PTGS2) to produce IL-1Ra. Both mechanogenetic circuits were able to
produce our therapeutic drug in response to mechanical, osmotic, and pharmacologic activation
of TRPV4 (63).

1.6.3 Maintenance of cartilage homeostasis through clock-preserving circuits
As mentioned earlier, preservation of the circadian clock is important to mitigate loss in
cartilage homeostasis and cartilage degradation. However, inflammation disrupts the circadian
clock. Therefore, we sought to create clock-preserving cell therapies to maintain circadian clock
synchrony. These circuits are detailed in Chapter 4. Through the use of cells non-responsive or
resistant to inflammation (53, 60, 62) we have created clock-preserving cell therapies as a novel
approach to establish new therapeutics and enhance tissue repair.

1.7 Chronotherapy: the newest generation of controlled and
prescribed cell therapies
Chronotherapy is based on the idea that the time of day when a drug is taken is important
to its efficacy. If the drug targets a clock-controlled gene that is only expressed at certain times
of the day, the drug will only be effective when the target is highly expressed. This finding is
important, as a recent study showed that over half (56) of the top 100 selling drugs in the United
States target the product of a circadian gene (64). To this end, there are research and clinical
trials looking into timed delivery of drugs and increasing their efficacy (16, 17, 20, 64-68). For
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example, taking low dose aspirin for heart disease is more effective if taken at night since aspirin
has a half-life of 6 hours and its target, Cox1, is upregulated at night (64). The timing of drugs
can be applied not only to heart disease, but also to many other diseases like metabolic diseases
and even brain cancers and the timing of chemotherapy (16, 17, 20, 64-69).
In musculoskeletal diseases such as OA and RA, there are daily inflammatory flares
normally in the early morning. Cytokines present in both OA and RA knee patients exhibited
diurnal expression patterns, with inflammatory cytokines peaking in the early hours of the
morning (16, 17, 66, 67). Patients with RA who took glucocorticoids at night instead of in the
morning reported reduced joint pain and inflammation, showing the importance of chronotherapy
in arthritis (68). Expanding beyond just cartilage and arthritis, cyclic delivery of parathyroid
hormone (PTH) has shown improved bone growth, whereas continuous delivery of PTH showed
enhanced bone resorption (70). Therefore, there are plenty of targets and instances where
intermittent or delivery of biologics at specific times of day are required for the drug to be
effective.
Unfortunately, this process can be difficult to maintain since it can require constant daily
injections or delivery of drugs at inconvenient times, such as the case of arthritis where delivery
of the drug in the early morning immediately before the inflammatory flare would be best. To
this end, we have created the first cell therapy using the cell’s own biologic circadian clock to
provide gene-based delivery of biologic drugs at prescribed times and frequencies. This cell
therapy is detailed in Chapter 5, but briefly the core clock gene Per2 was used to drive
production of a therapeutic transgene IL-1Ra in an oscillatory and timed way. This approach is
the very first creation of a cell-based therapy for chronotherapy.
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1.8 Summary
Taking all of this together, we worked to build upon synthetic biology, gene therapy, and
gene editing tools and applied these systems to musculoskeletal diseases in a way that is
controlled, prescribed, and localized. Taking into consideration the important drivers of arthritis,
we developed a synthetic system that can sense and attenuate inflammation, as detailed in
Chapter 2 (62). Basing the ability of chondrocytes to respond to mechanical stimuli, we created
mechanogenetic synthetic circuits that produce a biologic drug in response to loading, as detailed
in Chapter 3 (63), creating a new class of synthetic circuits. We then built systems based on
preserving an important and usually overlooked part of tissues, the circadian clock, for
maintaining tissue homeostasis and integrity, as detailed in Chapter 4. Finally, we developed the
first-of-its-kind cell-based chronogenetic therapy that delivers a therapeutic drug in a temporal
manner, as detailed in Chapter 5.
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Chapter 2: A Synthetic Gene Circuit for SelfRegulating Delivery of Biologic Drugs in
Engineered Tissues
Partially adapted from: Pferdehirt, L.*, Ross, A. K.*, Brunger, J. M., & Guilak, F. (2019).
A synthetic gene circuit for self-regulating delivery of biologic drugs in engineered
tissues. Tissue Engineering Part A, 25(9-10), 809-820.

2.1 Abstract
Transient, resolving inflammation plays a critical role in tissue repair and regeneration. In
the context of joint disease, however, chronic inflammation following injury or with
osteoarthritis can lead to irreversible articular cartilage degradation and joint pain. Developing
tissue engineering strategies for the regeneration of articular cartilage remains challenging due to
the harsh inflammatory environment of an injured or arthritic joint, which can promote
degradation of engineered tissues as well as native articular cartilage. Here, we developed an
artificial gene circuit for controlled, cell-based delivery of biologic drugs, based on a nuclear
factor kappa-light-chain enhancer of activated B cells (NF-κB)-responsive synthetic promoter.
Using lentivirus-based gene therapy, we engineered murine induced pluripotent stem cells
(iPSCs) capable of attenuating inflammation through controlled release of an anti-inflammatory
drug, interleukin-1 receptor antagonist (IL-1Ra), subsequently inhibiting gene circuit activation
in a self-regulating manner. Murine iPSCs were transduced with the synthetic gene circuit either
in monolayer or through biomaterial-mediated transduction. Cells were maintained in monolayer
or differentiated into cartilage constructs and stimulated with different doses of interleukin 1
alpha (IL-1α) to determine the ability of this synthetic NF-κB responsive system to inhibit
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inflammation and protect tissue-engineered constructs. In response to IL-1α, cells produced high
levels of IL-1Ra, which inhibited inflammatory signaling and protected tissue-engineered
cartilage from proteoglycan degradation. Our results show that the combination of gene therapy
and tissue engineering can be used to successfully create iPSCs capable of producing biologic
drugs in a controlled manner. This self-regulating system provides a tool for cell-based drug
delivery as the basis for a novel therapeutic approach for a variety of diseases.

2.2 Introduction
Osteoarthritis (OA) is a debilitating joint disease that causes severe pain and loss of joint
function, affecting over 32 million adults in the United States alone (71). OA is characterized by
the degeneration of articular cartilage, the hyaline cartilage that covers the articulating surfaces
of bones in diarthrodial joints. Because articular cartilage is avascular, aneural, and alymphatic,
it lacks an intrinsic ability to repair (23). While there are many risk factors for OA—including
injury, aging, metabolic disorders, obesity, and genetics—a common pathway for the
pathogenesis and progression of joint degeneration and pain involves the proinflammatory
activity of several cytokines, particularly the interleukin-1 (IL-1) family of cytokines, including
IL-1α and IL-1β, and tumor necrosis factor-α (TNF-α) (24). These cytokines primarily signal via
the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) to induce extracellular
matrix (ECM) degradation through the inhibition of anabolic activities and enhanced production
of degradative enzymes and catabolic cytokines, particularly in articular chondrocytes (25, 30).
Furthermore, inflammation can significantly inhibit repair of cartilage and other joint tissues, as
several studies have shown high sensitivity of stem cells and engineered cartilage to cytokines
such as IL-1 and TNF-α (26, 56, 72, 73).
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IL-1 receptor antagonist (IL-1Ra, anakinra), a competitive antagonist of IL-1, has been
shown to alleviate symptoms of rheumatoid arthritis (RA) and post-traumatic OA (36-38).
Furthermore, several gene therapy approaches to deliver IL-1Ra to the joints of patients with RA
and OA are in progress or pending (25, 45, 46). However, despite the potential for success of
anti-cytokine drugs and gene therapy approaches, there are currently no effective diseasemodifying treatments to address both the symptoms and structural change of OA (45, 47, 74).
Additionally, the inability of these approaches to accomplish a sustained delivery of biologic
drugs in a dynamically and spatially controlled manner is an important limitation. Anti-cytokine
therapies are often delivered at high doses, which may have significant off-target effects,
including an increased susceptibility to infection and certain autoimmune diseases (43), as well
as limited tissue regeneration and repair (75-77). Therefore, the long-term success of stem cell–
based therapies for cartilage repair or OA may require engagement of intrinsic cellular abilities
to regulate the inflammatory environment of the joint.
To address these limitations, tissue engineering and gene therapy approaches can be
combined to create a cartilaginous tissue that is capable of replacing damaged tissue while
delivering therapeutic drugs to diseased joints (48). Additionally, by using both gene delivery
and synthetic biology, cells can be transduced ex vivo with expression vectors designed to
produce a desired gene through specific inputs (51, 52). Furthermore, the implantation of tissueengineered constructs allows for localized delivery of biologic drugs to specific sites in the body.
The overall goal of this study was to create self-regulating (i.e., feedback-controlled)
stem cells capable of attenuating inflammation in a prescribed manner for a controlled release of
anti-inflammatory molecules. We engineered a synthetic transcriptional regulator system capable
of producing a therapeutic drug and packaged it into a lentiviral vector to allow for transduction
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into various cell types and through different transduction strategies. Specifically, we developed
an NF-κB-inducible synthetic promoter that controls the release of a biologic drug, IL-1Ra, to
maintain tissue homeostasis in response to the activation of NF-κB in a long-term and sustained
manner (Figure 2.1). We utilized this lentiviral vector to create murine induced pluripotent stem
cells (iPSCs) capable of sensing and responding to inflammation. Additionally, we show the
proof-of-concept for site-specific, scaffold-mediated delivery (57, 78) of this lentivirus to iPSCs.
The transduced iPSCs were chondrogenically differentiated into articular cartilage tissue to
determine the efficacy of this vector in protecting engineered tissue against cytokine-induced
degradation. We hypothesized that this NF-κB-inducible biologic drug delivery system will
allow for controlled, self-regulating production of anti-inflammatory molecules in direct
response to dynamic changes in inflammatory stimuli. This type of cell-based approach could
provide an effective method to treat OA and chronic inflammatory diseases while overcoming
limitations of current drug delivery techniques.
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Figure 2.1 Overview of synthetic promoter design and experimental approach. A synthetic
promoter was designed with five NF-κB recognition motifs upstream of IL-1Ra to create an
NF-κB inducible promoter. The EF1α constitutive promoter was used to drive continuous
expression of IL-1Ra. iPSCs were transduced with lentivirus containing an NF-κB inducible
promoter that drives expression of IL-1Ra. In the presence of IL-1α, the synthetic promoter is
activated and produces IL-1Ra, preventing IL-1α from binding to the IL-1 receptor and
inhibiting activation of inflammatory cascades within the cell.
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2.3 Materials and Methods
2.3.1 Overall Strategy
The overall strategy for this work was to create a synthetic transcription system that is
activated by inflammatory cytokines and, when incorporated into a lentiviral vector, can be
readily delivered to different types of cells for applications in cell therapy or tissue engineering.
Cells transduced by the lentiviral vectors were programmed to express anti-inflammatory
biologic drugs downstream of the synthetic promoter, providing a negative feedback system that
blocks the action of an inflammatory cytokine (Figure 2.1). Here, we specifically tested the
ability of our synthetic transcription system to protect engineered cartilage from its intrinsic
response to inflammatory cytokines through three different methods: in monolayer, in tissueengineered cartilage, and with biomaterial-mediated delivery of vectors.

2.3.2 Vector Design
A synthetic NF-κB-inducible promoter was designed to incorporate multiple NF-κB
response elements that drive a target gene of interest (60). Briefly, a synthetic promoter was
developed containing five consensus sequences approximating the NF-κB canonical recognition
motif based on genes that are upregulated by inflammatory challenge: InfB1, Il6, Mcp1,
Adamts5, and Cxcl10 (60, 79). Murine Il1rn or firefly luciferase from the pGL3 basic plasmid
(Promega) was cloned downstream of this synthetic promoter; a TATA box derived from the
minimal CMV promoter was cloned between the synthetic promoter and downstream target
genes; and an NF-κB-negative regulatory element (NRE-5’-AATTCCTCTGA-3’) (80) was
cloned upstream of the promoter to reduce background signal (Figure 2.1). This engineered
NRE-IL1Ra cassette results in transgene expression when the promoter is activated in response
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to NF-κB-based inflammatory stimuli, resulting in a ‘‘self-regulating’’ system. A constitutive
control vector was also tested using murine Il1rn cloned into the lentiviral transfer vector (No.
12250; Addgene) downstream of the EF1α promoter sequence (81) (EF1α-IL1Ra) using Gibson
Assembly (82). A nuclear-targeted green fluorescent protein (GFP) (83) (No. 11680; Addgene)
was cloned into a constitutive, lentiviral vector (84) (No. 11645; Addgene) and was used as a
transduction control (GFP).

2.3.3 Lentivirus Production
HEK293T cells were co-transfected with an expression transfer vector, second-generation
packaging plasmid psPAX2 (No. 12260; Addgene), and an envelope plasmid pMD2.G (No.
12259; Addgene) by calcium phosphate precipitation to make vesicular stomatitis virus
glycoprotein pseudotyped lentivirus (85). The expression transfer vectors include the NREIL1Ra, NRE- Luc, EF1α-IL1Ra, and GFP plasmids. The lentivirus was stored at -80°C until
further use. The functional titer of each virus group was determined via quantitative real-time
polymerase chain reaction to determine the number of lentiviral DNA copies integrated into the
genome of transduced HeLa cells (85).

2.3.4 Cell Culture and Differentiation
Murine iPSCs, generated from tail fibroblasts from adult C57BL/6 mice and validated for
pluripotency as described by Diekman et al. (49, 86), were maintained on mitomycin C-treated
mouse embryonic fibroblasts (Millipore). To track inflammatory activity in cells, an iPSC
reporter cell line was created via the CRISPR-Cas9 genome editing system to incorporate firefly
luciferase downstream of the Ccl2 locus (Ccl2-Luc) (60). In this cell line, proinflammatory
signaling activates Ccl2 promoter activity, resulting in the transcription of luciferase (87).
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Unedited and Ccl2-Luc cells were then differentiated toward a mesenchymal state using a
high-density micromass culture. Differentiation medium contained Dulbecco’s modified Eagle’s
medium high glucose (DMEM-HG); 1% culture medium supplement containing recombinant
human insulin, human transferrin, and sodium selenite (ITS+); minimum essential medium
(MEM) nonessential amino acids; 55 μM 2-mercaptoethanol; 24 ng/mL gentamicin; 50 mg/mL
L-ascorbic acid; and 40 mg/mL L-proline. On days 3–5, this medium was supplemented with
100nM dexamethasone and 50ng/mL bone morphogenetic protein 4 (BMP-4; R&D Systems)
(49). After 15 days of culture, the micromasses were dissociated with pronase and collagenase
type II and the predifferentiated iPSCs (PDiPSCs) were plated on gelatin-coated dishes in
expansion medium containing DMEM-HG, 10% fetal bovine serum, 1% ITS+, MEM
nonessential amino acids, 55 μM 2-mercaptoethanol, 1% penicillin/streptomycin, 50 mg/mL Lascorbic acid, 40 mg/mL L-proline, and 4 ng/mL of basic fibroblast growth factor (bFGF; R&D
Systems). These cells were then expanded, transduced, and either used for monolayer
experiments or in pellet cultures to produce engineered cartilage to evaluate the ability of these
cells to protect against inflammation.

2.3.5 Lentiviral Transduction and Culture of PDiPSCs
For initial characterization, PDiPSCs were transduced with the NRE-Luc virus. For all
other monolayer experiments, passage 4 PDiPSCs and Ccl2-Luc cells were transduced with
NRE-IL1Ra and EF1α-IL1Ra virus, and non-transduced (NT) cells were used as control.
In pellet experiments, PDiPSCs were transduced at passage 1 with NRE-IL1Ra, EF1αIL1Ra, or GFP virus. Passage 1 cells were trypsinized, and pellet cultures were created by
centrifuging 250k cells at 200xg for 5 min. The pellets were cultured in chondrogenic media
containing DMEM-HG, 1% ITS+, MEM nonessential amino acids, 55 μM 2-mercaptoethanol,
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1% penicillin-streptomycin, 50 mg/mL L-ascorbic acid, 40 mg/mL L-proline, 100 nM
dexamethasone, and 10 ng/mL transforming growth factor-β3 (TGF-β3) for 21 days (49).
For all monolayer and pellet studies, transduction media consisted of expansion medium
supplemented with 4 mg/mL polybrene (Sigma-Aldrich) and the desired number of viral
particles to achieve a multiplicity of infection = 3. Transduction media were exchanged with
expansion medium after 24 hours of transduction.

2.3.6 Biomaterial-mediated Delivery
Biomaterial-mediated lentiviral transduction was tested using a model system based on
poly(ε-caprolactone) (PCL; molecular weight 70,000–90,000; Sigma-Aldrich), a scaffold
material commonly used for cartilage tissue engineering (88, 89). PCL was dissolved in glacial
acetic acid at a 10% wt/vol ratio. Tissue culture-treated plates were coated with the dissolved
PCL, and the acid was evaporated overnight. The acid was quenched with 1N NaOH, washed
with phosphate buffered saline (PBS), and sterilized with an ethanol gradient. Plates were then
incubated in 0.002% poly-L-lysine (PLL) solution (Sigma-Aldrich). PLL was aspirated, and two
groups of lentivirus (NRE-IL1Ra and EF1α-IL1Ra) or PBS for NT controls were added to the
plates and allowed to incubate for 4 hours at 37°C (57, 88). After virus immobilization, viral
supernatant was aspirated, wells were washed with PBS, and passage 4 PDiPSCs and Ccl2-Luc
control cells were plated in the wells. After an additional 3 days of culture, the ability of these
cells to respond to and attenuate inflammation was evaluated through a luminescence activity
assay, protein production, and gene expression analysis.
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2.3.7 Inflammatory Challenge
To evaluate the response of the synthetic promoter to inflammatory cytokines, unedited
PDiPSCs transduced with NRE-Luc were challenged with 1 ng/mL IL-1α or 20 ng/mL TNF-α
and evaluated at 72 hours after challenge.
To determine the sensitivity and kinetics of the synthetic promoter, all groups of Ccl2Luc and unedited PDiPSCs (NT, NRE-IL1Ra, and EF1α-IL1Ra) were evaluated at 0, 4, 12, 24,
and 72 hours post supplementation of media with 0.05, 0.1, 0.5, or 1 ng/mL IL-1α and removal
of bFGF. Control cells were cultured in the absence of IL-1α.
For characterizing the pellets’ response to inflammation, after 21 days of chondrogenic
culture, pellets were challenged with 0.5 or 1 ng/mL IL-1α and removal of TGF-β and
dexamethasone for 72 hours. Control pellets were cultured in the absence of IL-1α.

2.3.8 Inflammation Activity Assay
Luciferase activity from NRE-Luc transduced cells and Ccl2-Luc cells in all monolayer
experiments was measured using the BrightGlo Luminescence kit (Promega) and a Cytation5
plate reader (Biotek). Luciferase activity is reported as a fold change of IL-1α-stimulated cells
over control cells cultured without IL-1α (n = 4–6).

2.3.9 Gene Expression
Unedited PDiPSCs from monolayer studies and pellets were harvested for quantitative,
reverse transcription polymerase chain reaction (qRT-PCR) after inflammatory challenge (n=4).
Monolayer cells were rinsed in PBS, lysed in Buffer RL (total RNA purification; Norgen
Biotek), and stored at -80°C until RNA isolation. Pellets of engineered cartilage tissue were
rinsed in PBS and stored at -80°C until RNA isolation. Pellets were homogenized using a
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miniature bead beater. RNA isolation was carried out following the manufacturer’s protocol
(Norgen Biotek). Reverse transcription was performed using Superscript VILO complementary
DNA (cDNA) master mix (Invitrogen). qRT-PCR was performed using Fast SyBR Green master
mix (Applied Biosystems) following the manufacturer’s protocol. Primer pairs (Table 2.1) were
synthesized by Integrated DNA Technologies, Inc. Fold changes were calculated using the ΔΔCT
method and are shown relative to the 0 hour no cytokine, NT control samples for monolayer
experiments, or GFP pellets without cytokines. For samples with no amplification, CT threshold
was set to the cycle limit.
Table 2.1 qRT-PCR primer pair sequences for inflammation and cartilage matrix genes, as well
as transgene expression analysis.
TARGET

FORWARD PRIMER

REVERSE PRIMER

R18S

5’-CGGCTACCACATCCAAGGAA-3’

5’-GGGCCTCGAAAGAGTCCTGT-3’

CCL2

5’-GGCTCAGCCAGATGCAGTTAA-3’

5’-CCTACTCATTGGGATCATCTTGCT-3’

IL6

5’-AAGTGCATCATCGTTGTTCATACA3’

5’-CGAACTTCGACACTGACAAGAAGT-3’

COL2A1

5’-TCCAGATGACTTTCCTCCGTCTA-3’

5’-AGGTAGGCGATGCTGTTCTTACA-3’

ACAN

5’-GCATGAGAGAGGCGAATGGA-3’

5’-CTGATCTCGTAGCGATCTTTCTTCT-3’

IL1RN

5’-GTCCAGGATGGTTCCTCTGC-3’

5’-TCTTCCGGTGTGTTGGTGAG-3’

2.3.10 Enzyme-linked Immunosorbent Assays
Culture media were collected from all unedited PDiPSC monolayer and pellet samples
after inflammation challenge and stored at -20°C. IL-1Ra concentration was measured with
DuoSet enzyme-linked immunosorbent assay (ELISA) specific to mouse IL-1Ra/IL-1F3 (n=4;
R&D Systems). Each sample was measured in technical duplicates. Absorbance was measured at
450 and 540 nm.
22

2.3.11 Biochemical Analysis of Pellet Cultures
After 72 hours of inflammatory challenge, pellets were washed with PBS and stored at 20°C until processing. Pellets were digested overnight in 125 mg/mL papain at 65°C for
biochemical analysis. DNA content was measured with PicoGreen assay (Thermo Fisher), and
total sulfated glycosaminoglycan (sGAG) content was measured using a 1,9-dimethylmethylene
blue assay at 525 nm wavelength (90) (n=4).

2.3.12 Histological Processing of Pellet Cultures
After 72 hours of cytokine challenge, pellets were washed with PBS and fixed in 10%
neutral buffered formalin for 24 hours, paraffin-embedded, and sectioned at 8 mm thickness.
Slides were stained for Safranin-O/hematoxylin/fast green using a standard protocol (91).

2.3.13 Statistical Analysis
Statistical analysis was performed with the JMP Pro soft- ware package. Luminescence
data and biomaterial-mediated delivery qRT-PCR data were analyzed using analysis of variance
(ANOVA) with Dunnett’s post hoc test using NT as the control (α = 0.05). A two-way ANOVA
with Tukey’s HSD post hoc test was used to analyze all ELISA data, pellet biochemistry, and
pellet qRT-PCR data (α = 0.05).

2.4 Results
2.4.1 Responsiveness of the NF-κB synthetic promoter to IL-1α or TNF-α
Pre-differentiated iPSCs (PDiPSCs) receiving the NRE-Luc vector responded to 1 ng/mL
IL-1α and 20 ng/mL TNF-α with a 10.17–0.54- and 8.40–0.32-fold increase in luminescence
after 72 hours of cytokine stimulation, respectively (Figure 2.2A).
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Figure 2.2 Evaluation of cells after cytokine stimulation in monolayer to determine
responsiveness of NRE-IL1Ra vector. (A) NRE-Luc cells were stimulated with 20 ng/mL TNFα or 1 ng/mL IL-1a and luminescence was measured after 72 hours. Bars represent the mean
relative luminescence units (RLU) ± SEM (n=4). (B) Fold change of NF-κB activity measured
by luminescence signal from Ccl2-Luc cells. Bars represent the mean fold change in RLU ±
SEM (n=6). Asterisks represent significance (p < 0.05) compared to NT control. (C) NT and
NRE-IL1Ra cells were treated with IL-1α and an ELISA was performed on samples to
determine IL-1Ra protein production. Values represent mean ± SEM (n=4). Groups not sharing
same letter are statistically significant (p < 0.05).

2.4.2 Self-Regulating attenuation of inflammation by iPSCs
Attenuation of inflammatory signaling was tested in Ccl2-Luc reporter cells that produce
luciferase in response to inflammatory stimuli. After transduction, cells transduced with either
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the NRE-IL1Ra or EF1α-IL1Ra lentivirus and NT control cells were treated with IL-1α at a
range of doses from physiologic (0.1 ng/mL) to supraphysiologic (1 ng/ mL) (73) and compared
with cells without cytokine. In all doses of IL-1α, by 4 hours there was significantly less
luminescence output in both NRE-IL1Ra and EF1α-IL1Ra groups compared with NT control.
This trend was sustained up to 24 hours in all doses in the NRE-IL1Ra groups and up to 72 hours
in all doses except 0.05 ng/mL of IL-1α (Figure 2.2B) (p < 0.01). This decrease in luminescence
shows that there was attenuation of IL-1 signaling with the NRE-IL1Ra group and that this
system is responsive at a range of cytokine concentrations.
To evaluate the ability of these vectors to produce therapeutic levels of IL-1Ra, unedited
PDiPSCs were lentivirally transduced with the NRE-IL1Ra or EF1α-IL1Ra vectors, and IL-1Ra
protein production was measured. The transduced cells and NT control cells were administered
with IL-1α and compared with cells without cytokine. Culture media were collected at 0, 4, 12,
24, and 72 hours to measure the production of IL-1Ra in response to an inflammatory challenge.
NRE-IL1Ra groups had an increase in IL-1Ra production over time and exhibited higher IL-1Ra
production with increased doses of IL-1α. There was a significant increase in IL-1Ra production
in the NRE-IL1Ra groups challenged with IL-1α compared with the NRE- IL1Ra cells without
cytokine at 24 and 72 hours (p < 0.0001) with 140.64–8.78 and 163.41–16.04 ng/mL IL-1Ra
produced with 0.5 and 1 ng/mL IL-1α stimulation at 72 hours, respectively. Additionally, there
was an increase in IL-1Ra in NRE-IL1Ra groups compared with the NT and EF1α-IL1Ra groups
(Figure 2.2C and Figure S2.1A) (p < 0.0001). These results taken together show that this iPSCbased NRE- IL1Ra system responds to an inflammation challenge by producing increased levels
of the biologic drug.
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2.4.3 Transduced NRE-IL1Ra iPSCs from tissue-engineered cartilage is
protected from IL-1α
Following lentiviral delivery to iPSCs and 21 days of chondrogenic differentiation,
pellets were administered 0.5 or 1 ng/mL IL-1α for 72 hours and were compared with pellets that
did not receive cytokine. GFP control pellets showed rich Safranin-O staining for sGAG, one of
the primary components of cartilage ECM. Pellets treated with 0.5 ng/ mL or 1 ng/mL IL-1α for
72 hours displayed reduced Safranin-O staining (Figure 2.3A). Pellets made from NRE-IL1Ra
PDiPSCs produced 72.90–2.42 and 92.24–2.31 ng/mL IL-1Ra in response to 0.5 and 1 ng/mL
IL-1α, respectively, which was significantly higher than both GFP and EF1α-IL1Ra pellets (p <
0.0001). EF1α-IL1Ra pellets produced significantly higher levels of IL-1Ra compared with GFP
control pellets (Figure 2.3B) (p < 0.001). NRE-IL1Ra pellets showed protection against IL-1αmediated matrix degradation, as indicated by robust Safranin-O staining and quantitative
biochemical analysis. NRE-IL1Ra pellets that received IL-1α had significantly higher amounts
of sGAG when normalized to the concentration of DNA in each pellet (normalized to pellets that
did not receive IL-1α) compared with EF1α-IL1Ra and GFP control pellets (Figure 2.3C) (p =
0.0322 and 0.0005, respectively). Despite the increased levels of IL-1Ra production, the EF1αIL1Ra pellets showed little or no inhibition of IL-1α-mediated sGAG loss, as indicated by the
loss of Safranin-O staining and sGAG/DNA content (Figure 2.3C).
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Figure 2.3 Assessment of engineered cartilage to determine if NRE-IL1Ra protects tissues
from cytokine stimulation. (A) Safranin-O/fast green/hematoxylin stained tissue sections of
engineered cartilage (scale bar = 200µm). (B) IL-1Ra production collected from media samples
after IL-1α stimulation (n=4). Groups not sharing same letter are statistically significant (p <
0.05). (C) % conserved sGAG/DNA in pellets after addition of IL-1α (n=4). Groups not sharing
same letter are statistically significant (p < 0.05). (D) Relative gene expression compared to 0
hour control measured by qRT-PCR (n=4). Hash represents significance (p < 0.05).
Gene expression analysis of the pellets showed a significantly decreased expression of
inflammation-related genes, Ccl2 and Il6, in pellets engineered with the NRE-IL1Ra vector
compared with GFP control (p = 0.0164 and 0.0004, respectively) and EF1α-IL1Ra (p=0.0054
and 0.0008, respectively) pellets. Furthermore, NRE-IL1Ra pellets had significantly higher
levels of expression of cartilage matrix- related genes, Col2a1 and Acan, compared with GFP
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control (p = 0.0088 and 0.0090, respectively) and EF1α-IL1Ra pellets (Figure 2.3D) (p = 0.0044
and 0.041, respectively).

2.4.4 Biomaterial-mediated lentiviral delivery shows self-regulating
production of IL-1Ra and attenuation of inflammation
Ccl2-Luc reporter cells were seeded on a PCL film and were transduced through
biomaterial-mediated delivery of either NRE-IL1Ra or EF1α-IL1Ra vectors. Cell were also
seeded on PCL without virus as a NT control. Cells were then administered with IL-1α. For all
doses of IL-1α, the NRE-IL1Ra group had significantly less luminescence out-put compared
with NT controls by 24 hours (p < 0.001) (Figure 2.4). At 72 hours post stimulation, NRE-IL1Ra
and EF1α- IL1Ra cells had decreased luminescent output compared with NT controls in all
doses, showing attenuation of inflammation (p < 0.0001).
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Figure 2.4 NF-κB activity of cells transduced via biomaterial-mediated lentiviral delivery. Reported
as fold change measured by luminescence signal from Ccl2-Luc cells. Bars represent the mean fold
change in RLU ± SEM of cells treated with IL-1α compared with controls cultured with no cytokine
(n=6). Asterisks represent significance (p < 0.05) compared to NT control.
Culture media were collected at 0, 4, 12, 24, and 72 hours to measure IL-1Ra production
from cells transduced via biomaterial-mediated transduction. The NRE-IL1Ra group exhibited a
time- and dose-dependent response of IL-1Ra production. IL-1Ra protein production was
significantly increased at higher doses of IL-1α, with 139.31–19.6 and 165.91–15.83 ng/mL IL1Ra being produced when stimulated with 0.5 and 1 ng/mL IL-1α, respectively, at 72 hours (p <
0.001). Additionally, IL-1Ra production was increased in the NRE-IL1Ra group compared with
NT and EF1α-IL1Ra groups (Figure 2.5A and Figure S2.1B) (p < 0.0001). There was an increase
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in Il1rn gene expression in all cells that received the NRE-IL1Ra vector at 24 hours (Figure
2.5B), and in EF1α-IL1Ra cells at 0, 12, and 24 hours (Figure S2.2C). By 72 hours, NT and
NRE-IL1Ra groups were not significantly different from each other, indicating that a decreased
inflammatory signaling led to an autoregulated decrease in Il1rn gene expression due to IL-1Ramediated inhibition of inflammation and subsequent gene circuit activation.

A

B

Figure 2.5 Transgene induction in cells transduced via biomaterial-mediated lentiviral delivery.
(A) NT and NRE-IL1Ra cells were treated with IL-1α and an ELISA was performed on samples
to determine IL-1Ra protein production. Values represent mean ± SEM (n=4). Groups not
sharing same letter are statistically significant (p < 0.05). (B) Il1rn gene expression. Fold
changes were determined relative to 0 hour NT cells without cytokine. Error bars represent
means of fold change ± SEM (n=6).
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Figure 2.6 Gene expression of cells transduced through biomaterial-mediated delivery and
challenged with IL-1α. Fold changes were determined relative to 0 hour NT cells without
cytokine. Error bars represent means of fold change ± SEM (n=6). Asterisks represent
significance relative to NT control group (p < 0.05). (A) Ccl2 gene expression. (B) Il6 gene
expression.
Gene expression analysis showed a dose-dependent increase in inflammation-related
genes, Ccl2 and Il6, as early as 4 hours following the delivery of inflammatory cytokines to all
groups of cells, which persisted through 72 hours. However, the biomaterial-mediated delivery
of the self-regulating NRE-IL1Ra compared with NT controls significantly decreased the
expression of Ccl2 starting at 4 hours and was maintained through 72 hours (Figure 2.6A) (p <
0.01). Ccl2 was also decreased in EF1α-IL1Ra cells compared with NT controls at 24 and 72
hours (Figure S2.2A). Il6 was significantly decreased in NRE-IL1Ra cells from 4 hours through
24 hours (Figure 2.6B) (p < 0.0001) and was significantly decreased in EF1α-IL1Ra cells at 24
hours (Figure S2.2B). Together, these results show that this system responds to inflammatory
stimulus and suggests that the therapeutic levels produced could inhibit inflammation.
Additionally, these findings show a successful proof-of-concept experiment for the delivery of
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either our transduced cells for implantation into the joint (56-58) or of our gene therapy vectors
for transduction of endogenous cells in vivo.

2.5 Discussion
A significant challenge in the field of regenerative medicine has been the ability to tissueengineer cartilage that is capable of withstanding the harsh inflammatory environment of an
injured or arthritic joint. We developed an iPSC-based lentiviral system in which cells sense and
respond to inflammatory stimuli by producing anti-inflammatory mediators. Using a
combination of regenerative medicine, synthetic biology, and gene therapy, we developed selfregulating iPSCs that are capable of forming engineered cartilage for the replacement of diseased
tissue and mitigating the inflammatory effects of IL-1α (49). Additionally, the versatility of both
the iPSCs and the lentiviral system allows for translation to various cell types or tissues. Lastly,
by leveraging the flexibility of lentiviral transduction in tissue engineering applications, we
demonstrated proof-of-concept of a targeted delivery method allowing for spatial control of
therapy via biomaterial-mediated lentiviral transduction.
Using lentivirus-based gene therapy, we engineered iPSCs with the NRE-IL1Ra vector,
creating a system that can dynamically respond to and attenuate NF-κB signaling. Cells receiving
the NRE-IL1Ra vector responded rapidly to IL-1α as all groups had reduced inflammatory
signaling by 4 hours after stimulation. Importantly, NRE-IL1Ra cells responded to both
physiologic and supraphysiologic doses of IL-1α, and this response was sustained throughout 72
hours for all doses, except 0.05 ng/mL IL-1α. In addition, all doses of IL-1α activated the
synthetic promoter to produce therapeutic levels of IL-1Ra by 24 and 72 hours and in a dosedependent manner. This dose response provides a controlled production of the therapeutic drug
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in response to different levels of inflammation. Cells that received the EF1α-IL1Ra vector
produced IL-1Ra, however, at a significantly lower amount than the NRE-IL1Ra vector. This
could be due to the low production of the transgene from the constitutive promoter, which has
previously been reported in lentiviral systems with constitutive reporters (92).
An important advance of this work is the application of our lentiviral system in iPSCs.
iPSCs are attractive for tissue engineering and regenerative medicine because they can be
expanded, patient-matched, and differentiated into a variety of different cell types to treat
multiple tissues, overcoming the limitations of other common cell sources (49, 50). Here, we
show that the NRE-IL1Ra vector can be delivered to PDiPSCs, and these cells can form
cartilaginous tissues, and that in the presence of 0.05 or 1 ng/mL IL-1α, engineered cartilage
pellets produced high levels of IL-1Ra. This indicates the potential use of this system for the
repair of diseased articular cartilage and mitigation of inflammation through a soluble release of
IL-1Ra into the joint. We observed less IL-1Ra production from tissue-engineered cartilage than
cells in monolayer. This difference can be attributed to the different differentiation states of the
cells, as well as their accessibility to the culture media. In pellets, cells are embedded within a
dense ECM, which may bind or hinder the transport of IL-1Ra and/or IL-1α (93). Despite these
transport limitations, NRE-IL1Ra pellets were protected from IL-1α-mediated degradation, as
evidenced by rich Safranin-O staining and significantly higher levels of sGAG/ DNA.
Furthermore, NRE-IL1Ra pellets had decreased expression of inflammation-related genes, while
cartilage matrix-related genes were sustained, showing the attenuation of inflammatory pathways
and protection of the matrix.
In previous approaches, gene therapy for the treatment of OA has been performed with
plasmid DNA (94), retrovirus (95), lentivirus (96-98), and most commonly non-integrating viral
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vectors such as adeno-associated virus (88, 99-102). Lentiviral delivery is advantageous for this
system due to its ability to stably integrate into the genome of dividing and non-dividing cells for
long-term gene expression, its larger packaging capacity, low immunogenicity, and low
cytotoxicity (103, 104). The vector used in this study is self-inactivating and, therefore,
replication-defective, overcoming safety concerns previously associated with viral gene therapy
(105-107). Additionally, our group and others have shown that viral vectors can be immobilized
to biomaterial surfaces or scaffolds for the delivery of therapeutic vectors to cells (56-58, 78,
108). Our study showed that biomaterial-mediated delivery of NRE-IL1Ra from PCL provided
efficient transduction and effectively decreased inflammatory signaling. Specifically,
biomaterial-mediated transduction of NRE-IL1Ra significantly decreased the expression of
inflammation-related genes, Ccl2 and Il6, and stimulated high levels of IL-1Ra production in a
dose-dependent manner. These results indicate that this approach provides an effective method
for delivering therapeutic vectors and can be applied for broader tissue engineering applications.
This strategy could address limitations of existing gene therapy approaches such as the loss of
therapeutic transgene expression over time when using non-integrating delivery methods, lack of
spatial control of transduction when using systemic injections of vectors, and lack of controllable
or inducible production of transgenes when using constitutive expression vectors.
Previously, investigators have developed various systems for inflammation-inducible
expression of pro-regenerative or anti-inflammatory transgenes. Rachakonda et al. created a selflimiting promoter construct that was based on truncated promoter sequences of cyclooxygenase2 upstream of IL-4 to express IL-4 only in the presence of inflammation (54). Others have also
created expression systems based on NF- κB binding sequences for luciferase reporting vectors
(109, 110) or inducible systems driving the expression of anti-inflammatory mediators in adeno34

associated viral vectors (111, 112). Previous work in our lab utilized CRISPR-Cas9 technology
to genome-engineer stem cells capable of using the endogenous systems within the cells to sense
inflammation and produce therapeutic transgenes (60). While this system has specific advantages
in terms of the precision of CRISPR-based gene editing, by packaging our NRE-IL1Ra system
into a lentiviral expression cassette, we expand the vector’s applicability to transduce different
cell types and tissues, such as mesenchymal stem cells, adipose-derived stem cells, or primary
cells such as articular chondrocytes or synovial cells, all of which are commonly used in tissue
engineering or targeted for gene therapy but are more challenging to edit with CRISPR-Cas9.
The sensitivity of the synthetic promoter can be tuned dependent on the sequence, number of
tandem repeats, and neighboring regulatory elements, as well as through gene editing (53) or
epigenetic modification (113) of the cells’ receptors. Additionally, other inflammatory cytokines,
such as TNF-α, or intracellular signaling components can be targeted for specific or broad
inhibition of inflammation.
Our synthetic lentiviral system can create self-regulating cells capable of sensing and
responding to inflammation with a therapeutic level of biologic drug. The continued
development of designer circuits through gene switches (114-116), microRNA classifiers (117,
118), and synthetic transcription systems (119-121) provides a toolkit to engineer more complex
circuits with specialized control. This work adds to our long-term goals of developing a
molecular toolbox (122, 123) of biological building blocks for novel synthetic applications in
mammalian cells for ameliorating chronic diseases.
The autoregulatory capabilities of this system allow applications for regenerative
medicine or for use as a preventative approach to inflammatory disease. Applying this
methodology not only allows for protection against inflammation to aid in cartilage repair, but
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also provides protection of any tissue-engineered constructs inserted to help repair an
osteoarthritic joint or biomaterial-mediated lentiviral transduction of any infiltrating cells
through localized transduction. The customization aspect of this system and its functionality in
monolayer, an engineered tissue replacement, and through scaffold-mediated delivery gives
innovative opportunities for effective treatments that are applicable in a variety of diseases.
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2.6 Supplemental Figures
A

B

Figure S2.1 IL-1Ra protein production in EF1α-IL1Ra group at different IL-1α doses over time
in (A) monolayer cells and (B) in monolayer cells transduced through biomaterial-mediated
delivery. Values represent mean ± SEM (n=4).
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Figure S2.2 Relative gene expression of cells transduced through biomaterial-mediated
delivery and challenged with IL-1α for the EF1α-IL1Ra group. Fold changes were determined
relative to 0 hour controls. Error bars represent means of fold change ± SEM (n=6). Asterisks
represent significant relative to NT control group (p < 0.05). (A) Ccl2 gene expression. (B) Il6
gene expression. (C) Il1rn gene expression.
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2.7 Conclusions
We engineered a synthetic transcription system based on NF-κB signaling that can
attenuate the effects of the inflammatory cytokine IL-1α in a self-regulating manner. This system
responds in a time- and dose-dependent manner to rapidly produce therapeutic levels of IL-1Ra.
The use of lentiviral gene therapy allows this system to be utilized through different transduction
methods and in different cell types for a variety of applications. Broadly, this approach may be
applicable in developing autoregulated biologic systems for tissue engineering and drug delivery
in a range of disease applications.
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Chapter 3: A Synthetic Mechanogenetic
Gene Circuit for Autonomous Drug Delivery
in Engineered Tissues
Partially adapted from: Nims, R. J.*, Pferdehirt, L.*, Ho, N. B., Savadipour, A., Lorentz,
J., Sohi, A., Kassab, J., Ross, A. K., O’Conor, C. J., Leidtke, W. B., Zhang, B., McNulty, A. L.,
& Guilak, F. (2021). A synthetic mechanogenetic gene circuit for autonomous drug delivery in
engineered tissues. Science Advances, 7, eabd9858.

3.1 Abstract
Mechanobiologic signals regulate cellular responses under physiologic and pathologic
conditions. Using synthetic biology and tissue engineering, we developed a mechanically
responsive bioartificial tissue that responds to mechanical loading to produce a preprogrammed
therapeutic biologic drug. By deconstructing the signaling networks induced by activation of the
mechanically sensitive ion channel transient receptor potential vanilloid 4 (TRPV4), we created
synthetic TRPV4 responsive genetic circuits in chondrocytes. We engineered these cells into
living tissues that respond to mechanical loading by producing the anti-inflammatory biologic
drug, interleukin-1 receptor antagonist. Chondrocyte TRPV4 is activated by osmotic loading and
not by direct cellular deformation, suggesting that tissue loading is transduced into an osmotic
signal that activates TRPV4. Either osmotic or mechanical loading of tissues transduced with
TRPV4 responsive circuits protected constructs from inflammatory degradation by interleukin1a. This synthetic mechanobiology approach was used to develop a mechanogenetic system to
enable long-term, autonomously regulated drug delivery driven by physiologically relevant
loading.
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3.2 Introduction
Smart biomaterials or bioartificial tissues that autonomously respond to biologic cues and
drive a therapeutic or restorative response are promising technologies for treating both chronic
and acute diseases (124). Mechanotherapeutics, in particular, are a rapidly growing class of smart
biomaterials that use mechanical signals or mechanical changes within diseased tissues to elicit a
therapeutic response (125-127) and ameliorate the defective cellular mechanical environment
(128-131). Current mechanotherapeutic technologies rely on exogenous protein drug delivery or
ultrasound stimulation, or on synthetic polymer implants that offer a finite lifespan for drug
delivery (132-134). Creating systems with cellular-scale resolution of mechanical forces that
offer long-term, feedback-controlled synthesis of biologic drugs could provide a completely new
approach for therapeutic delivery.
In contrast to synthetic polymers, biological tissues grow, adapt, and respond to
mechanobiologic signals through the use of specialized molecular components, such as
mechanically sensitive ion channels and receptors that transduce specific stimuli from the
physical environment (5, 6). In particular, mechanosensitive ion channels are sensitive to both
context and deformation mode, making them uniquely suited as mechanotherapeutic sensors
(135-137). The transient receptor potential (TRP) family is a class of selective ion channels
including some mechanically sensitive members, such as TRPA1, TRP vanilloid 1 (TRPV1), and
TRPV4 (138, 139). TRPV4 is activated by osmotic stress and plays an important role in the
mechanosensitivity of various tissues such as articular cartilage, uterus, and skin (7, 9-11, 140).
In cartilage, TRPV4 has been shown to regulate the anabolic biosynthesis of chondrocytes in
response to physiologic mechanical strain (141).
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Osteoarthritis is a chronic joint disease for which there are no available disease
modifying drugs, ultimately leading to a total joint replacement once the diseased and degraded
cartilage and surrounding joint tissues incapacitate a patient from pain and a loss of joint
function (142). Cartilage tissue engineering is a promising strategy to resurface damaged and
diseased articular cartilage with an engineered cartilage tissue construct as a means to reduce the
need for, or prolong the time before, a total joint replacement (56, 143). An ongoing challenge
in the field, however, is developing engineered cartilage constructs that withstand both the high
mechanical loads present within the articular joint and the chronic inflammation present within
an osteoarthritic joint (72, 144). For example, the knee cartilage of healthy individuals can
experience compressive strains of ~5 to 10% during moderate exercise, while individuals with a
history of joint injury or high body mass index, populations at risk for developing osteoarthritis,
can experience higher magnitudes of cartilage compression under similar loading (145-147). In
this regard, a bioartificial tissue that can synthesize biologic drugs in response to inflammation or
mechanical loading, either independently or concurrently, could greatly enhance the therapeutic
potential of an engineered tissue replacement.
In this study, we engineered a mechanically responsive bioartificial tissue construct for
therapeutic drug delivery by using the signaling pathways downstream of the
mechano/osmosensitive ion channel TRPV4 to drive synthetic mechanogenetic gene circuits
(Figure 3.1). To do this, we first establish that mechanical loading of tissue engineered cartilage
activates TRPV4 through fluctuations in the local osmotic environment and not direct
mechanical deformation of chondrocytes. We next deconstructed the gene regulatory networks
(GRNs) and signaling pathways evoked by TRPV4 activation and revealed the transient
activation of several mechanosensitive transcription factors. We engineered synthetic gene
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circuits to respond to mechanical TRPV4 activation for driving transgene production of an antiinflammatory molecule, interleukin-1 receptor antagonist (IL-1Ra). While IL-1Ra (drug name
anakinra) is approved as a therapy for rheumatoid arthritis and has successfully attenuated
osteoarthritis progression in preclinical models, clinical trials of IL-1Ra therapy patients with
established osteoarthritis have not shown efficacy, suggesting that controlled long-term delivery
may be necessary for disease modification (38, 41, 42). Here, we show that mechanical or
osmotic loading of implantable engineered cartilage tissue constructs induces an autonomous
mechanogenetic response and protects tissue constructs from inflammatory insult, suggesting a
modality for long-term in vivo drug delivery.
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Figure 3.1 Mechanogenetic transduction and therapeutic drug delivery approach. TRPV4 is an
osmotically sensitive cation channel in the cell membrane of chondrocytes, which can be
activated by mechanical loading secondary to mechano-osmotic coupling through the
extracellular matrix or pharmacologically with the agonist GSK101. TRPV4 can also be
inhibited with the antagonist GSK205. Upon TRPV4 activation, chondrocytes respond with
intracellular calcium signaling that initiates NF-kB signaling and upregulation of the PTGS2
gene. By lentivirally transducing synthetic mechanogenetic circuits that respond to either NFkB activation or PTGS2 upregulation into chondrocytes within an engineered cartilage tissue,
mechanically activated TRPV4 signaling was used to drive transgene production of either a
luciferase reporter or the therapeutic anti-inflammatory biologic IL-1Ra. GOI, gene of interest.

3.3 Materials and Methods
3.3.1 Tissue harvest, cell isolation, agarose gel casting, and culture
Full-thickness porcine articular chondrocytes were enzymatically isolated using
collagenase (Sigma-Aldrich) from the femurs of pigs obtained from a local abattoir (~30 kg; 12
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to 16 weeks old) postmortem in accordance with an exemption protocol by the Institutional
Animal Care and Use Committee. Filtered cells were mixed 1:1 with 4% molten type VII
agarose (Sigma-Aldrich) and the cell-agarose mixture was injected into a gel apparatus and
allowed to set at room temperature. Chondrocyte-laden disks were punched out yielding
engineered cartilage at a final concentration of 2% agarose and 15 to 20 million cells/mL. All
constructs were given 2 to 3 days to equilibrate, and media were changed three times per week
during chondrogenic culture using a base medium that consisted of Dulbecco’s modified Eagle’s
medium (DMEM) High Glucose (Gibco) supplemented with 10% fetal bovine serum (FBS)
(Atlas), 0.1 mM nonessential amino acids (Gibco), 15 mM Hepes (Gibco), 40 µg/mL proline
(Sigma-Aldrich), 1x penicillin/streptomycin, and fungizone (Gibco), and fresh 50 µg/mL
ascorbyl-2-phosphate (Sigma-Aldrich) and maintained at 37°C and 5% CO2 (12).

3.3.2 Chondrocyte mechanical and pharmacologic stimulation
Confocal imaging of mechanical compression
A custom mechanical compression device was used to compress agarose constructs while
simultaneously performing intracellular calcium imaging on a confocal microscope (Zeiss
LSM880) using fluo-4 AM and fura-red AM (ThermoFisher Scientific) based on the
manufacturer’s protocols. Opposing platens were controlled with stepper motors to apply 60
rounds of compressive loading (10%) after a 2% tare strain. Ratiometric calcium imaging
(Calcium Ratio = Intensityfluo-4/Intensityfura-red) was analyzed within each sample with ImageJ for
2.5 min before and for 2.5 min after the mechanical loading.
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High-throughput mechanical compression
A custom mechanical compression device was used for sinusoidal compression of 24individual tissue constructs simultaneously using a closed loop displacement-feedback system
(12). This system allows for compression at 37º C and 5% CO2.
Osmotic stimulation
For calcium imaging studies, osmotic loading media were prepared using Hanks’
balanced salt solution medium (Gibco). For mechanogenetic tissue culture studies, osmotic
loading media were prepared using DMEM supplemented with 1% culture medium supplement
containing recombinant human insulin, human transferrin, and sodium selenite (ITS+). These
media were titrated to hypoosmotic media by adding distilled water and measured with a
freezing-point osmometer (Osmette 2007; Precision Systems). For osmotic stimulation of
mechanogenetic samples, standard culture medium (containing 10% FBS) was replaced with isoosmotic (380 mOsm) ITS+ base medium, containing 1% ITS+ premix (Corning), 0.1 mM
nonessential amino acids, 15 mM Hepes, and 1x penicillin/streptomycin, 3 days before osmotic
loading to acclimate tissues.
Micropipette aspiration
Detailed methods for micropipette aspiration are described previously (148). Briefly,
glass micropipettes were drawn to a diameter of ~10 µm and coated with Sigmacote (SigmaAldrich) to prevent cell binding to the glass micropipette. The micropipette was brought in
contact with a cell, and a tare pressure of 10 Pa was applied for a period of 3 min. Increasing
step pressures were then applied in increments of 100 Pa for 3 min each until the cell was fully
aspirated. Laser scanning microscopy was used to measure cell deformation (DIC channel) and
[Ca2+]i throughout the experiment. Ratiometric calcium imaging, as described above, was
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performed to assess the mechanoresponse of chondrocytes to micropipette aspiration; however,
we found that the application of step increases in pressure to the cell surface using a micropipette
rarely initiated a Ca2+ transient.
Atomic force microscopy
Freshly isolated chondrocytes were plated on glass coverslips and incubated for 2 to 3
days. Before atomic force AFM compression, cells were incubated with 10 µM GSK205 or
DMSO (vehicle) and stained with intracellular calcium dye Fura-2 AM (Molecular Probes)
according to the manufacturer’s protocols. Cells were loaded to 400 nN using an AFM (Asylum
Research MFP-3D) with tipless cantilevers (k=6.2 N/m; MikroMasch) while simultaneously
recording intracellular calcium levels with an Olympus microscope and cycled with 340- and
380-nm light to produce a ratiometric output (Calcium Ratio = IntensityFura-2 @ 380 nm /
IntensityFura-2 @ 340 nm) for intracellular calcium levels which were analyzed with ImageJ (149).
Pharmacologic TRVP4 modulation
GSK1016790A (GSK101, Millipore-Sigma) was resuspended at final concentrations (1
to 10 nM) and matched with a DMSO (vehicle) control. GSK205 (manufactured at the Duke
Small Molecule Synthesis Facility) was used as a TRPV4-specific inhibitor and preincubated
with samples before analysis to allow diffusion within three-dimensional tissues and used at a
final concentration of 10 µM with appropriate DMSO (vehicle) controls.
FLIPR assay
After digestion and isolation, filtered chondrocytes were plated in a 96-well plate at
10,000 cells per well and left for 24 hours before stimulation on a fluorescent imaging plate
reader (FLIPR) by which individual wells were stimulated with either osmotic or GSK101containing medium. Cellular response in each well was measured via fluo-4 intracellular calcium
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dye using the Fluo-4 No-Wash Calcium Assay Kit (Molecular Probes) according to the
manufacturer’s directions. GSK205 was preincubated and added alongside stimulated and
unstimulated chondrocytes to directly assess the TRPV4-dependent response of osmotic and
pharmacologic stimulation.

3.3.3 Finite element modeling
Finite element models of cellular deformation were performed using the FEBio
(www.febio.org) finite element software package (version 2.6.4). Models were run using a neoHookean elastic material for the cell and membrane compartments of the cell (150). All model
geometries use axisymmetry boundary conditions to reduce the model size. Osmotic loading
was assessed using a Donnan osmotic loading material with parameters taken from the van’t
Hoff relation for chondrocytes under osmotic loading and loading chondrocytes with a -60
mOsm osmotic medium shift. Models for micropipette aspiration were run assuming a cell
modulus of 1 kPa and Poisson’s ratio of 0.4 while imposing a pressure of -200 Pa to the cell
(148). Models of single-cell direct deformational loading (AFM) were performed by simulating
an elastic sphere being compressed to 13% of its original height. FEBio testing suites were used
to validate the shell, contact, and neo-Hookean code features, and the Donnan model was
validated against the van’t Hoff equation.

3.3.4 Microarray collection and analysis
After a 14-day preculture, engineered cartilage constructs (Æ4 mm ´ 2.25 mm) were
stimulated under 10% compressive loading or 1 nM GSK101 for 3 hours/day for 3 days. An
unstimulated control (free swelling) was cultured under identical conditions. Immediately after
stimulation, constructs were washed and then fed with culture medium. Constructs were snap
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frozen in liquid N2 at 0, 3, 6, 12, 20, 24, and 72 hours after initial stimulation. Total RNA was
extracted from the constructs using a pestle homogenizer and the Norgen Biotek RNA/protein
purification plus kit. RNA quantity and quality were assessed with NanoDrop (Thermo Fisher
Scientific) and the Agilent Bioanalyzer. Total RNA was processed using the Ambion WT
expression labeling kit and the Porcine Gene 1.0 ST Array (Affymetrix). The raw signal of
arrays was induced into R environment and quantile-normalized by using “affy” and “oligo”
package. The significant DEGs were identified and analyzed by using one regression model in R
with package “genefilter”, “limma”, “RUV”, “splines”, “gplots” and “plotly” at an adjusted pvalue cutoff of 0.05. Then, the DEGs were imported into Ingenuity Pathway Analysis (IPA) to
perform the pathway enrichment analysis. The DEG heatmap was plotted by using “gplots” in R.
The microarray data generated and analyzed are publicly available (GEO Accession:
GSE165027).

3.3.5 Mechanogenetic circuit design, development, viral development, and
culture
We developed two lentiviral systems consisting of an NF-κB inducible promoter
upstream of either IL-1Ra (NFKBr-IL1Ra) or luciferase (NFKBr-Luc). Therefore, upon NF-κB
signaling, either IL-1Ra (NFKBr -IL1Ra) or luciferase (NFKBr -Luc) is expressed as a measure
of mechanogenetic circuit activation. In addition, we developed two lentiviral systems consisting
of a synthetic human PTGS2 promoter upstream of either IL-1Ra (PTGS2r-IL1Ra) or luciferase
(PTGS2r-Luc). Therefore, when PTGS2 is activated either IL-1Ra or luciferase is expressed.
NFκBr circuit design
A synthetic NF-κB inducible promoter was designed to incorporate multiple NF-κB
response elements as previously described (62). A synthetic promoter was developed containing
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five consensus sequences approximating the NF-κB canonical recognition motif based on genes
upregulated through inflammatory challenge: InfB1, Il6, Mcp1, Adamts5, and Cxcl10. A TATA
box derived from the minimal CMV promoter was cloned between the synthetic promoter and
downstream target genes, either murine Il1rn or firefly luciferase from the pGL3 basic plasmid
(Promega), and an NF-κB-negative regulatory element (NRE-5’-AATTCCTCTGA-3’) was
cloned upstream of the promoter to reduce background signal (62, 79, 151).
PTGS2r circuit design
A synthetic human PTGS2 promoter was obtained from SwitchGear Genomics and
cloned into the NFKBr-IL1Ra or NFKBr-Luc lentiviral transfer vectors in place of the NF-κB
inducible promoter. The NF-κB inducible promoter was excised using Eco RI and Psp XI
restriction enzymes and the PTGS2 promoter was inserted in its place using the Gibson
Assembly method to create the PTGS2r-IL1Ra and PTGS2r-Luc circuits (82).
Lentivirus production and chondrocyte transduction
Human embryonic kidney (HEK) 293T cells were co-transfected with second-generation
packaging plasmid psPAX2 (No. 12260; Addgene), the envelope plasmid pMD2.G (No. 12259;
Addgene), and the expression transfer vector by calcium phosphate precipitation to make
vesicular stomatitis virus glycoprotein pseudotyped lentivirus (85). The lentivirus was harvested
at 24- and 48-hours post-transfection and stored at -80℃ until use. The expression transfer
vectors include the NFKBr-IL1Ra, NFKBr-Luc, PTGS2r-IL1Ra, and PTGS2r-Luc plasmids. The
functional titer of the virus was determined with quantitative real-time polymerase chain reaction
to determine the number of lentiviral DNA copies integrated into the genome of transduced
HeLa cells (85). For chondrocyte transductions, freshly isolated chondrocytes were plated in
monolayer at a density of 62,000 cells/cm2 and incubated overnight in standard 10% FBS
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medium. The following day, virus was thawed on ice and diluted in 10% FBS medium to obtain
the desired number of viral particles to achieve a multiplicity of infection of 3 (62). Polybrene
was added to a concentration of 4 µg/mL to aid in transduction. The conditioned medium of the
chondrocytes was aspirated and replaced with the virus-containing medium, and cells were
incubated for an additional 24 hours before aspirating the viral medium and replacing with
standard 10% FBS medium. Five days later, cells were trypsinized, counted, and cast in agarose
as described above to prepare mechanogenetic constructs at 15 million cells/mL in 2% agarose
gel. Constructs were cultured as described above until testing. Viral titers measured by qPCR
revealed that ~95% of chondrocytes were transduced with this method.
Mechanogenetic circuit testing outcome measures
Assessing mechanogenetic tissue construct activation in IL-1Ra producing constructs was
measured with an enzyme linked immunosorbent assay (ELISA) for mouse IL-1Ra (R&D
Systems) according to the manufacturer’s protocols. Data are reported as the amount of IL-1Ra
produced per construct (in nanogram) normalized by the tissue wet weight mass of the construct
(in grams). Luciferase-based mechanogenetic protection was assessed using a bioluminescent
imaging reader (Cytation5, BioTek) at 37 °C and 5% CO2 and cultured in phenol-red free highglucose DMEM supplemented with 1% ITS+, 2 mM GlutaMAX, 1 mM sodium pyruvate, 15
mM Hepes, 40 µg/mL proline, 1x-penicillin/streptomycin, and 1 µM luciferin. Before
stimulation, samples were imaged under free swelling conditions for ~1 day to get a baseline
bioluminescent level (Fo). For mechanical loading studies, constructs were then mechanically
loaded or similarly transferred for a free swelling control and then returned to the bioluminescent
imaging. For GSK101 pharmacologic studies, the bioluminescent medium (above) was
supplemented with GSK101 or DMSO (vehicle control) to the appropriate dose (1 to 10 nM) and
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simultaneously imaged for 3 hours, before washing and replacing with standard bioluminescent
medium. Pre-stimulation baseline was normalized from post-stimulation bioluminescent readings
(F) to yield F/Fo as the outcome measure.

3.3.6 Coculture studies
To assess mechanogenetic anti-inflammatory protection, NFKBr-IL1Ra constructs were
cultured with a porcine cartilage explant for 72 hours in the presence of 0 or 0.1 ng/mL porcine
IL-1α. Porcine cartilage explants (3 mm diameter) were cored from condyle cartilage and the
subchondral bone was removed, leaving a cartilage explant ~1-2 mm thick including the
superficial, middle, and deep zones and cultured in iso-osmotic ITS+ medium (380 mOsm,
formulation listed above) base medium until experimentation. Mechanical loading was applied
daily with hypo-osmotic loading (3 hours/day) (180 mOsm) before returning to the iso-osmotic
medium (380 mOsm) containing the explant and IL-1α. Iso-osmotic controls were moved
similarly to an iso-osmotic medium (380 mOsm). Control, non anti-inflammatory
mechanogenetic tissue constructs, consisted of NFKBr-Luc tissues. Tissue S-GAG content in the
engineered tissue construct and medium were assessed with the 1,9-dimethylmethylene blue
assay (90). Tissue samples were digested with papain overnight (65 °C) to measure tissue SGAG using the DMB assay. Bulk S-GAG amount was normalized to tissue wet weight.
Constructs were fixed in neutral buffered formalin overnight before embedding in paraffin and
sectioning to 7 µm. Histological slices were stained with safranin-O to examine S-GAG
distribution and abundance.
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3.3.7 Statistical analysis
Data were analyzed with one-way analysis of variance (ANOVA) or two-way ANOVA
(a=0.05) where appropriate using R software (www.r-project.org). For two-way ANOVAs,
individual groups were compared using a Tukey post-hoc analysis when the interaction of factors
was also significant. Correlation trends of strain magnitude to IL-1Ra production was analyzed
in R using linear model analysis. Temporal bioluminescent data were analyzed using a twotailed t-test comparison between the groups at each analyzed time point.

3.4 Results
3.4.1 The mechano-osmotic response of chondrocytes to loading is regulated
by TRPV4
To deconstruct the mechanotransduction pathways through which chondrocytes perceive
mechanical loading, we encapsulated freshly isolated primary porcine chondrocytes within an
agarose hydrogel scaffold to engineer cartilage tissue constructs. Constructs were cultured for 3
weeks to allow extracellular matrix deposition before applying compressive loading and
simultaneously imaging the intracellular calcium levels of the chondrocytes. This engineered
cartilage system allows mechanical signals to be transduced to chondrocytes through de novo
synthesized extracellular matrix in a manner similar to in vivo mechanotransduction (57, 152,
153). Chondrocytes express an array of mechanically-sensitive ion channels and receptors,
including TRPV4, PIEZO1 and PIEZO2, integrins, and primary cilia (154), so we investigated
the mechanism by which physiologic magnitudes of dynamic mechanical loading are transduced
by chondrocytes. Dynamic mechanical loading of engineered cartilage constructs immediately
provoked a 108% increase of intracellular calcium response compared with unloaded tissues
(Figure 3.2A) (p=0.022). Inhibiting TRPV4 activity using the TRPV4 antagonist GSK205
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suppressed calcium signaling (p=0.03, GSK205 supplementation reduced signaling by ~47%),
implicating TRPV4 as a critical component in transducing compressive loading in chondrocytes.
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Figure 3.2 Mechanical responsiveness of chondrocytes is mediated by hypo-osmotic stimulation of
TRPV4. (A) Set up of real-time cellular imaging of mechanical loading. Loading chondrocytes
within engineered cartilage increases intracellular calcium compared to free swelling. Arrows
indicate immediately responsive cells. Scale bar, 50 µm. The number of cells exhibiting intracellular
calcium signaling increased by 108% after loading, and GSK205 suppressed cellular calcium
signaling (n=4-5 constructs per treatment). TE, tissue engineered. (B) Isolated chondrocytes are
sensitive to osmotic perturbations and exhibit intracellular calcium increases in response to hypoosmotic stimulation (n=15-20 cells per group, calcium response is normalized to calcium levels at
354 mOsm). (C) Chondrocyte responsiveness to hypo-osmotic stimulation is inhibited with GSK205
(n=6 per treatment). (D) Chondrocytes are not sensitive to direct membrane stretch applied under
iso-osmotic, iso-volumetric conditions with micropipette aspiration (n=38, scale bar, 10 µm). RFU,
relative fluorescence units. (E) Direct cellular compression under a 400 nN load with an AFM
induces intracellular calcium signaling. Scale bar, 10 µm. (F) GSK205 does not modulate calcium
response of chondrocytes to AFM loading. (G) TRPV4 inhibition alters neither the intensity of
calcium responsiveness nor the population response to AFM compression (n=23-30 cells per group).
Data are presented as mean ± SEM.
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While the molecular structure of TRPV4 has recently been reported (155), the
mechanisms underlying TRPV4 activation are complex and may involve direct mechanical
activation or osmotic activation secondary to mechanical loading of the charged and hydrated
extracellular matrix (9, 138, 156, 157). To determine the physical mechanisms responsible for
TRPV4 activation secondary to tissue compression, we subjected freshly isolated chondrocytes
to osmotic loading, direct membrane stretch, and direct single-cell mechanical compression
(Figure 3.2B, 3.2D, 3.2E). To better understand the biophysical mechanisms underlying TRPV4
activation, we determined the mechanical state of the chondrocyte membrane in each of these
cases using finite element modeling (FEBio; www.febio.org) (158). Chondrocytes rapidly
responded to physiologically relevant changes in medium osmolarity through intracellular
calcium signals (Figure 3.2B). Calcium signaling was highly sensitive to modest changes in
osmolarity, with an osmolarity shift of -20 mOsm inducing intracellular signaling in 35% of
chondrocytes and -80 mOsm inducing activation of 100% of chondrocytes. Inhibition of TRPV4
with GSK205 suppressed calcium signaling caused by hypo-osmotic loading (Figure 3.2C) or by
the TRPV4 agonist GSK1016790A (GSK101) (Figure S3.1). Chondrocyte volumetric analysis
and finite element modeling of hypo-osmotic stress showed that a change of -60 mOsm,
sufficient to induce signaling in nearly all chondrocytes, increased cellular volume by 13% and
induced an apparent first principle strain of 0.04 homogeneously throughout the membrane
(Figure S3.2 and S3.3). To investigate the role of direct membrane stretch in TRPV4 activation
in the absence of osmotic fluctuations, we used micropipette aspiration of individual
chondrocytes to apply controlled deformation of the cell membrane (Figure 3.2D).
Unexpectedly, micropipette aspiration did not provoke any calcium signaling response in
chondrocytes, with only 1 of 38 tested cells responding with increased intracellular calcium,
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indicating that membrane deformation per se was not the primary signal responsible for
mechanical activation. Finite element simulations of the micropipette experiment showed the
presence of heterogenous apparent membrane strains in aspirated chondrocytes, with a first
principle strain reaching 0.31 around the micropipette mouth and ~0.04 within the micropipette
under an applied pressure of 100 Pa (Figure S3.3E to S3.3H). To test whether calcium signaling
in response to direct mechanical compression of chondrocytes is mediated by TRPV4, we loaded
isolated chondrocytes with an atomic force microscope (AFM) to 400 nN (149). Only at high,
pathologic levels of mechanical compression did direct chondrocyte compression provoke
intracellular calcium signaling, but this response was not inhibited by GSK205 (Figure 3.2E to
3.2G). Finite element modeling predicted high membrane strains with an ultimate apparent first
principle membrane strain of 2.27 around the cell at the peak cell deformations necessary to elicit
intracellular calcium signaling (Figure S3.3I to 3.3L). Together, these findings suggest that
activation of TRPV4 in chondrocytes in situ may not result directly from cellular strain but rather
from osmotic fluctuations induced from the deformation of a chondrocyte’s osmotically active
environment. Because of the complex relationship between deformational compressive loading
of engineered cartilage and osmotic loading, we will hereafter refer to deformational
compressive loading (concomitant with the secondary osmotic effects) as mechanical loading
and direct changes in the medium osmolarity as osmotic loading.

3.4.2 TRVP4 activation in chondrocytes induces transient anabolic and
inflammatory signaling networks
We next sought to understand the time course of specific downstream signaling pathways
and GRNs regulated by mechanical activation of TRPV4 using microarray analysis. Because
TRPV4 is a multimodal channel, downstream signaling is likely dependent on the activation
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mode, as well as cell and tissue type. For these studies, primary porcine chondrocytes were cast
in agarose to create engineered cartilage constructs, and subjected to either compressive
mechanical loading [10% sinusoidal peak-to-peak strain at 1 Hz for 3 h as described in (12)] or
pharmacologic stimulation with the TRPV4 agonist GSK101 (1 nM for 3 hours), or left unloaded
(free-swelling controls), and measured the transcriptional activity at 0, 3, 12, and 20 hours
following an initial round of stimulation and then at 24 and 72 hours after additional daily bouts
of mechanical loading or GSK101 (n=3 per condition per time point) (Figure 3.3A). In the first
20 hours following initial stimulation there were 43 transcripts upregulated under both
mechanical loading and pharmacologic stimulation (Figure 3.3B) compared to unloaded controls.
Up-regulation of these targets was immediate and subsided quickly, with transcript levels
returning to baseline 12 to 20 hours after activation. In particular, the adenosine 3’,5’monophosphate (cAMP)/Ca2+-responsive transcription factors C-JUN, FOS, NR4A2, and EGR2
(Figure 3.3C) were all up-regulated in response to TRPV4-mediated calcium signaling.
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Figure 3.3 Transcriptomic profile induced by TRPV4 activation. (A) Engineered cartilage tissue constructs
were made from isolated primary porcine chondrocytes cast into agarose hydrogels. Tissue constructs were
subjected to deformational mechanical loading or GSK101 pharmacologic stimulation (red, 3 hours/round)
following the indicated time course and cartilage construct harvest (arrows). (B) 41 genes were differentially
upregulated in response to TRPV4 activation and levels returned back to baseline after 12-20 hours post
loading (n=3/treatment/timepoint). (C) cAMP and calcium-responsive transcription factors were immediately
and highly regulated by both mechanical loading and GSK101 stimulation (red arrows indicate loading
removal). (D) Pathway analysis based on transcription activity suggests that both inflammatory and anabolic
pathways are strongly regulated by TRPV4 activation. (E) Analysis of gene target response after all bouts of
mechanical loading and of GSK101 stimulation produces a list of distinctly TRPV4 sensitive genes. (F)
TRPV4 responsive targets from the microarray analysis were confirmed by qPCR (n=2-3), and a one-tailed ttest was used to test whether loaded or GSK101 groups were significantly upregulated with treatment.
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We then used Ingenuity Pathway Analysis to identify candidate targets for a synthetic
gene circuit that would be responsive to TRPV4 activation. The most enhanced pathway was
“the role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis,” with members
including transcription factors (FOS and NFATC2), extracellular matrix synthesis gene (SPP1),
growth factors (BMP2 and BMP6), and TNFSF11, the decoy ligand for RANKL, all of which
were upregulated by TRPV4 activation (Figure 3.3D). The inflammatory pathways “IL-6
signaling” and “B cell activating factor signaling” were also up-regulated by TRPV4 activation,
as were the established chondrocyte anabolic pathways “TGF-b signaling” and “glucocorticoid
signaling.” Because of the rapid response times of nearly all of the differentially expressed genes
(DEGs), we further analyzed which genes responded to repeated bouts of TRPV4 stimulation at
all three time points (0, 24, and 72 hours). There were 41 transcripts repeatedly responsive to
mechanical loading and 112 transcripts repeatedly responsive to GSK101 supplementation. Of
these targets, 15 genes were commonly responsive to both mechanical loading and
pharmacologic activation of TRPV4 (Figure 3.3E) and include both pathways associated with
inflammation (PTGS2, SPP1, and ATF3) and cartilage development and homeostasis (BMP2,
DUSP5, NFATC2, and INHBA). The most robustly regulated and cartilage-relevant genes were
confirmed by quantitative polymerase chain reaction (qPCR) (Figure 3.3F). Together, these data
suggest that the TRPV4 mechanotransduction pathway involves activation of a rapidly resolving
inflammatory pathway as part of the broad anabolic response to physiologic mechanical loading.

3.4.3 Synthetic mechanogenetic circuits respond to TRVP4 activation to drive
transgene expression
TRPV4 activation in response to mechanical loading upregulates a diverse group of
targeted genes. On the basis of the TRPV4-activated signaling pathway (Figure S3.4), we
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identified activation of the nuclear factor kappa-light-chain enhancer of activated B cells (NFkB) pathway and upregulation of the prostaglandin-endoperoxide synthase 2 (PTGS2) gene as
two distinct avenues to construct TRPV4-responsive synthetic mechanogenetic gene circuits.
Targeting the NF-kB signaling pathway and regulation of the PTGS2 promoter (Figure 3.1), we
developed two lentiviral systems that would either (i) respond to NF-kB activity by linking five
synthetic NF-kB binding motifs and a NF-kB negative regulatory element (62) with the
cytomegalovirus (CMV) enhancer to drive transgene expression of either the therapeutic antiinflammatory biologic IL-1Ra or a luciferase reporter (henceforth referred to as NFKBr-IL1Ra
and NFKBr-Luc, respectively) or (ii) respond to PTGS2 regulation by using a synthetic human
PTGS2 promoter to drive either IL-1Ra or luciferase expression (henceforth referred to as
PTGS2r-IL1Ra and PTGS2r-Luc, respectively). We then created mechanogenetically sensitive
engineered cartilage tissue constructs by lentivirally transducing primary porcine chondrocytes
with a mechanogenetic circuit and seeding these cells into an agarose hydrogel to produce
synthetically programmed cartilage constructs (Figure 3.4A).
To test whether mechanogenetic tissues actively respond to mechanical stimulation for
transgene production, we first applied compressive mechanical loading to NFKBr-IL1Ra
transduced mechanogenetic cartilage constructs, which showed a 38% increase in IL-1Ra
production (p=0.006) with mechanical loading (Figure 3.4B) compared to free swelling controls.
To establish whether this response was dependent on TRPV4, we antagonized TRPV4 with
GSK205 and observed a significant attenuation of NFKBr-IL1Ra circuit activity (Figure 3.4B),
demonstrating that the mechanogenetic circuit responded to both mechanical loading (p<0.001)
and TRPV4 antagonism (p<0.001). GSK205 also reduced circuit activation in unloaded tissues,
suggesting TRPV4 activation in chondrocytes may not be entirely dependent on mechanical
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loading. To further assess the specificity of TRPV4 regulation in mechanogenetic cartilage
constructs, we applied direct hypo-osmotic loading and pharmacologic GSK101 stimulation to
NFKBr-IL1Ra tissues. A step change to hypo-osmotic medium (-200 mOsm change) activated
the NFKBr-IL1Ra mechanogenetic circuit (Figure 3.4C) (p=0.019) compared with an isoosmotic medium change (0 mOsm change). In addition, daily pharmacologic activation of
TRPV4 with 1 nM GSK101 for 3 hours/day over the course of 5 days activated the NFKBrIL1Ra circuit compared to dimethyl sulfoxide (DMSO) controls (Figure 3.4D) (p<0.001).
Engineered cartilage constructs responded repeatedly and reproducibly to the daily GSK101
stimulation (Figure S3.5), demonstrating the role of TRPV4 in activating the mechanogenetic
NFKBr circuits and confirming that a cell-based mechanotherapy can offer prolonged and
unabating biologic drug delivery. Testing of conditioned medium from constructs seeded with
either non-transduced chondrocytes or chondrocytes transduced with a green fluorescent protein
(GFP) expression cassette found that only cells transduced with a mechanogenetic IL-1Ra
producing circuits were capable of synthesizing detectable levels of IL-1Ra.
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Figure 3.4 Mechanogenetic constructs respond to TRPV4 activation. (A) Mechanical loading, osmotic
loading, or GSK101 stimulation was applied to mechanogenetic tissues; GSK205 inhibit TRPV4
activation. (B) NFKBr-IL1Ra tissues respond to mechanical loading through increased IL-1Ra
(p<0.001). IL-1Ra is reduced with GSK205 supplementation (p<0.001, n=6 per treatment). (C)
Exposure of NFKBr-IL1Ra to hypo-osmotic medium produces more IL-1Ra than iso-osmotic medium
exposure (p=0.019, n=7 per group). (D) NFKBr-IL1Ra tissues exposed to GSK101 stimulation produce
more IL-1Ra than vehicle controls (p<0.001, n=20 per group). (E) Mechanical loading of NFKBr-Luc
tissues quickly activates and inactivates circuits, while PTGS2r-Luc tissues take longer to reach the peak
and return to baseline (gray line denotes p<0.05 between free-swelling and load, n=3-6 per group). (F)
NFKBr-IL1Ra tissue response to loading after 24 and 72 hours, indicating differential expression in first
24 hours. (G) PTGS2r-IL1Ra tissues respond to loading through 72 hours. (H) NFKBr-Luc tissues
respond dose-dependently to TRPV4 activation via GSK101 through 9 nM GSK101 (p<0.05, n=2-4 per
group). (I) PTGS2r-Luc tissues are sensitive to GSK101 up to 6 nM (p<0.05, n=2-4 per group). (J)
NFKBr-IL1Ra tissue response is dose-dependent to compressive mechanical loading strain from 0 to 15
% (p<0.001, n=5-12). Data are presented as mean ± SEM.
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To determine the sensitivity and temporal response kinetics of our engineered tissue
system, factors critical for the effectiveness of any drug delivery system, we used
bioluminescence imaging of NFKBr-Luc or PTGS2r-Luc constructs to determine the dynamic
response of mechanogenetic cartilage constructs to TRPV4 activation by mechanical loading or
GSK101 pharmacologic stimulation. In response to 10% compressive mechanical loading
(Figure 3.4E), NFKBr-Luc tissue constructs rapidly peaked (1.8 ± 0.2 hours to peak) and
decayed (T50% decay time = 3.4 ± 0.4 hours) with loaded samples returning to baseline 4 hours
after loading. PTGS2r-Luc tissue constructs were slower to activate (21.7 ± 2.7 hours to peak)
and remained activated for a longer duration (T50% decay time = 22.3 ± 1.7 hours). This
differential in time delivery kinetics may provide strategies by which mechanical loading inputs
can drive both short- and long-term drug production by judicious mechanogenetic circuit
selection in a single therapeutic tissue construct. To test whether IL-1Ra production followed
similar differential production rates, we mechanically loaded NFKBr-IL1Ra and PTGS2r-IL1Ra
tissue constructs and measured protein levels of IL-1Ra released in the medium. One round of
mechanical loading activated NFKBr-IL1Ra tissues by 24 hours, as measured by an increase in
IL-1Ra produced by loaded tissue constructs compared to unloaded constructs (an increase in IL1Ra production of 372 ± 265 ng/g, mean ± 1 SD). This differential in IL-1Ra concentration
between loaded and free swelling constructs remained unchanged by 72 hours (loaded tissues
produced 220 ± 223 ng/g more than unloaded constructs at this time point), indicating that
loaded NFKBr-tissues were not continually activated and resumed baseline activity levels after
24 hours (Figure 3.4F). Conversely, in a preliminary experiment, a single round of mechanical
loading did not differentially activate PTGS2r-IL1Ra in the 24 hours after loading (Figure S3.6).
Informed by the bioluminescent imaging, we measured conditioned medium of PTGS2r-IL1Ra
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tissues 48 and 72 hours after a single round of mechanical loading, however, and found that
tissues produced more IL-1Ra after 48 hours compared to free swelling tissues (difference in
means of 21 ng/g) and that the IL-1Ra difference between loaded and free swelling tissues
continued to increase by 72 hours (difference in means of 61 ng/g). This increased effect size
confirmed that mechanically loaded PTGS2r tissue constructs remained activated up to 72 hours
after loading and demonstrated a longer acting mechanogenetic response in the PTGS2r system
(Figure 3.4G). Based on the bioluminescent imaging results, we did not measure IL-1Ra levels
past 72 hours. These results show that complex drug delivery strategies can be programmed into
a single mechanogenetic tissue constructs to produce multiple modes and timescales of
therapeutic or regenerative biologic drug delivery.
For insight into the dose-response relationship and sensitivity of the mechanogenetic
gene circuits, we imaged NFKBr-Luc and PTGS2r-Luc bioluminescence in response to different
doses of GSK101. Temporal imaging revealed that GSK101 stimulation produced similar rise
and decay kinetics as TRPV4 activation from mechanical loading (Figure 3.4E) in NFKBr-Luc
(Figure 3.4H) and PTGS2r-Luc (Figure 3.4I) cartilage tissue constructs compared to
unstimulated controls. Both mechanogenetic tissue constructs displayed a clear dose-dependent
activation from GSK101 stimulation as demonstrated by the area under the curve (AUC).
NFKBr-Luc tissue constructs were responsive from 1 to 9 nM GSK101, whereas PTGSr-Luc
tissue constructs plateaued in response at 6 nM GSK101. On the basis of this pharmacologic
sensitivity, we hypothesized that mechanogenetic constructs would be increasingly activated by
higher mechanical loading strains through increased osmotic stimulation (Figure 3.2B). As
NFKBr-Luc tissues demonstrated the most pronounced GSK101 dose-dependent response, we
applied dynamic compressive strain amplitudes from 0 to 15% to NFKBr-IL1Ra tissue
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constructs to span the range of physiologic strains expected for articular cartilage in vivo (159).
We measured elevated production of IL-1Ra with increasing compressive strains (Figure 3.4J)
(slope = 8 ± 2 ng/g IL-1Ra per %strain, p<0.001), demonstrating that drug production is directly
responsive to the magnitude of mechanical loading in our mechanogenetic engineered tissues.

3.4.4 Mechanogenetic engineered cartilage activation protects cartilage tissues
from IL-1⍺-induced inflammation-driven degradation
The long-term success of engineered cartilage implants depends on the ability of implants
to withstand the extreme loading and inflammatory stresses within an injured or osteoarthritic
joint (109). We hypothesized that TRPV4 activation would activate mechanogenetic tissue
constructs to produce therapeutic levels of IL-1Ra and protect engineered cartilage constructs
and the surrounding joint from destructive inflammatory cytokines. As our mechanogenetic
circuits rely on signaling pathways that overlap with the cellular inflammatory response, we
examined the dose-response of IL-1Ra production in response to the inflammatory cytokine IL1a (Figure 3.5A and 3.5C). NFKBr-IL1Ra mechanogenetic constructs responded to exogenous
IL-1a supplementation following a dose-dependent characteristic, consistent with findings of IL1-induced NF-kB signaling in chondrocytes (Figure 3.5B) (101). This dose-dependent response
to IL-1a was present up to 10 ng/mL and offered prolonged and robust production of IL-1Ra,
promoting the notion that cell-based tissues may offer a more sustained ability to produce
therapeutic biomolecules relative to traditional acellular approaches (Figure S3.7). Mechanical
loading further enhanced IL-1Ra production in the presence of IL-1a, demonstrating that even in
the presence of high levels of inflammation, mechanical loading further potentiates NF-kB
signaling (Figure S3.8). Mechanogenetic PTGS2r-IL1Ra and PTGS2r-Luc constructs
demonstrated no sensitivity to IL-1a (Figure 3.5D and 3.5E). In contrast to NFKBr tissue
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constructs, the selective sensitivity to TRPV4 activation and not to IL-1a in PTGS2r tissue
constructs suggests that this system is distinctively sensitive to mechano- or osmo-activation of
TRPV4. This distinction was further demonstrated in tissues exposed to both IL-1a
inflammation and osmotic loading, wherein only loading played a significant influence (Figure
S3.9) (p=0.0002 for loading and p=0.14 for inflammation).
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Figure 3.5 Activation of TRVP4 via osmotic loading of mechanogenetic constructs protects against IL1a. (A) Inflammatory response of NFKBr-IL1Ra constructs under IL-1a supplementation. (B) NFKBrIL1Ra tissues produce IL-1Ra in response to IL-1a (n=3, p<0.001). (C) Inflammatory response of
PTGS2r-IL1Ra tissues under IL-1a supplementation. (D) PTGS2r-IL1Ra tissues do not respond to IL1a (n=5). (E) PTGS2r-Luc tissues that are not altered by IL-1a are modulated by chronic GSK101 (n=2
per condition, arrow indicates stimulation). (F) Osmo-inflammatory response of NFKBr-Luc tissues
using osmotic loading (3 hours/day) and IL-1a (0 or 0.1 ng/mL) applied to NFKBr-Luc tissues. (G)
NFKBr-Luc tissues do not produce IL-1Ra (n=7). n.d., no difference. (H) NFKBr-Luc tissues lost SGAG in the presence of IL-1a (n=5 per group). (I) Histological reduction of safranin-O staining with
IL-1a supplementation. (J) Osmo-inflammatory response of NFKBr-IL1Ra tissues using osmotic
loading (3 hours/day) and IL-1a (0 or 0.1 ng/mL). (K) IL-1Ra was increased with inflammation and
osmotic loading (n=7, p<0.001). (L) S-GAG content in NFKBr-IL1Ra tissues with IL-1a
supplementation (0 or 0.1 ng/mL) and/or osmotic loading (different letters denote significant
differences, p<0.05, n=5). (M) NFKBr-IL1Ra tissues displayed similar safranin-O staining without IL1a supplementation, while IL-1a supplementation reduced safranin-O staining in iso-osmotic tissues but
not hypo-osmotic tissues. Data are presented as mean ± SEM.
To test whether TRPV4 activation induced IL-1Ra production would protect engineered
mechanogenetic tissue constructs against IL-1a, we cocultured mature, 21-day-old NFKBr tissue
constructs with articular cartilage explants in the presence of IL-1a inflammation and daily
hypo-osmotic loading (incubation in 180 mOsm medium for 3 hours/day; standard iso-osmotic
medium was maintained 380 mOsm) to model the inflammation and osmotic conditions present
in the cartilage of arthritic joints exposed to daily loading (Figure 3.5F and 3.5J). Using NFKBrLuc tissue constructs, which lack an anti-inflammatory response to TRPV4 or IL-1a activation
(Figure 3.5G), to simulate how conventional engineered cartilage constructs would respond in an
arthritic joint, constructs lost 45.6% of their sulfated glycosaminoglycan (S-GAG) content after
72 hours of IL-1a treatment (Figure 3.5H). S-GAGs are essential structural molecules that
impart mechanical integrity and strength in both engineered and native cartilage (160, 161).
Osmotic loading did not modulate this response and the substantial S-GAG loss was observable
histologically through diminished safranin-O staining throughout the tissue (Figure 3.5I). In the
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anti-inflammatory NFKBr-IL1Ra tissue constructs, osmotic loading in the presence of
inflammatory IL-1a increased IL-1Ra production by 93% over iso-osmotic control tissues also
cultured with IL-1a (Figure 3.5K). After 72 hours of treatment, IL-1a induced a 30.8% loss of
S-GAG in NFKBr-IL1Ra engineered cartilage constructs under iso-osmotic conditions, while
NFKBr-IL1Ra engineered cartilage that was incubated with IL-1a and osmotically loaded did
not significantly lose their S-GAG content (Figure 3.5L). Histologically, hypo-osmotic loading
NFKBr-IL1Ra engineered cartilage constructs maintained rich safranin-O staining of S-GAG
throughout the constructs, even in the presence of IL-1a (Figure 3.5M). Explant proteoglycan
levels were similar across all IL-1a treatment groups. Together, these data demonstrate
engineered mechanogenetic cartilage constructs that can produce anti-inflammatory IL-1Ra in
response to osmotic loading at levels sufficient for engineered tissue protection in a
proinflammatory environment mimicking the conditions present in an osteoarthritic joint (162).

3.5 Discussion
By combining synthetic biology and tissue engineering, we developed a novel class of
bioartificial material that is mechanogenetically sensitive. This system functions by redirecting
endogenous mechanically sensitive ion channels to drive synthetic genetic circuits for converting
mechanical inputs into programmed expression of a therapeutic transgene. By engineering these
cells into a functional tissue construct, this system provides the potential to repair or resurface
damaged cartilage, while providing site-specific, mechanically induced anti-cytokine therapy
against inflammation. Our approach is based on redirection of the downstream response to
activation of the TRPV4 ion channel – a critical mechanosensor in cartilage – to transduce
tissue-scale deformational mechanical loading via mechano-osmotic coupling in the charged
69

extracellular matrix. By deconstructing the GRNs activated by mechanically induced TRPV4,
we coopted chondrocyte-endogenous signaling machinery to drive synthetic circuits for the
production of therapeutic biologic drugs, using the anti-inflammatory drug IL-1Ra as a model
system for proof of concept. Our results also demonstrate the use of distinct signaling networks
for defining the specificity, timing, and dose-response for the expression of therapeutic biologic
drugs. We show that a single round of mechanical loading can induce short-term and long-term
responses based on the particular response of the synthetic circuit. While we targeted a treatment
for cartilage repair and osteoarthritis, pathologic mechanical loading and mechanosignaling play
a role in a broad range of acute and chronic diseases (5), suggesting a wide range of potential
therapeutic applications for mechanogenetically regulated cells or tissues requiring autonomous
cellular control systems.
While we developed mechanogenetic cartilage tissues based on TRPV4 activation here,
the use of other native, mechanically sensitive ion channels and receptors provide an attractive
source of mechanosensors that can be elicited to provoke synthetic outputs. Expanding
mechanogenetic approaches to additional mechanosensors with applications to other tissues
would increase the range of physical stimuli that synthetic circuits can respond to but requires an
in-depth understanding of both the mechanical contexts necessary for mechanosensor activation
and the resulting downstream signaling pathways. The fact that primary chondrocytes have an
array of different mechanically sensitive ion channels and receptors highlights the potential
opportunities to layer mechanosensor specific circuits and produce systems responsive to
different mechanical inputs that drive specific synthetic outputs. Our analysis here demonstrates
that physiologic (~10%, 1 Hz) mechanical loading of engineered cartilage is converted to a
mechano-osmotic signal that activates TRPV4, evidenced by the GSK205 inhibition of
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chondrocyte calcium signaling in response to mechanical loading or osmotic loading of
engineered cartilage but not to direct cellular deformation or membrane deformation. To this
end, we examined the mechanoresponsiveness of TRPV4 signaling and developed two genetic
circuits that respond to TRPV4 activation. Note that while endogenous PTGS2 regulation
subsided within 24 hours after mechanical loading, our PTGS2r-circuit remained activated up to
72 hours after loading, highlighting the role that endogenous mechanisms of gene regulation may
play, which are likely absent in our synthetic circuits. In this regard, the use of alternate
chondrocyte mechanosensors remains an attractive area of research. For instance, the lack of a
TRPV4-dependent response to high-strain compression via AFM loading is consistent with our
earlier finding that high, potentially injurious, cellular strains are transduced via the PIEZO
family of ion channels (149). The multimodal nature of TRPV4, and the TRP family more
generally (163), suggests that additional genetic circuits may be developed for alternate
activation modes by characterizing the downstream signaling networks that respond to
temperature or biochemical activation of the channel (164). Moreover, engineering novel
mechanosensors may open the opportunity for developing custom mechanical activation modes
and orthogonal downstream signaling in future mechanogenetic systems.
Our findings offer a detailed perspective of the complex cellular events initiated by
TRPV4 activation in chondrocytes. TRPV4 has been thought to play a largely anabolic role in
chondrocytes through enhanced synthesis of matrix molecules, S-GAG and collagen, and
upregulation of transforming growth factor-b (TGF-b3) (141), which is evident in our Gene
Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway hits of “TGF-b
signaling” and “glucocorticoid receptor signaling.” However, our findings also revealed the
presence of an acute, transiently resolving inflammatory response (pathways including
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“chondrocytes in RA,” “IL-6 signaling,” “April mediated signaling,” and “B cell activating
factor signaling”). These findings are particularly striking, as the physiologic levels of
mechanical loading applied here (10% compressive strain) are typically associated with
promoting chondrocyte anabolism (141), although our data are consistent with other reports
suggesting a proinflammatory role of TRPV4 (10, 165, 166). Together, the rapidly resolving
mechanical load induced inflammation in this context may be part of a natural cascade by which
a quickly decaying inflammatory response is characteristic of the regenerative, anabolic response
to mechanical loading (167, 168). In addition, increasing evidence suggests a potential role for
TRPV4 in mediating cellular and tissue inflammation, and studies of chondrocyte-specific
TRPV4 knockout mice report decreased severity of age-associated osteoarthritis (165). A loadinduced mechanism of chondrocyte inflammation through TRPV4 may provide a target for
osteoarthritis and other age-related diseases (10, 166, 169). The synthetic gene circuits developed
in this study highlight the opportunities to target different responses through downstream
pathway selection, namely, using an NFKBr circuit that is sensitive to IL-1a inflammation and a
PTGS2r circuit that is IL-1a insensitive. To this end, the pathologic conditions present in
osteoarthritis generate a milieu of inflammatory agents and factors that may, in addition to
TRPV4 activation, induce NF-kB signaling and PTGS2 regulation. Deep RNA-sequencing and
promotor engineering may provide a unique strategy for developing distinct, mechanoresponsive tools in an inflammatory, osteoarthritic joint. Additional therapeutic targets can also
be readily inhibited or activated as well; our laboratory has investigated using intracellular
inhibitors of NF-kB signaling and the soluble tumor necrosis factor receptor 1 as two alternative
options for inhibiting inflammation (59, 60).
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It is important to note some potential limitations, and future directions of this work. The
microarray analysis offers us a first-ever look at the unique transcriptomic landscape induced by
TRPV4 activation. To this end, while we used a positive strategy for the groups, i.e., comparing
mechanical loading to GSK101 TRPV4 activation, using a negative strategy, i.e., comparing the
mechanical loading response to mechanical loading in the presence of GSK205, may offer
alternative transcriptomic targets that are TRPV4 regulated. Similarly, with the advent of nextgeneration sequencing technologies, performing a transcriptomic analysis of the targets of
TRPV4 activation would likely increase target resolution, allowing more precise analysis of
GRNs induced by TRPV4 activation. Subsequent GRN analysis would permit identification and
discrimination between uniquely mechanically responsive and uniquely inflammation responsive
networks to enable our long-term goals toward identifying precise genetic regulatory events
driven by TRPV4 activation. Next-generation sequencing technologies may also reveal more
robust negatively regulated transcript targets of mechanical loading. Our data here only
uncovered several TRPV4 repressed targets, including collagen type VIII a1, suggesting that
more refined transcript resolution may be necessary to detect additional targets.
Using an engineered, living tissue construct for coordinated drug delivery obviates many
of the traditional limitations of “smart” materials, such as long-term integration, rapid dynamic
responses, and extended drug delivery without the need for replacement or reimplantation of the
drug delivery system. The modular approach of using cells as both the mechanosensors and the
effectors within engineered tissues allows for regulation and sensitivity at the mechanically
sensitive channel or receptor level, the signal network level, and the gene circuit level. While we
used the primary chondrocyte’s endogenous TRPV4 to drive our synthetic system, engineering
novel mechanically sensitive proteins may beckon a new frontier for coordinating inputs or
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driving receptor activation from novel and precise mechanical inputs. Together, this framework
for developing mechanically responsive engineered tissues is a novel approach for establishing
new autonomous therapeutics and drug delivery systems for mechanotherapeutics.
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3.6 Supplemental Figures
A

B

Figure S3.1 The TRPV4 agonist GSK101 stimulated intracellular calcium signaling immediately
after addition (top) and this signaling was potently abolished by the antagonist GSK205. (A)
Calcium signaling temporal dynamics of GSK101 activation. (B) Cumulative area-under-curve
(AUC) of the temporal data (p<0.001, n=6). RFU, relative fluorescence units.
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Figure S3.2 (A) Chondrocytes respond mechanically to changes in external osmolarity through a
wide range of osmolarities as measured by cell volume. (B) DIC images from isolated chondrocytes
undergoing osmotic loading. (C) Chondrocytes behave as ideal osmometers to changes osmolarity
as displayed on a Ponders plot which plots the normalized inverse osmolarity to the normalized cell
volume. The slope of the line (0.618) corresponds to the volume fraction that is osmotically active
within the chondrocyte (n=18 cells). (D) Figure in (C) converted to demonstrate non-linear influence
on apparent membrane strain resulting from osmotic fluctuations.
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Figure S3.3 Finite element models of cellular loading conditions: hypo-osmotic (A-D), micropipette
aspiration (E-H), and direct AFM loading (I-L). Models are run of an octant or quadrant cell by
employing appropriate axisymmetry boundary conditions. Simulation figures represent the original
geometry (A, E, I, center and membrane views), the pre-strained membrane state (B, F, J), and the
deformed states (C, G, K). For osmotic loading, a hypo-osmotic step of -60 mOsm was applied; for
micropipette aspiration 100 and 200 Pa pressures were applied; for AFM compression a 86% cell
deformation was applied. Scale bar depicts the first principle strain of the cell membrane. Plots (D,
H, L) represent the relationship between the applied deformation method and the first principal
membrane strain; the micropipette plotted relationship is shown for a membrane element residing
within the pipette and the AFM plotted relationship is shown for a membrane element residing along
the equatorial (peak) region of membrane strain.
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Figure S3.4 Network schematic for intracellular pathways stimulated by TRVP4 activation

Figure S3.5 Daily IL-1Ra production from NKFBr-IL1Ra mechanogenetic cartilage exposed to
either 1 nM GSK101 or vehicle (DMSO) constructs for 3 hour/day every 21 hours. Data are pooled
and presented cumulatively in Fig. 4C. n=4 per group/timepoint, * denotes p<0.05 between GSK101
and vehicle compared on each day.

Figure S3.6 Preliminary study of PTGS2r-IL1Ra response to mechanical loading after 24 hours
demonstrated no significant changes in IL-1Ra levels prior to 24 hours.
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Figure S3.7 NFKBr-IL1Ra engineered cartilage responds in a dose-dependent manner to IL-1a
robustly for extended durations (24 and 72 hours of exposure). Subset data from 24 hours exposure
depicted in Fig. 5A. Different letters depict significant differences in groups.

Figure S3.8 NFKBr-IL1Ra mechanogenetic tissues respond to both IL-1a and deformational
mechanical loading at 24 hours in a coculture system with graded IL-1a conditions (interaction n.s.,
p>0.05; *** denotes p<0.05). n.s., not significant.
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Figure S3.9 Iso-osmotic (control) and hypo-osmotic (loaded) treatments of PTGS2r-IL1Ra
constructs in the presence of 0 or 0.1 ng/mL IL-1a in a coculture setting responded only to the
loading factor produced a significant difference in IL-1Ra production response (p<0.001). Data are
presented as mean ± SEM.
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3.7 Conclusions
We engineered two mechanogenetic synthetic transcription systems that can sense
mechanical loading via TRPV4 activation and produce a biologic drug, IL-1Ra, in response. The
first mechanogenetic circuit relies on TRPV4 mediated NF-κB signaling (NFKBr circuit) while
the second mechanogenetic circuit is responsive to TRPV4 mediated upregulation of PTGS2
(PTSG2r circuit). Both circuits respond to both compressive mechanical stimuli, osmotic
loading, and pharmacologic activation of TRVP4 in a dose-dependent manner and can protect
engineered cartilage from IL-1α mediated degradation. The NFKBr circuit showed fast-acting
short term drug delivery and was also responsive to IL-1α, while the PTSG2r circuit showed
longer term drug delivery kinetics and was solely responsive to mechanical stimuli. This
mechanogenetic system is a novel approach for establishing new autonomous biologic drug
delivery systems for mechanotherapeutics.
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Chapter 4: Synthetic gene circuits for
preventing disruption of the circadian clock
due to inflammation
Partially adapted from: Pferdehirt, L.*, Damato, A.*, Dudek, M., Meng, Q.J., Herzog,
E.D., & Guilak, F. (2021). Synthetic gene circuits for preventing disruption of the circadian
clock due to inflammation. PNAS, in submission.

4.1 Abstract
The circadian clock regulates and maintains tissue homeostasis through temporal control
of tissue-specific clock-controlled genes. In articular cartilage, disruptions in the circadian clock
are linked to disruptions in anabolic pathways within chondrocytes, leading to a pro-catabolic
state and cartilage degradation. In the presence of inflammation, the cartilage circadian clock is
disrupted, which can further contribute to the pathogenesis of diseases such as osteoarthritis.
Using synthetic biology and tissue engineering, we developed genetically engineered cartilage
constructs from murine induced pluripotent stem cells (miPSCs) capable of preserving the
circadian clock in the presence of inflammation. We tested the ability of three cellular
engineering approaches to preserve circadian pace-making function. We found that circadian
rhythms arise following miPSC differentiation into tissue-engineered cartilage. Exposure of
tissue-engineered cartilage to inflammatory cytokine interleukin-1 (IL-1) disrupted circadian
rhythms and degraded cartilage extracellular matrix (ECM). In contrast, tumor necrosis factor-α
(TNF⍺) did not lead to circadian rhythm disruption or ECM loss. The three cell lines engineered
to resist inflammation (CRISPR/Cas9 gene-edited cells lacking a functional IL-1 receptor 1,
gene-edited cells programmed to produce IL-1 receptor antagonist (IL-1Ra) in response to
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inflammation, and cells transduced using lentivirus expressing a synthetic promoter activated by
inflammatory signaling to produce IL-1Ra) all showed similar protection against IL-1 induced
ECM degradation and loss of circadian rhythms. These synthetic gene circuits reveal a unique
approach to support daily rhythms in cartilage and provide a strategy for creating cell-based
therapies to preserve the functional circadian clock.

4.2 Introduction
The circadian clock is an internal genetic timing mechanism that exists in the brain and
nearly all cells in peripheral tissues, operating on a roughly 24-hour period (13-15). The
circadian clock coordinates tissue-specific physiology with different cycles such as light and
darkness, body temperature, and rest and activity (13). The core clock mechanism, comprised of
transcriptional activators Bmal1 and Clock and transcriptional repressors Per1/2 and Cry1/2 and
output genes, such as Rev-erbs, Dbp, and Nfil3, forms an auto-regulatory negative feedback loop
that drives rhythmic gene expression (14, 15). The circadian clock drives expression of many
other genes, referred to as clock-controlled genes, that are tissue-specific and play important
roles in maintaining tissue homeostasis through their temporal nature (13, 16, 170, 171).
Disruptions in the circadian clock and subsequent disruptions in expression of these clockcontrolled genes have been linked to several diseases such as obesity, diabetes, cardiovascular
disease, and osteoarthritis (OA) (14, 16, 172, 173).
Clock genes play a critical role in maintaining tissue homeostasis in many different
musculoskeletal tissues including muscle, tendon, bone, and articular cartilage (16, 22). Articular
cartilage consists of an abundant ECM synthetized by the only resident cell type, chondrocytes
(2, 3, 174). Articular cartilage is avascular and aneural and is maintained through a balance
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between anabolic and catabolic activities. Disruption to this balance, for example through
increased inflammation, drives the degradation of articular cartilage which is a key characteristic
of OA, the leading cause of pain and disability worldwide (27, 28, 175). It has been shown that
many anabolic and catabolic pathways in articular cartilage have different daily dynamics, driven
by a functional circadian clock in chondrocytes, that help maintain cartilage homeostasis (16, 17,
19-22, 176-179). Pathways that have different activity at different times include metabolic, ECM
remodeling, and catabolic pathways (16, 21), and disruptions in the clock cause loss in rhythmic
expression and altered expression of these pathways (21). For example, the cartilage-specific
knockout of one of the core clock genes, Bmal1, results in a catabolic response and cartilage
degradation in mice (19). These findings suggest that the disruption of the circadian clock in
cartilage could be an important contributor to the pathogenesis of OA (34).
Inflammation is a key driver in the pathogenesis of OA, characterized by increased levels
of proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-α (TNFα), which in
turn induce ECM degradation through the enhanced production of degradative enzymes and
other pro-inflammatory mediators that shift chondrocyte activity to a pro-catabolic state (24, 26,
29-31). Importantly, inflammation has been shown to disrupt circadian rhythms in cartilage (33).
The addition of IL-1 to cartilage explants caused a loss in circadian rhythms that was only
rescued with the administration of dexamethasone (dex), an anti-inflammatory agent (33). Anticytokine therapies such as IL-1 receptor antagonist (IL-1Ra, anakinra) have shown promise in
alleviating symptoms of post-traumatic OA (36-38); however, systemically delivered anticytokine therapies are administered at high doses, which may have significant off-target effects,

84

including an increased susceptibility to infection and certain autoimmune diseases (43) as well as
limited tissue regeneration and repair (75-77).
Because of the drawbacks with anti-cytokine therapies and lack of effective diseasemodifying treatments to address both the symptoms and structural changes of OA (45, 47, 74),
we previously used genetic engineering to develop various self-regulating cellular systems to
address these limitations (59). Using CRISPR/Cas9 gene editing we created murine induced
pluripotent stem cells (miPSCs) lacking a functional IL-1 receptor 1 (IL1R1) that can
successfully be differentiated into tissue engineered cartilage that is protected from IL-1 induced
matrix degradation (IL1R1 KO) (53). We also used CRISPR/Cas9 gene editing in miPSCs to
incorporate IL-1Ra, a competitive antagonist of IL-1, downstream of the Ccl2 locus (Ccl2IL1Ra) to drive controlled production of IL-1Ra in response to inflammation and subsequent
activation of Ccl2 (60). These cells were also able protect cartilage from inflammation (60).
Furthermore, we have also developed a synthetic promoter that is activated by nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) to drive production of our desired
transgene, IL-1Ra (NFκBr-IL1Ra) (59). This lentiviral gene therapy has been shown to inhibit
IL-1 in response to inflammation or mechanical loading in miPSC-derived tissue engineered
cartilage and also in primary porcine chondrocytes (59, 63).
Due to the role of the circadian clock in maintaining cartilage tissue homeostasis shown
by disruptions in circadian rhythms leading to altered gene expression (21) and cartilage
degradation (19), and the recent finding that inflammation can drive disruption in the
chondrocyte circadian clock, the goal of this study was to develop tissue-engineered cartilage
using stem cells that have been genetically engineered to preserve the circadian clock in response
to inflammation (Figure 4.1). Therefore, we sought to establish a platform for testing the role of
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circadian rhythms in cartilage maintenance and accomplished this by first testing when circadian
rhythms arise while differentiating our miPSCs into chondrocytes and then the consequences of
inflammatory signals on chondrocyte circadian rhythms and cartilage integrity, before testing the
ability of our genetically engineered circuits to preserve circadian rhythms. However, it is
important to note that undifferentiated stem or progenitor cells generally do not exhibit circadian
rhythms (180). Therefore, we first examined the hypothesis that miPSCs do not exhibit a clock
but establish circadian rhythms as they progress through chondrogenic differentiation and the
development of an engineered cartilage matrix. We next determined the effect of inflammatory
cytokines on the circadian clock in our tissue engineered pellets and determined that IL-1α and
IL-1β, but not TNFα, drive disruptions in circadian rhythm. We then tested the ability of our
genetically engineered cell-based therapies targeting IL-1 to protect the clock from IL-1 induced
disruption. We show the ability of our self-regulating synthetic gene circuits to preserve the
circadian clock and protect against inflammation-mediated disruption and cartilage degradation.
These findings further our understanding of the circadian rhythm synchronization in cartilage
and its disruption in response to inflammatory cytokines, and introduce the concept of a “clockpreserving” mechanism through the combination of synthetic biology and tissue engineering of
stem cell gene circuits.
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Figure 4.1 Inflammation resistant cell-based therapies and circadian measurements. Tissue
engineered cartilage pellets with a circadian reporter (Per2-Luc) were tracked to measure their
circadian clock. (A) In the presence of IL-1α the circadian clock was disrupted. Three different
genetic engineering-based cell therapies were developed to be resistant to IL-1α: (B) IL1R1 KO
– CRISPR/Cas9 edited cells lacking the IL-1 receptor 1; (C) Ccl2-IL1Ra – CRISPR/Cas9 edited
cells that produce an IL-1 antagonist, IL-1Ra in response to inflammation and subsequent
expression of Ccl2; and (D) NFκBr-IL1Ra – lentiviral gene therapy circuit with a synthetic
promoter activated by NF-κB signaling driving production of IL-1Ra. The ability of these cell
therapies to preserve the circadian clock in the presence of inflammation was tested.

4.3 Materials and Methods
4.3.1 Cell culture and differentiation
Murine induced pluripotent stem cells (miPSCs)
Murine induced pluripotent stem cells (miPSCs), derived from tail fibroblasts from adult
C57BL/6 mice and validated for pluripotency as described by Diekman et al. (49, 86) were
cultured in Dulbecco’s Modified Eagle’s Medium High Glucose (DMEM-HG, Gibco), 20% lot
selected fetal bovine serum (FBS, Atlanta Biologicals), 100 nM minimum essential medium
nonessential amino acids (NEAA, Gibco), 55 μM 2-mercaptoethanol (2-me, Gibco), 24 ng/mL
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gentamicin (Gibco), and 1000 U/mL mouse leukemia inhibitory factor (LIF, Millipore), and
maintained on mitomycin C-treated mouse embryonic fibroblasts (Millipore).
miPSCs were differentiated toward a mesenchymal state using a high-density micromass
culture (49). Differentiation medium contained DMEM-HG, 1% culture medium supplement
containing recombinant human insulin, human transferrin, and sodium selenite (ITS+, Corning),
100 nM NEAA, 55 μM 2-me, 24 ng/mL gentamicin, 50 μg/mL L-ascorbic acid, and 40 μg/mL Lproline. On days 3–5, this medium was supplemented with 100 nM dexamethasone and 50
ng/mL bone morphogenetic protein 4 (BMP-4; R&D Systems). After 15 days of culture, the
micromasses were dissociated with pronase (Millipore Sigma) and collagenase type II
(Worthington Biochemical) and the pre-differentiated iPSCs (PDiPSCs) were plated on gelatincoated dishes in expansion medium containing DMEM-HG, 10% lot-selected FBS, 1% ITS+,
100 nM NEAA, 55 μM 2-me, 1% penicillin/streptomycin (P/S, Gibco), 50 μg/mL L-ascorbic
acid, 40 μg/mL L-proline, and 4 ng/mL of basic fibroblast growth factor (bFGF, R&D Systems).
To create a 3D PDiPSC system, passage 2 PDiPSCs were cast in agarose (4% molten type VII
agarose, Sigma Aldrich) at a final density of 100 million cells/mL in 1% agarose (49).
To create tissue engineered cartilage passage 2 PDiPSCs were pelleted by centrifugation
of 250K cells (49). Pellets were cultured for 14-21 days in chondrogenic medium consisting of
DMEM-HG, 1% ITS+, 100 nM NEAA, 55 μM 2-me, 1% P/S, 50 μg/mL L-ascorbic acid, 40
μg/mL L-proline, 100 nM dexamethasone, and 10 ng/mL TGF-β3 (R&D Systems).
Porcine primary chondrocytes
Full-thickness porcine articular chondrocytes were enzymatically isolated using
collagenase II (Worthington Biochemical) from the femurs of pigs obtained from a local abattoir
(~30 kg; 12 to 16 weeks old) postmortem in accordance with an exemption protocol by the
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Institutional Animal Care and Use Committee. Filtered cells were mixed 1:1 with 4% molten
type VII agarose (Sigma-Aldrich) and the cell-agarose mixture was injected into a gel apparatus
and allowed to set at room temperature. Chondrocyte-laden disks were punched out yielding
engineered cartilage at a final concentration of 2% agarose and 15 to 20 million cells/mL. All
constructs were cultured in chondrogenic medium for 2-21 days containing DMEM-HG, 10%
FBS (Atlas), 100 nM NEAA, 15 mM HEPES (Gibco), 50 μg/mL L-ascorbic acid, 40 μg/mL Lproline, and 1% P/S (12).

4.3.2 Circadian reporter design
Two luciferase reporter lentiviral vectors, one driven by the murine Bmal1 promoter and
one driven by the murine Period 2 (Per2) promoter, were used (181). These cassettes result in
luciferase expression with the circadian promoters Bmal1 (Bmal1-Luc, B1L) or Per2 (Per2-Luc,
P2L) are activated.

4.3.3 Development of inflammation resistant and self-regulating iPSCs
Three different cellular engineering approaches were used to test the ability to maintain
the circadian clock in response to inflammatory cytokine interleukin-1α (IL-1α): a knockout
miPSC line lacking the IL-1 receptor 1 (IL1R1 KO) (53), a CRISPR/Cas9 edited miPSC line that
incorporates IL-1 receptor antagonist (IL-1Ra) downstream of the Ccl2 promoter (Ccl2-IL1Ra)
(60) , and cells transduced with a lentiviral gene therapy that includes a synthetic promoter
activated by the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway
that drives IL-1Ra production (NFκBr-IL1Ra) (59). IL1R1 KO, Ccl2-IL1Ra, and NFκBr-IL1Ra
transduced PDiPSCs were all transduced with Per2-Luc (P2L) lentivirus and pelleted to grow
into tissue engineered cartilage for experimentation.
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IL1R1 KO miPSC line
The IL1R1 KO line was created using CRISPR/Cas9 technology to create a homozygous
deletion of the IL1R1. These cells do not respond to the presence of IL-1α and have been
previously shown to be effective in mitigating inflammation induce degradation of tissue
engineered cartilage (53).
Ccl2-IL1Ra miPSC line
The Ccl2-IL1Ra line was created using CRISPR/Cas9 technology to insert IL-1Ra
downstream of the Ccl2 promoter creating a heterozygous cell line. Ccl2 is a common gene
upregulated with inflammation in cartilage and therefore the Ccl2-IL1Ra cells effectively sense
inflammation and produce an anti-inflammatory therapeutic in an autoregulated manner (60).
NFκBr-IL1Ra lentiviral vector
To create the NFκBr-IL1Ra lentiviral vector, a synthetic NF-κB inducible promoter was
designed to incorporate multiple NF-κB response elements as previously described (59). A
synthetic promoter was developed containing five consensus sequences approximating the NFκB canonical recognition motif based on genes upregulated through inflammatory challenge:
InfB1, Il6, Mcp1, Adamts5, and Cxcl10. A TATA box derived from the minimal CMV promoter
was cloned between the synthetic promoter and downstream target gene, murine Il1rn, and an
NF-κB-negative regulatory element (NRE-5’-AATTCCTCTGA-3’) was cloned upstream of the
promoter to reduce background signal (59, 79, 151). This lentiviral vector has been shown to
protect tissue engineered cartilage from inflammation mediated degradation and has been shown
to be mechanoresponsive and utilized in porcine tissue engineered cartilage (59, 63).
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4.3.4 Lentivirus production and cell transduction
Human embryonic kidney (HEK) 293T cell were co-transfected with second-generation
packaging plasmid psPAX2 (No. 12260; Addgene), the envelope plasmid pMD2.G (No. 12259;
Addgene), and the expression transfer vector (B1L, P2L, or NFκBr-IL1Ra plasmids) by calcium
phosphate precipitation to make vesicular stomatitis virus glycoprotein pseudotyped lentivirus
(85). The lentivirus was harvested at 24- and 48- hours post transfection and stored at -80℃ until
use. The functional titer of the virus was determined with quantitative real-time polymerase
chain to determine the number of lentiviral DNA copies integrated into the genome of transduced
HeLa cells (85). For all cell transductions, virus was thawed on ice and diluted in medium to
obtain the desired number of viral particles to achieve a multiplicity of infection of 3 (59).
Polybrene was added to a concentration of 4 µg/mL to aid in transduction. The medium of the
cells was aspirated and replaced with virus-containing medium, and cells were incubated for 24
hours before aspirating the viral medium.

4.3.5 Circadian clock characterization through bioluminescence recordings
and imaging
miPSCs and PDiPSCs were transduced with either Bmal1-Luc (B1L) or Per2-Luc (P2L)
virus. PDiPSCs were either cultured in monolayer, cast in agarose, or pelleted. miPSCs,
PDiPSCs, PDiPSCs freshly cast in agarose (PDiPSC agarose), and mature pellets (tissue
engineered cartilage pellets) were plated in 35 mm petri dishes with 1 mL of recording medium
containing D-luciferin (Goldbio), sealed with vacuum grease, and placed in a light-tight36º
incubator containing photo-multiplier tubes (PMTs) (Hamamatsu Photonics). Each dish was
placed under one PMT and the bioluminescence was recorded as photons per 180 seconds.
Bioluminescence data were detrended with a 24h moving average and analyzed in ChronoStar
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1.0 (182). Recoding medium contained DMEM powder (Sigma), B27 supplement (Invitrogen),
P/S, L-glutamine (Invitrogen), HEPES (Sigma), and D-glucose (Invitrogen). Porcine
chondrocytes were also transduced with P2L, cast in agarose, cultured, and then subjected to
bioluminescence recordings in the dark incubator. As a control, the femoral head from 10 week
old PER2::LUC reporter mice (founders generously provided by Dr. Joseph Takahashi, UTSW)
(170) was obtained and the bioluminescent output from the cartilage explants was also recorded .

4.3.6 Inflammatory challenge and bioluminescence recordings and imaging
After 14 days of chondrogenic culture, pellets transduced with P2L underwent
inflammatory challenge with 20 ng/mL TNFα, 1 ng/mL IL-1α, 1 ng/mL IL-1β, or a PBS control.
Pellets were placed in recording medium and bioluminescence was recorded for 72 hours. After
72 hours of recording, cytokine or PBS was added to the dish and bioluminescence was recorded
for an additional 72 hours. Pellets with a period of bioluminescence 18-32h, mean
bioluminescence >30,000 photons, and pre-cytokine amplitude >20,000 photons were included
in analysis. Damping ratio was calculated as amplitude two days following treatment divided by
amplitude the day prior to treatment. Additional pellets were treated with cytokines or PBS and
stored at -80℃ for quantitative reverse transcription polymerase chain reaction (qRT-PCR), 20℃ for biochemical analysis, or fixed in 10% neutral buffered formalin (NBF). As a
comparison, Per2::Luc mouse femoral head articular cartilage was dissected from 4-6 week old
mice. The cartilage explants were cultured in DMEM/F12 (without phenol red and FBS, with Lglutamine and non-essential amino acids). Explants were synchronized by 1h treatment with 100
nM dexamethasone and their bioluminescence was recorded in Lumicycle as described
previously (19). 36 hours after synchronization explants underwent inflammatory challenge with
20 ng/mL TNFα, 1 ng/mL IL-1α, 1 ng/mL IL-1β, or a PBS control. After 48 hours of exposure to
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cytokines 100 nM dexamethasone was added to the medium and bioluminescence recorded for
another 48 hours. Damping of the circadian clock was assessed by measuring of the amplitude of
peak before and after treatment. For each explant the peak before treatment was normalized as
100% and the peak after treatment was expressed as % of that value.
IL1R1 KO, Ccl2-IL1Ra, NFκBr-IL1Ra, and P2L control pellets were all subjected to
inflammatory challenge with 1 ng/mL IL-1α or a PBS control. Bioluminescence was recorded 72
hours pre addition of cytokine and for 72 hours post addition of cytokine. Additional pellets were
treated with cytokines or PBS, media was collected, and pellets were stored at -80℃ for qRTPCR, -20℃ for biochemical analysis, or fixed in 10% NBF. Additionally, dishes with pellets in
recording media were recorded for 72h using an Andor iKon-M electron multiplying charged
coupled device (Oxford Instruments) at 20x magnification with 1h exposures and 2x2 binning.
During multi-day recordings, samples were maintained at 36º in darkness. Image sequences were
concatenated into videos using ImageJ.

4.3.7 Histological and biochemical analysis of pellet cultures
After 72 hours of inflammatory challenge, pellets were washed with PBS and fixed in
10% NBF for 24 hours, paraffin embedded, and sectioned at 8 μm thickness. Slides were stained
for Safranin-O/hematoxylin/fast green (91).
For biochemical analysis, pellets were digested overnight in 125 μg/mL papain at 65℃.
DNA content was measured with PicoGreen assay (Thermo Fisher) and total sulfated
glycosaminoglycan (sGAG) content was measured using a 1,9-dimethylmethylene blue assay at
525 nm wavelength (90).
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4.3.8 Gene expression with quantitative real time polymerase chain reaction
Pellets were homogenized using a miniature beat beater, lysed in Buffer RL, and RNA
was isolated following the manufacturer’s protocol (total RNA purification; Norgen Biotek).
Reverse transcription was performed using Superscript VILO complementary DNA master mix
(Invitrogen). qRT-PCR was performed using Fast SyBR Green master mix (Applied
Biosystems). Primer pairs were synthesized by Integrated DNA Technologies, Inc: Ccl2
[forward (F), 5’-GGCTCAGCCAGATGCAGTTAA-3’; reverse (R), 5’CCTACTCATTGGGATCATCTTGCT-3’], Il6 [F, 5’-GAGGATACCACTCCCAACAGACC3’; R, 5’-AAGTGCATCATCGTTGTTCATACA-3’] r18s [F, 5’CGGCTACCACATCCAAGGAA-3’; R, 5’-GGGCCTCGAAAGAGTCCTGT-3’]. Data are
reported as fold changes and were calculated using the ΔΔCT method and are shown relative to
the P2L PBS control group and ribosomal 18s is used as the reference gene.

4.3.9 Enzyme-linked immunosorbent assays
After 72 hours of inflammatory challenge, culture media was collected from pellets and
stored at -20℃. IL-1Ra concentration was measured with DuoSet enzyme-linked immunosorbent
assay (ELISA) specific to mouse IL-1Ra/IL-1F3 (R&D Systems).

4.3.10 Statistical Analysis
Statistical analysis was performed using Prism. A one-way ANOVA with Dunnett’s post
hoc test was used to analyze all biochemistry data for P2L pellets given TNF-α, IL-1α, IL-1β, or
PBS with PBS as the control (α = 0.05). A one-way ANOVA with Fisher’s LSD post hoc test
was used to analyze damping ratios for pellets given TNF-α, IL-1α, IL-1β, or PBS with PBS as
the control (α = 0.05). Additionally, a one-way ANOVA with Dunnet’s post hoc test was used to
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analyze biochemistry data for IL1R1 KO, Ccl2-IL1Ra, and NFκBr-IL1Ra pellet experiments
within each group with 0 ng/mL dose as the control (α = 0.05). A two-way ANOVA with
Tukey’s HSD post hoc test was used to analyze qRT-PCR data for P2L pellets given cytokines
and all biochemistry, qRT-PCR, and ELISA data for IL1R1 KO, Ccl2-IL1Ra, and NFκBr-IL1Ra
pellet experiments (α = 0.05). Statistical analysis for cartilage explants and their response to
inflammatory cytokines was performed using student t-test comparing the values of the peak
after control or cytokine treatment.

4.4 Results
4.4.1 The circadian clock develops by chondrogenic stage of murine iPSC
chondrogenesis
To assess the development of the circadian clock in our in vitro chondrogenesis protocol
of murine iPSCs (miPSCs), we transduced miPSCs and pre-differentiated iPSCs (PDiPSCs) with
Per2-Luc (P2L) or Bmal1-Luc (B1L) lentivirus and tracked the bioluminescence output of
miPSCs, PDiPSCs in monolayer, PDiPSCs freshly cast in agarose, and chondrogenic cartilage
pellets (Figure 4.2A). We found that miPSCs expressed P2L and B1L, but with no evidence of
circadian oscillation (e.g., periods >32h), Figure 4.2B). Additionally, at the PDiPSC
differentiation stage, P2L transduced PDiPSCs began to oscillate (average period=28.12±3.1h,
mean±SEM), and B1L oscillation, which appears after Per2 expression in development (180),
had not yet occurred (period length >32h, Figure 4.2B). However, PDiPSCs cast in a 3D agarose
system showed enhanced rhythmicity in Per2 (average period=26.3±2.2h), while Bmal1
remained arrhythmic (period length >32h, Figure 4.2B). Tissue engineered cartilage pellets
showed high amplitude oscillations of Per2 and Bmal1 in anti-phase, meaning the circadian
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clock had fully developed in our tissue engineered cartilage (P2L period=23.2±3.1h, B1L
period=21.5±4.9h, Figure 4.2B).
Murine cartilage explants were taken from the femoral head of 10 week old homozygous
PER2::LUC mice (170). Bioluminescence recording of these cartilage explants demonstrated
sustained circadian rhythms, as shown previously (Figure 4.2C). Our tissue engineered cartilage
pellets had similar period length compared to PER2:LUC oscillations in the cartilage explants,
further confirming the development and maturation of the circadian clock in our tissue
engineered cartilage (engineered cartilage period=23.2±3.1h, explant period=23.9±1.5h).
Additionally, we transduced primary porcine chondrocytes with our P2L lentivirus, and these
porcine chondrocytes also showed sustained daily oscillations similar to our tissue engineered
pellets (period=23.5±3.3h, Figure 4.2D). Together, these findings suggest that our in vitro
chondrogenesis protocol develops a circadian clock in our tissue engineered cartilage that has
robust and sustained oscillations similar to mature cartilage explants and primary chondrocytes
in another species.
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Figure 4.2 Development of the circadian clock in miPSC chondrogenesis. (A) Differentiation
of miPSCs to chondrocytes. miPSCs were subjected to high-density micromass culture to create
PDiPSCs. PDiPSCs were then either cast in agarose or pelleted and cultured in chondrogenic
media for 14-21 days to create tissue engineered cartilage. (B) Per2-Luc bioluminescence
intensity (BLI) of miPSCs (n=10), PDiPSCs (n=2), PDiPSCs in agarose (n=4), and pellets
(n=10) (left) and Bmal1-Luc bioluminescence intensity (BLI) of miPSCs (n=5), PDiPSCs
(n=4), PDiPSCs in agarose (n=5), and pellets (n=5). (C) BLI of femoral head cartilage explant
from PER2::LUC mice (n=3, 1 hip per mouse). (D) Per2-Luc BLI in porcine chondrocytes cast
in agarose (n=5).
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4.4.2 Inflammation disrupts the circadian clock in native and tissue
engineered cartilage
We next sought to understand the effect of inflammatory cytokines IL-1α, IL-1β, and
TNFα on the circadian clock in tissue engineered cartilage pellets. It has previously been shown
that IL-1β causes disruption in the circadian rhythms of murine cartilage explants through loss in
bioluminescence oscillations and changes in clock gene expression, however TNFα had no effect
(33). For these studies, we treated mature tissue engineered cartilage transduced with the P2L
lentiviral reporter with 1 ng/mL IL-1α, 1 ng/mL IL-1β, 20 ng/mL TNFα, or PBS as a control.
Bioluminescence tracking of P2L was recorded for 3 days prior to addition of cytokines.
Cytokines were added in 2 µL volumes to not disrupt circadian rhythms and pellet
bioluminescence was tracked for an additional 3 days post-cytokine addition. Pellets subjected to
inflammatory challenge were also collected for histological and biochemical analysis of a main
component of articular cartilage, sulfated glycosaminoglycans (sGAG) and analyzed for
upregulation of inflammatory genes Il6 and Ccl2. Pre-cytokine addition, all pellets showed
circadian oscillations of P2L (n=45, Figure 4.3A). Pellets given PBS maintained circadian
rhythms to the end of the recording (n=20, pre-PBS period=25.4±3.1h, post-PBS
period=25.6±7.2h, Figure 4.3A). Pellets treated with TNFα also continued to maintain circadian
oscillations (n=7, Figure 4.3A). Pellets treated with IL-1β showed a lengthening of period in all
pellets and a 2.5-fold decrease in mean bioluminescence (n=8, Figure 4.3A) Additionally, 5
pellets treated with IL-1α showed rapid loss in circadian rhythms and all pellets show
dramatically reduced amplitude of rhythms following a 2.8-fold decrease in bioluminescence
(n=12, Figure 4.3A). The amplitude of bioluminescence was significantly decreased (p=0.0236)
following IL-1α treatment (Figure 4.3B). Cartilage explants from PER2::LUC mice were also
subjected to inflammatory challenge and bioluminescence output was recorded (Figure 4.4).
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Similar to our tissue engineered cartilage pellets, TNFα had no effect on the circadian rhythm of
the cartilage explants, however both IL-1α and IL-1β given at 1 ng/mL showed a rapid loss in
circadian rhythms compared to controls and significant decrease in amplitude compared with
controls (p<0.05) (Figure 4.4). The difference between the effect of TNFα and IL-1β on the
circadian clock has previously been attributed to the activation of NF-κB signaling pathway by
IL-1β and lack of activation by TNFα (33). The similar response of the effect of inflammatory
cytokines on the circadian rhythm of our tissue engineered cartilage compared to ex vivo
cartilage explants is encouraging for using our tissue engineered cartilage pellets as an in vitro
model system.
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Figure 4.3 Tissue engineered cartilage response to inflammatory cytokines. (A) Tissue
engineered cartilage pellets were treated with TNFα, IL-1β, IL-1α, or PBS control for 72
hours. Bars show addition of cytokine or PBS control. (B) Bioluminescence traces of pellets
pre and post cytokine (TNFα (n=7), IL-1β (n=8), IL-1α (n=12), or PBS (n=20)). (C) Pellets
treated with IL-1α show rapid decrease in bioluminescence, followed by lower amplitude
circadian rhythm (p=0.0236). Asterisks represent significance compared to PBS control. (D)
Safranin-O staining for sGAGs (n=4/treatment, scale bar = 100 μM). Pellets treated with IL1β and IL-1α show loss in stain. (E) Quantification of sGAGs normalized to DNA content
within each pellet (n=4/treatment). Pellets treated with IL-1β and IL-1α show significant loss
in sGAG compared to PBS controls (p < 0.0001). Asterisks represents significant differences
as compared to PBS controls. (F) Gene expression analysis of Il6 and Ccl2 (n=4/treatment,
fold change relative to PBS control). Only IL-1β and IL-1α treatment caused upregulation of
Il6 (p = 0.0002). All cytokine treatments caused upregulation in Ccl2 (p < 0.05). Different
letters denote groups that are significantly different.

To better understand the effect of each cytokine on circadian rhythm and begin to
elucidate the functional outputs of the cartilage clock we examined the effect of cytokines on the
degradation of cartilage extracellular matrix, since the circadian clock is known to maintain
cartilage homeostasis (16, 17, 19-22, 176). Pellets were stained with safranin-O to look at sGAG
content (n=4/group, Figure 4.3C). Additionally, sGAG content within pellets was quantified by
biochemical analysis and normalized to DNA content within each pellet (n=4/group, Figure
4.3D). The staining for sGAG showed rich red stain in the PBS control pellets as well as the
pellets treated with TNFα, while pellets treated with IL-1β showed reduced sGAG staining and
pellets treated with IL-1α showed a loss in sGAG (Figure 4.3D). The quantification of sGAG
content matched the histological images, where the TNFα treated pellets had similar sGAG
content compared to PBS controls, whereas the IL-1β and IL-1α treated pellets showed
significant sGAG loss compared to PBS controls (p<0.0001, Figure 4.3D). This loss in ECM
components in pellets treated with IL-1 but not TNFα suggests that pathways activated by IL-1
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leading to matrix degradation could also be driving the loss of the circadian clock, which in turn
exacerbates matrix loss.

Figure 4.4 Cartilage circadian clock in response to inflammatory cytokines. Cartilage
explants from the femoral head of PER2::LUC mice were recorded for bioluminescence
intensity. Explants were treated with 1 ng/mL of IL-1β, IL-1⍺, 20 ng/mL of TNF⍺, or vehicle
controls (n=3 per each condition). Loss of circadian rhythm was seen in explants given IL-1
and circadian rhythm was rescued with the administration of dexamethasone (dex). Grey,
blue, orange, and red bars indicate administration of cytokine, black bars indicate
administration of dex. Asterisks represent significance compared to controls (p<0.05).
Finally, inflammatory genes Il6 and Ccl2 were examined in pellets treated with
cytokines. IL-6 is a cytokine that upregulates inflammatory pathways within the joint and CCL-2
is a chemokine that attracts immune cells to the joint. Here we see that treatment of pellets with
TNFα caused significantly upregulated Ccl2 gene expression compared to PBS controls (n=4,
p=0.0002), but did not cause any significant upregulation in Il6 (n=4, Figure 4.3E). However,
addition of IL-1β and IL-1α caused a significant increase in Ccl2 compared to PBS controls
(n=4, p=0.0086 & p=0.0122 respectively) and a significant upregulation of Il6 especially in the
pellets given IL-1α (n=4, p<0.0001 for both IL-1β and IL-1α, Figure 4.3E). This data also
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suggests that, although upregulation of chemokines such as Ccl2 for immune cell recruitment is
important, cytokines such as IL-1 and IL-6 are more likely to be involved in the disruption of the
circadian clock. Taken together, this suggests that inflammatory cytokines IL-1β and IL-1α can
disrupt the cartilage circadian clock in cartilage explants and our tissue engineered cartilage, and
this effect might be through the upregulation of inflammatory cytokines, such as IL-6, that lead
to matrix degradation.

4.4.3 IL-1 resistant engineered tissues are resistant to circadian disruption
Cartilage explants treated with IL-1α and IL-1β recovered the loss in circadian rhythms
with the addition of dex, an anti-inflammatory agent (Figure 4.4). Because of the ability to
recover the circadian clock with an anti-inflammatory treatment, we sought to test whether our
anti-inflammatory cell therapies could preserve the circadian clock in the presence of IL-1α. Due
to the enhanced impact of IL-1α on the disruption of the circadian clock, increased matrix
degradation, and upregulation of Il6 we used IL-1α in these studies. For these studies we used
miPSCs CRISPR/Cas9 edited without IL1R1 that do not respond to IL-1 (IL1R1 KO) (53),
miPSCs edited with CRISPR/Cas9 to incorporate IL-1Ra downstream of the Ccl2 locus to drive
IL-1Ra production in response to inflammation (Ccl2-IL1Ra) (60), and a lentiviral circuit
incorporating a synthetic promoter activated by the NF-κB signaling pathway that drives
production of IL-1Ra (NFκBr-IL1Ra) (59). All of the miPSC lines or miPSCs were transduced
with the lentiviral vector containing the P2L reporter and differentiated into tissue engineered
cartilage pellets. We then treated with IL-1α (Figure 4.5A) and assessed the ability of these
pellets to maintain cartilage integrity and circadian expression.
First, the ability of the two self-regulating therapeutic groups, Ccl2-IL1Ra and NFκBrIL1Ra pellets, to produce IL-1Ra was determined. As expected, all four groups (P2L controls,
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IL1R1 KO, Ccl2-IL1Ra, and NFκBr-IL1Ra) showed no difference in IL-1Ra production when
given no IL-1α and the P2L and IL1R1 KO pellets also showed no difference in IL-1Ra
production when treated with 1 ng/mL of IL-1α (n=10/group, Figure 4.5B). Both Ccl2-IL1Ra
and NFκBr-IL1Ra had significantly increased IL-1Ra production in response to 1 ng/mL of IL1α, with the NFκBr-IL1Ra producing the highest amount of IL-1Ra (n=10/group, Ccl2-IL1Ra
~36 ng/mL IL-1Ra, NFκBr-IL1Ra ~74 ng/mL IL-1Ra, p<0.0001, Figure 4.5B).
After confirming that our self-regulating cells were producing sufficient IL-1Ra to inhibit
IL-1 activity, we next tracked P2L through bioluminescence before the addition of cytokine and
for 3 days after addition of 1 ng/mL of IL-1α. All four groups before the addition of cytokine
were rhythmic, showing that the addition of any gene editing did not disrupt the clock (n=13,
pre-IL-1α period=24.6±2.9h, Figure 4.5C). All three of our cell therapy groups showed
maintained circadian rhythms in response IL-1α (n=13, post-IL-1α period=24.4±2.0h, Figure
4.5C), whereas the non-engineered controls showed loss in circadian rhythm as shown
previously (n=12, Figure 4.3A). Cytokine-treated resistant pellets show a similar consistency in
period to what we observed in PBS-treated control pellets. In addition to whole-pellet
bioluminescence data, we recorded bioluminescence videos of untreated and our cell therapy
groups at single-cell resolution.
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Figure 4.5 Engineered cell therapies response to IL-1α. (A) Three different anti-inflammatory
cell therapies were used to test the ability to protect the circadian rhythm of tissue engineered
cartilage: CRISPR/Cas9 edited miPSCs lacking the IL1 receptor (IL1R1 KO), CRISPR Cas9
edited miPSCs that produce IL-1Ra downstream of the Ccl2 promoter (Ccl2-IL1Ra), and a
lentiviral gene therapy comprised of a NF-κB responsive synthetic promoter that drives
production of IL-1Ra (NFκBr-IL1Ra). (B) IL-1Ra concentration in response to IL-1α
stimulation (n=10/group). The Ccl2-IL1Ra and NFκBr-IL1Ra groups showed increased IL1Ra production in response to IL-1α. (C) Bioluminescence traces of pellets pre and post
cytokine (n=13). All three cell therapy groups showed preservation of the clock post cytokine
treatment. Grey bar represents addition of PBS, red bar represents addition of IL-1⍺. (D)
Safranin-O staining for sGAGs (n=4-6/group, scale bar = 100 μM). (E) Quantification of
sGAGs normalized to DNA content within each pellet (n=8=10/treatment). Cell therapy
groups showed no significant loss in sGAG in response to IL-1α. Asterisks denotes
significance compared to PBS control within group. n.s. = not significant (F) Gene expression
analysis of Il6 and Ccl2 (n=6-8/group fold change relative to P2L untreated control). All cell
therapy groups showed significantly less inflammatory gene expression compared to IL-1α
treated controls.
Additionally, when examining staining and quantification of sGAG content of the
cartilage ECM, the IL1R1 KO, Ccl2-IL1ra, and NFκBr-IL1Ra groups exhibited rich safranin-O
staining similar to P2L controls and no difference in sGAG content between control pellets (no
cytokine treatment) and pellets treated with 1 ng/mL of IL-1α (n=4-6/group for histology, n=810/group for biochemical analysis, Figure 4.5D,E). Maintaining that there could be a potential
link between protection of the cartilage ECM and preservation of the circadian clock. Finally,
when examining gene expression of Il6 and Ccl2 72 hours after treatment, all groups showed no
upregulation of genes in response to no cytokine, however when stimulated with 1 ng/mL of IL1α only the P2L controls showed significant upregulation of Ccl2 (n=6-8, p<0.0001, Figure
4.5F) and the P2L group had the highest expression of Il6 (n=6-8, p<0.0001, Figure 4.5F). The
Ccl2-IL1Ra group showed no upregulation of Ccl2 when treated with IL-1α at 72 hours due to
the self-regulating response that rapidly inhibits IL-1 signaling (60), however there was a
moderate increase in Il6 expression compared to the IL1R1 KO and NFκBr-IL1Ra groups given
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no cytokine and cytokine (n=6-8, p<0.05, Figure 4.5F) most likely due to the lower production of
IL-1Ra to inhibit IL-1α compared to the NFκBr-IL1Ra (Figure 4.5F). Together, these data
demonstrate that our cell therapies edited to either be non-responsive to IL-1α (IL1R1 KO) or to
be self-regulating and produce an anti-inflammatory therapeutic, IL-1Ra, can effectively protect
their cartilage ECM from degradation and importantly maintain the circadian clock in the
presence of IL-1α.

4.5 Discussion
By combining tissue engineering, synthetic biology, and circadian biology, we have
developed cell-based therapies that are capable of preserving the cartilage circadian clock in
response to disruptive stimuli such as inflammation. While significant advances have been made
in understanding the physiology of the circadian clock in recent years, the use of genetic
approaches has not been employed previously to create cell-based clock preserving therapeutic
systems. Here we used chondrocytes and tissue engineered cartilage as our model system, which
provides a homogeneous cell population that avoids the complexities of interpreting data from
multiple cell types. Using this system, we have been able to uncover characteristics of cartilage
circadian rhythms and established a robust system for peripheral clock studies. These types of
tools can be utilized to mitigate disease where circadian disruption plays a role (16), can be used
to create better engineered tissues by ensuring tissue homeostasis through clock-controlled genes
(16, 22),and may be used to uncover important characteristics of the circadian clock not yet
known. In combination with tissue engineering, the use of genetically modified cells may allow
the formation of functional bioartificial tissues with intrinsic clock-preserving characteristics.
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In quantifying the circadian clock in miPSCs, we observed that undifferentiated cells
were not rhythmic and developed their circadian clock over the course of chondrogenic
differentiation. This is consistent with prior reports that mouse embryonic stem cells and other
stem/progenitor cells cannot generate circadian rhythms until they differentiate (180), suggesting
that formation of a mature circadian clock is an integral characteristic of cellular differentiation.
However, the circadian clock is developed in adult stem cell populations, as well as most somatic
cells, further confirming the importance of the clock in regulating tissue and cell homeostasis
after cell development (183). Furthermore, we observed that iPSC-derived chondrocytes or
primary porcine chondrocytes in tissue-engineered cartilage pellets showed a similar circadian
response as primary murine cartilage and responded similarly to inflammatory cytokines,
indicating that this model of iPSC chondrogenesis replicates many of the features of native
cartilage. In this respect, such in vitro model systems can be utilized to uncover key
characteristics of the circadian clock development throughout chondrogenesis and in response to
inflammatory cytokines that drive disease progression. This can be expanded to other iPSC
differentiation lineages and additional stimuli to further understand the circadian clock in
development.
Although it is clear that the circadian clock plays a critical role in articular cartilage
physiology and OA pathology, the mechanisms by which clock genes maintain chondrocyte
homeostasis remain to be determined. Here we showed different responses of the circadian clock
to cytokines in cartilage (33). By examining the effect of the cytokines IL-1 and TNF-α on the
circadian clock as well as the cartilage ECM and inflammation associated genes, we determine
that cytokines, IL-1β and IL-1α, that lead to matrix degradation and upregulation of other proinflammatory cytokines such as Il6, drive the disruption in the circadian clock instead of
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cytokines such as TNF-α that had no effect on the circadian clock, matrix degradation, or
upregulation of Il6. This information and this model system to test cytokines will help elucidate
what each cytokine is directly acting on and help us uncover the direct link between
inflammatory cytokines and the circadian clock.
An interesting observation made throughout this study was the maintenance of the
circadian rhythms in cartilage explants, porcine chondrocytes, and tissue engineered cartilage
pellets over many days, where cells or tissues lack exogenous entrainment cues (184). Cartilage
explants especially maintained their oscillations for over 10 days without any perturbations such
as media changes or plate movement. This type of maintained circadian clock is not common in
tissue explants and highlights a potential interesting area of study (185, 186). Although there is
research looking into the cartilage circadian clock, it is not known how the chondrocytes
maintain their circadian clock within articular cartilage. It is hypothesized that changes in body
temperature and factors within the synovial fluid help with clock synchronization (13, 22) but the
prolonged maintenance of the circadian clock ex vivo without any synchronizing cues highlights
that there might be a factor secreted by the chondrocytes themselves that maintains this
synchrony, or the abundant ECM maintains the biochemical and biomechanical niche for
synchrony (187). Future work looking into potential synchronizing factors will be key in
uncovering this mechanism.
The ability of our genetic engineering approaches to maintain the circadian clock also
opens a different area of therapeutic development. There are many diseases that are associated
with disruptions in the circadian clock (14). Using gene therapy approaches to create cell
therapies that focus on preserving or synchronizing the clock can be a useful arsenal to help
ameliorate diseases beyond OA. For example, in the context of clock preservation in the
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presence of inflammation, these circuits can be used to protect the intervertebral disc (16, 172,
181). Additionally, with the use of iPSCs there is the capability to expand this to create
autologous cellular therapeutics and treatments against diseases where circadian disruption plays
a role, such as in age-related clock dampening or cancer (188, 189). Using tissue engineering and
creating cells that are capable of maintaining the circadian rhythm can also be used to develop
better engineered tissues through maintenance of the circadian clock and associated genes
involved in tissue homeostasis (16, 22).
Using an engineered tissue that is capable of protecting itself against inflammation and
preserving the circadian clock in response to inflammation can overcome the current limitations
in OA therapies and articular cartilage repair. This work can be expanded to create clock
preserving cell therapies across many tissues by differentiating already developed iPSC lines into
other tissues or using lentiviral approaches. For example, the NFκBr-IL1Ra lentiviral system has
been used in both miPSCs and primary porcine chondrocytes for inflammation-activated and
mechano-responsive drug delivery (59, 63). Future work in comparing rhythmic transcriptomes
and understanding the beneficial effects of rhythm preservation will additionally help further
insights into the physiology of the cartilage clock. This approach opens an innovative frontier for
creating cell-based therapies to maintain the circadian clock. Together, this framework for
developing clock preserving cell systems is an innovative approach to establish therapeutics and
enhance tissue repair.
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4.6 Conclusions
We engineered cell therapies that are capable of preserving the circadian clock in
response to inflammation and protecting tissue engineered cartilage. Murine induced pluripotent
stem cells (miPSCs) were differentiated into tissue engineered cartilage and the circadian rhythm
of the cells undergoing chondrogenesis was tracked. We found that miPSCs do not have
developed circadian rhythms, however the tissue engineered cartilage has fully developed
circadian rhythms. Both our tissue engineered cartilage and cartilage explants from C57 mice
showed loss in circadian rhythms with the addition of IL-1, however TNF⍺ had no effect on the
circadian rhythms. We developed three cell therapies capable of preserving circadian rhythms in
the presence of IL-1. The first cell therapy was engineered using CRISPR/Cas9 to lack the
functional IL-1 receptor 1 (IL1R1 KO) so it could not sense the presence of IL-1. The second
cell therapy was engineered using CRISPR/Cas9 to produce IL-1 receptor antagonist
downstream of the Ccl2 promoter which is activated by inflammation (Ccl2-IL1Ra). The final
circuit was a lentiviral system with a synthetic promoter activated by NF-κB signaling that
produced IL-1Ra (NFκBr-IL1Ra). All three of these systems were capable of preserving the
circadian clock and cartilage ECM from IL-1 induced inflammation. This is the first approach at
using cellular engineering to preserve the circadian clock in peripheral tissues.
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Chapter 5: A synthetic chronogenetic
therapy gene circuit for temporal drug
delivery
5.1 Abstract
Chronotherapy, the delivery of therapeutic interventions personalized to patient’s
circadian rhythms, has shown enhanced therapeutic efficacy and reduced side-effects. Currently,
many drugs taken in the United States target the product of a circadian gene and therefore there
is a need to focus on the timing of drug delivery. In rheumatoid arthritis, patients exhibit diurnal
changes in cytokines that lead to inflammatory flares and enhanced disease severity in the early
morning. There has been important work showing the administration of anti-inflammatory
treatments in the early morning, immediately before the inflammatory flare, in reducing
symptoms of RA. Using synthetic biology, we developed chronotherapy-based gene circuits,
chronogenetic therapies, that produce our prescribed transgene downstream of the core circadian
clock component, Per2. We transduced these lentiviral chronogenetic therapies into murine
induced pluripotent stem cells and developed tissue-engineered cartilage as our model system for
timed drug delivery. Our anti-inflammatory chronogenetic circuit was capable of producing
interleukin-1 receptor antagonist (IL-1Ra) in an oscillatory manner tracking with circadian
rhythms in vitro. Additionally, the tissue engineered pellets were able to entrain to host circadian
rhythms when implanted into mice and produce differing levels of IL-1Ra in the serum at
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different times of day. The chronogenetic synthetic gene circuits provide a novel cell therapy
driving by the circadian clock for controlled biologic delivery at prescribed times of day.

5.2 Introduction
Chronotherapy, or the delivery of therapeutic interventions based on the patient’s
circadian rhythm, is emerging as an important method for minimizing side effects and increasing
efficacy of drugs. Circadian rhythms are driven by the circadian clock, an internal genetic timing
mechanism that operates on a roughly 24-hour period and exists within the brain and nearly all
cells in peripheral tissues (13-15). The core clock genes, comprised of transcriptional activators
Bmal1 and Clock and transcriptional repressors Per1/2 and Cry1/2 and output genes, such as
Rev-erbs, Dbp, and Nfil3, create an auto-regulatory negative feedback loop that drives the
oscillatory and timed behavior of the clock (14, 15). These core clock genes drive expression of
many other tissue-specific clock-controlled genes that help maintain tissue homeostasis (16).
Recently, it was discovered that around 50% of mammalian genes are expressed with 24-hour
rhythms and their expression is regulated in some way by the circadian clock (65). Therefore,
there has been an increase in research trying to understand the importance of therapeutic delivery
and matching it to circadian rhythms.
Recently it was found that over half (56) of the top 100 selling drugs in the United States
target the product of a circadian gene (64). To this end, there are research and clinical trials
looking into timed delivery of drugs for increasing their efficacy and minimizing side effects (16,
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17, 20, 64-68). Studies have shown that time of day is critical to outcomes in heart surgery (190),
cardiovascular disease treatment (64), cancer treatment (69, 191, 192), as well as others.
In musculoskeletal diseases, such as rheumatoid arthritis (RA) and osteoarthritis (OA),
there are diurnal expression patterns in cytokines that demonstrate circadian patterns in the
intensity of symptoms, with inflammatory flares occurring in the early morning (16, 17, 66, 67,
193). There is great evidence for the importance of chronotherapy in patients with RA. In trials
of non-steroidal anti-inflammatory drugs (NSAIDs) or methotrexate, patients that took these
drugs at night showed improved outcomes and reduced adverse effects to the drugs.
Additionally, patients who received drugs at night instead of in the morning, to combat the
increase in IL-6 in the early morning, reported reduced joint pain and inflammation (68).
Therefore, there is a need for intermittent or timed delivery of biologics at specific times of day
for enhanced efficacy in musculoskeletal diseases such as RA.
Unfortunately, this process of taking drugs at specific times of day can be difficult to
maintain since it requires constant daily injections or delivery of drugs at inconvenient times,
such as the case of arthritis where delivery of the drug in the early morning immediately before
an inflammatory flare would be best. However, with recent advances in synthetic biology and
genetic engineering, cell-based therapies that harness cells for localized, controlled, and longlasting delivery of prescribed biologic drugs, can be a promising approach to ensure drug
delivery at specific times of day and over specific frequencies. To this end, the goal of this study
was to create cell-based chronotherapy gene circuits, chronogenetic therapies, that use the cell’s
own biologic circadian rhythm to provide gene-based delivery of biologic drugs at prescribed
times and frequencies. Therefore, we developed two lentiviral synthetic gene circuits driven by
the core clock gene, Per2, to produce a destabilized green fluorescence protein (d2eGFP) as an
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initial proof-of-concept reporter circuit (Per2-d2eGFP-t2a-Luc) and interleukin-1 receptor
antagonist (IL-1Ra) as an anti-inflammatory approach to target RA (Per2-IL1Ra-t2a-Luc). All
circuits contained a 2A linker to produce luciferase in addition to the therapeutic drug for
circadian monitoring. We first examined the ability of the GFP reporter circuit to produce protein
in an oscillating manner in transduced murine induced pluripotent stem cells (miPSCs)
differentiated into tissue-engineered cartilage. Tissue-engineered cartilage was used as the model
delivery system due to the fact that its avascular and aneural and can easily be implanted and
survive in any location (23, 61). We then worked to characterize the Per2-IL1Ra-t2a-Luc circuit
in vitro to ensure oscillating production of IL-1Ra and to determine if this circuit could maintain
its circadian clock in the presence of inflammatory cytokines, which has previously been shown
to disrupt the clock (33). We then worked to test our Per2-IL1Ra-t2a-Luc circuit in vivo to
understand tissue-engineered cartilage circadian clock entrainment to the host and the ability for
timed drug delivery and IL-1Ra concentrations in the serum (Figure 5.1). We show the ability of
these chronogenetic circuits to deliver our therapeutic biologics at specific times of day, driven
by Per2 expression both in vitro and in vivo. This approach is the very first creation of a cellbased therapy for chronotherapy applications through the use of synthetic biology and tissue
engineering of stem cell gene circuits.
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Figure 5.1 Cell-based chronotherapy approach. The therapeutic chronogenetic circuit was
created and transduced into murine induced pluripotent stem cells (miPSCs) using lentivirus.
These miPSCs were then differentiated into tissue engineered cartilage. The circuit was driven
by the Per2 promoter, activated by core clock component Per2 and produced both a luciferase
reporter and the therapeutic drug, IL-1Ra. The Per2-IL1Ra-t2a-Luc circuit is capable of
delivering an anti-inflammatory drug to target inflammatory flares.

5.3 Materials and Methods
5.3.1 Murine induced pluripotent stem cell culture and differentiation
Murine induced pluripotent stem cells (miPSCs) were derived from tail fibroblasts from
adult C57BL/6 mice and validated for pluripotency as described by Diekman et al. (49, 86).
miPSCs were cultured in Dulbecco’s Modified Eagle’s Medium High Glucose (DMEM-HG,
Gibco), 20% lot selected fetal bovine serum (FBS, Atlanta Biologicals), 100 nM minimum
essential medium nonessential amino acids (NEAA, Gibco), 55 μM 2-mercaptoethanol (2-me,
Gibco), 24 ng/mL gentamicin (Gibco), and 1000 U/mL mouse leukemia inhibitory factor (LIF,
Millipore), and maintained on mitomycin C-treated mouse embryonic fibroblasts (Millipore).
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miPSCs were differentiated toward a mesenchymal state using a high-density micromass
culture (49) in differentiation medium containing DMEM-HG, 1% culture medium supplement
containing recombinant human insulin, human transferrin, and sodium selenite (ITS+, Corning),
100 nM NEAA, 55 μM 2-me, 24 ng/mL gentamicin, 50 μg/mL L-ascorbic acid, and 40 μg/mL Lproline. On days 3–5, this medium was supplemented with 100 nM dexamethasone and 50
ng/mL bone morphogenetic protein 4 (BMP-4; R&D Systems). After 15 days, the micromasses
were dissociated with pronase (Millipore Sigma) and collagenase type II (Worthington
Biochemical) and the pre-differentiated iPSCs (PDiPSCs) were plated on gelatin-coated dishes in
expansion medium containing DMEM-HG, 10% lot-selected FBS, 1% ITS+, 100 nM NEAA, 55
μM 2-me, 1% penicillin/streptomycin (P/S, Gibco), 50 μg/mL L-ascorbic acid, 40 μg/mL Lproline, and 4 ng/mL of basic fibroblast growth factor (bFGF, R&D Systems).
To create tissue engineered cartilage, passage 2 PDiPSCs were pelleted by centrifugation
of 250K cells (49). Pellets were cultured for 14-21 days in chondrogenic medium consisting of
DMEM-HG, 1% ITS+, 100 nM NEAA, 55 μM 2-me, 1% P/S, 50 μg/mL L-ascorbic acid, 40
μg/mL L-proline, 100 nM dexamethasone, and 10 ng/mL TGF-β3 (R&D Systems).

5.3.2 Cell-based chronotherapy circuit design
We developed two lentiviral systems activated by Per2 expression, a core circadian clock
gene. All circuits contained a t2a component that linked luciferase (Luc) downstream of the
transgene, with the goal of creating a chronotherapy circuit that had its own luciferase reporter
system. Therefore, upon activation of the repressive arm of the circadian clock and subsequent
activation of Per2, the chronotherapy circuits would be activated and produce either a short-lived
green fluorescence protein (Per2-d2eGFP-t2a-Luc) or interleukin-1 receptor antagonist (Per2IL1Ra-t2a-Luc) over a 24-hour period.
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Per2-d2eGFP-t2a-Luc circuit
The murine Per2 promoter was obtained from a lentiviral Per2-Luc plasmid (181). This
promoter was cloned in place of the CMV promoter in a CMV-GFP-t2a-Luc lentiviral cassette
purchased from Systems Biosciences. The CMV promoter was removed with restriction enzymes
and the Per2 promoter was incorporated using Gibson Assembly (82). A destabilized green
fluorescence protein (d2eGFP) was obtained [No. 26821, Addgene] and cloned in place of the
stable GFP in the backbone cassette using restriction enzymes and Gibson Assembly (82) to
create the Per2-d2eGFP-t2a-Luc circuit. The d2eGFP transgene came from the
pcDNA3.3_d2eGFP plasmid which was a gift from Derrick Rossi (194). Therefore, a dual
reporter chronotherapy gene circuit was created that would express both short-lived GFP and
luciferase downstream of Per2 activation for initial concept characterization.
Per2-IL1Ra-t2a-Luc circuit
Murine interleukin-1 receptor antagonist (IL-1Ra) was incorporated into the Per2d2eGFP-t2a-Luc cassette in place of the d2eGFP through restriction enzyme removal of d2eGFP
and Gibson Assembly (82) to incorporate IL-1Ra. The IL-1Ra was obtained from a plasmid
created to sense and respond to inflammation (62, 63). This lentiviral circuit was then able to
produce IL-1Ra and luciferase in response to Per2 activation (Per2-IL1Ra-t2a-Luc) and can be
used as an anti-inflammatory therapeutic.

5.3.3 Lentivirus production and cell transduction
Human embryonic kidney (HEK) 293T cells were co-transfected with second-generation
packaging plasmid psPAX2 (No. 12260; Addgene), the envelope plasmid pMD2.G (No. 12259;
Addgene), and the expression transfer vector (Per2-d2eGFP-t2a-Luc or Per2-IL1Ra-t2a-Luc) by
calcium phosphate precipitation to make vesicular stomatitis virus glycoprotein pseudotyped
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lentivirus (85). The lentivirus was harvested at 24- and 48- hours post transfection and stored at 80℃ until use. The functional titer of the virus was determined with quantitative real-time
polymerase chain to determine the number of lentiviral DNA copies integrated into the genome
of transduced HeLa cells (85). PDiPSCs were transduced before being pelleted. For PDiPSC
transductions, virus was thawed on ice and diluted in medium to obtain the desired number of
viral particles to achieve a multiplicity of infection of 3 (62). Polybrene was added to a
concentration of 4 µg/mL to aid in transduction. The medium of the cells was aspirated and
replaced with virus-containing medium, and cells were incubated for 24 hours before aspirating
the viral medium.

5.3.4 In vitro characterization of chronogenetic therapy circuits
All chronogenetic therapy circuits were characterized in vitro once the cells had become
tissue engineered cartilage pellets after 14 days in chondrogenic culture. Both circuits were
subject to bioluminescence recordings to track circadian oscillations. Per2-d2eGFP-t2a-Luc
constructs were also subject to fluorescence imaging to quantify GFP expression over time.
Media from the Per2-IL1Ra-t2a-Luc pellets was collected every 3 hours for 72 hours to
determine IL-1Ra production, and pellets were harvested every 3 hours for 72 hours for Il1rn
gene expression.
Bioluminescence recordings
Tissue engineered cartilage pellets (Per2-d2eGFP-t2a-Luc or Per2-IL1Ra-t2a-Luc) were
plated in 35 mm petri dishes with 1 mL of recording medium containing D-luciferin (Goldbio),
sealed with vacuum grease, and placed in a light-tight36º incubator containing photo-multiplier
tubes (PMTs) (Hamamatsu Photonics). Each dish was placed under one PMT and the
bioluminescence was recorded as photons per 180 seconds. Bioluminescence data were
119

detrended with a 24h moving average and analyzed in ChronoStar 1.0 (182). Recoding medium
contained DMEM powder (Sigma), B27 supplement (Invitrogen), P/S, L-glutamine (Invitrogen),
HEPES (Sigma), and D-glucose (Invitrogen).
Fluorescence imaging
After 14 days of chondrogenic culture Per2-d2eGFP-t2a-Luc pellets were digested with
collagenase type II (Worthington Biochemicals), cast in a thin layer of agarose at a density of 10
million cells/mL on glass bottom black 96-well plates (Grier Bio), and cultured in chondrogenic
medium. Plates were placed in a Cytation5 plate reader (BioTek) and agarose was subjected to
fluorescence imaging at 4x magnification for 48 hours with images taken every hour. Image
sequences were concatenated into videos using Gen5 software and individual cells were
visualized and traced for GFP output.
Gene expression with quantitative real time polymerase chain reaction
Per2-IL1Ra-t2a-Luc pellets were collected every 3 hours for 72 hours. Pellets were
homogenized using a miniature beat beater, lysed in Buffer RL, and RNA was isolated following
the manufacturer’s protocol (total RNA purification; Norgen Biotek). Reverse transcription was
performed using Superscript VILO complementary DNA master mix (Invitrogen). qRT-PCR
was performed using Fast SyBR Green master mix (Applied Biosystems). Primer pairs were
synthesized by Integrated DNA Technologies, Inc: Il1rn [forward (F), 5’GTCCAGGATGGTTCCTCTGC-3’; reverse (R), 5’-TCTTCCGGTGTGTTGGTGAG-3’] and
r18s [F, 5’-CGGCTACCACATCCAAGGAA-3’; R, 5’-GGGCCTCGAAAGAGTCCTGT-3’].
Data are reported as fold changes with a 6h moving average and were calculated using the ΔΔCT
method and are shown relative to the non-transduced (NT) control group at 0 hours and
ribosomal 18s is used as the reference gene.
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Enzyme-linked immunosorbent assays
Media from Per2-IL1Ra-t2a-Luc pellets was collected every 3 hours for 72 hours and
stored at -20℃. IL-1Ra concentration was measured with DuoSet enzyme-linked immunosorbent
assay (ELISA) specific to mouse IL-1Ra/IL-1F3 (R&D Systems). Data are reported as rates of
formation with a 6h moving average.
Histological and biochemical analysis of tissue engineered cartilage
After 14 days of chondrogenic culture pellets were washed with PBS and fixed in 10%
NBF for 24 hours, paraffin embedded, and sectioned at 8 μm thickness. Slides were stained for
Safranin-O/hematoxylin/fast green (91).
For biochemical analysis, pellets were digested overnight in 125 μg/mL papain at 65℃.
DNA content was measured with PicoGreen assay (Thermo Fisher) and total sulfated
glycosaminoglycan (sGAG) content was measured using a 1,9-dimethylmethylene blue assay at
525 nm wavelength (90).

5.3.5 Inflammatory challenge
Per2-IL1Ra-t2a-Luc pellets underwent inflammatory challenge with 1 ng/mL IL-1α.
Pellets were placed in recording medium and bioluminescence was recorded for 72 hours. After
72 hours of recording, cytokine was added to the dish and bioluminescence was recorded for an
additional 72 hours.

5.3.6 In vivo characterization of chronogenetic therapy circuits
Per2-IL1Ra-t2a-Luc pellets were implanted into mice subcutaneously for circuit
characterization and evaluation of therapeutic effect. 4 pellets per group were implanted into
adult C57B/6 mice and were subject to evaluation. All procedures were approved by IACUC at
Washington University in St. Louis.
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Per2-IL1Ra-t2a-Luc entrainment characterization
Per2-IL1Ra-t2a-Luc pellets were characterized based on ability to entrain to mouse
circadian rhythms through mouse actigraphy collection and bioluminescence imaging.
Additionally, the ability for the Per2-IL1Ra-t2a-Luc circuit was evaluated through IL-1Ra serum
concentration.
Mice were subjected to normal light/dark cycle and wheel running activity was collected.
Bioluminescence was imaged every 4 hours for 36 hours. After bioluminescence imaging, pellet
peak and trough were determined to be ZT 13 and ZT 5 respectively. To account for IL-1Ra
translation, blood draws were taken from mice 4 hours after luminescence peak through cheek
stab and serum collection. IL-1Ra serum levels were assessed by ELISA (Quantikine-IL1Ra,
R&D Systems).
To evaluate if pellets have the ability to continue to entrain to mice circadian rhythm,
mice were phase delayed 12h using a reversed light/dark schedule. Actigraphy data was collected
continuously to monitor entrainment of activity and after 14 days, pellets were imaged for
bioluminescence every 12 hours for 48 hours at ZT1 and ZT13. Additionally, serum was
collected at the new peak and trough of bioluminescence expression and IL-1Ra serum was
quantified by ELISA.

5.3.7 Statistical Analysis
Statistical analysis was performed using Prism. For all in vitro characterization of Per2d2eGFP-t2a-Luc and Per2-IL1Ra-t2a-Luc circuits a one-way ANOVA with Tukey’s HSD post
hoc test was used to analyze GFP expression, IL-1Ra concentration, and Il1rn expression (α =
0.05). For biochemistry data a one-way ANOVA with Dunnett’s post hoc test was used with NT
as the control (α = 0.05). In vivo IL-1Ra serum was analyzed with a paired t-test (α = 0.05).
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5.4 Results
5.4.1 Characterization of chronogenetic reporter circuits and tissue
engineered cartilage
To first evaluate the ability to create chronogenetic circuits, the ability of our synthetic
circuits to drive production of both bioluminescence and a destabilized green fluorescence
protein reporter (d2eGFP) in an oscillating manner was assessed. We found that our Per2d2eGFP-t2a-Luc circuit had oscillating expression of luminescence (n=3, period=22.73±1.31h,
Figure 5.2A) and d2eGFP protein expression (n=5, period=25±1.4h, Figure 5.2B), showing that
our chronogenetic circuit concept is capable of driving timed expression of a desired output.
Additionally, tissue engineered cartilage was evaluated for sulfated glycosaminoglycans
(sGAG), a main component of the cartilage extracellular matrix. Non-transduced (NT) pellets
and Per2-d2eGFP-t2a-Luc pellets were stained with safranin-O and both showed rich red stain
for sGAGs (n=4/group, Figure 5.2C). Additionally, sGAG content was quantified and
normalized to DNA content within each pellet (n=7/group, Figure 5.2D). There were no
significant differences in sGAG content between groups, showing that our lentiviral
chronogenetic therapy did not impact tissue-engineered cartilage formation. Therefore, our
reporter chronogenetic circuit, Per2-d2eGFP-t2a-Luc, showed protein production driven by the
circadian clock at prescribed times of day.
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Figure 5.2 Characterization of chronogenetic therapy reporter circuit and tissue engineered
cartilage. (A) Per2-d2eGFP-t2a-Luc bioluminescence intensity (BLI) in tissue engineered
cartilage (n=3). (B) Mean GFP fluorescence intensity in digested pellets cast in agarose (n=5).
(C) Safranin-O staining for sGAGs (n=4/group, scale bar=100 μM). (D) Quantification of
sGAGs normalized to DNA content within each pellet (n=7/group). No significance between
non-transduced (NT) and Per2-d2eGFP-t2a-Luc pellets (n.s.=no significance).

5.4.2 Synthetic chronogenetic IL-1Ra circuit produces IL-1Ra in a circadian
manner
After seeing that our reporter circuit functioned well, we sought to test the ability of our
Per2-IL1Ra-t2a-Luc chronogenetic circuit to produce IL-1Ra at different concentrations over
time, with the overall goal of creating a circuit capable of inhibiting inflammatory flares at
specific times of day. Per2-IL1Ra-t2a-Luc pellets showed circadian oscillations driven by Per2
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(n=3, period=22.19±1.27h, Figure 5.3A). Additionally, it has been reported that inflammatory
cytokines such as IL-1 can disrupt the circadian clock in cartilage (33) [See Chapter 4].
Therefore, we tested the ability of our Per2-IL1Ra-t2a-Luc circuit to maintain its oscillations in
the presence of IL-1 and saw the maintenance of circadian oscillations after the addition of IL-1
(n=2, period=20.89±1.04h, Figure 5.3B). The maintenance of oscillations even in the presence
inflammation provides additional support for the ability to use this circuit as a cell-based
therapeutic to target inflammatory flares.
To determine the production of IL-1Ra, our therapeutic drug, we collected the media
from Per2-IL1Ra-t2a-Luc pellets and collected the pellets for gene expression every 3 hours for
72 hours. Per2-IL1Ra-t2a-Luc pellets had increased Il1rn gene expression compared to NT
controls (n = 6/group, p<0.001, Figure 5.3C). Additionally, Il1rn expression in our
chronogenetic circuit showed circadian oscillations and a significant difference between one
peak and trough of the Il1rn expression (period=22.8±3.6h, p<0.05, Figure 5.3C). Importantly,
IL-1Ra production followed a similar oscillating trend to Il1rn gene expression and maintained a
roughly 24-hour period of peak IL-1Ra expression driven by the circadian clock (n=6,
period=22.5±2.9h, Figure 5.3D). Additionally, there were significant peaks of IL-1Ra production
(33, 63, and 66 h, p<0.04) compared to troughs in IL-1Ra expression (42, 54, 57, 72 h, p<0.01,
Figure 5.3D). Excitingly, this showed that our chronogenetic anti-inflammatory therapy had the
ability to produce IL-1Ra at different times of day in vitro.
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Figure 5.3 In vitro characterization of Per2-IL1Ra-t2a-Luc chronotherapy circuit. (A) BLI of
Per2-IL1Ra-t2a-Luc pellets (n=3). (B) BLI of Per2-IL1Ra-t2a-Luc pellets after addition of 1
ng/mL of IL-1α (n=2). (C) Gene expression analysis of Il1rn (n=6/group, fold change relative
to NT control at 0h). Samples collected every 3 hours for 72 hours. In the Per2-IL1Ra-t2aLuc group there were oscillations of Il1rn expression and a significant decrease in expression
at 27 and 39h compared to peak expression at 69h (p<0.05). Asterisks denotes significance
compared to 69h. (D) IL-1Ra production over the course of 3 days in the Per2-IL1Ra-t2a-Luc
circuits (n=6). The chronogenetic circuit produced oscillating IL-1Ra levels with a significant
decrease in expression at 42, 57, and 60h compared to peak expression time of 63h (p<0.01)
and a significant increase in expression at peak times 33, 63, and 66h compared to 72h
(p<0.04). Asterisks denotes significance compared to 72h and hash denotes significance
compared to 63h.

5.4.3 Chronogenetic IL-1Ra therapy circuits are capable of delivering IL-1ra
at different times of day and can entrain to the circadian clock of the host in
vivo
However, we wanted to test the effectiveness of this chronogenetic therapy approach in
vivo both in our delivery mechanism and its ability to synchronize to the circadian clock of the
host and in its ability to deliver therapeutic proteins at prescribed times. Therefore, we implanted
the Per2-IL1Ra-t2a-Luc pellets into C57 mice in the flank. The bioluminescence of the pellets
was monitored via around the clock (36h) bioluminescence intensity (BLI) imaging three days
following implant and was found to be oscillatory, peaking at ZT13 (n=4, Figure 5.4B).
Following the confirmation of circadian Per2-Luc gene expression in vivo, we assayed for IL1Ra levels in serum through serial blood draws at 4h post BLI peak and trough, to account for
the time to translation of IL-1Ra following peak Per2 promoter activation (Figure 5.4A). IL-1Ra
concentration was significantly increased in the serum at 4h following the peak time of BLI
compared to the trough of Per2 expression (n=4, p=0.0342, Figure 5.4C).
To assess entrainment of the implanted pellets to the mouse, the lighting schedule was
reversed from standard 7a lights on/7p lights off to 8a lights off/8p lights on. For a week prior to
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this transition and for a month following, mouse wheel-running actigraphy was tracked to
monitor circadian entrainment to the light cycle. Within one-week post-delay, all mice were once
again active during the dark phase and inactive in the light (Figure 5.4A). Following
confirmation of re-entrainment via wheel running, the BLI of the implanted pellets was reassessed. Bioluminescence imaging of pellets showed pellet entrainment to mouse circadian
activity, with BLI peaking at ZT13, as observed previously (Figure 5.4D). Serum was again
collected for IL-1Ra concentration 12 hours apart and IL-1Ra concentration was significantly
increased during peak expression of Per2 than during trough expression (n=2, p = 0.046, Figure
5.4E). Taken together, these results show the ability of our synthetic circuit to deliver IL-1Ra at
different times of day, tracking with the clock component Per2, and the ability of our drug
delivery system, a tissue engineered pellet, to entrain to the host for prescribed time of day
treatment.
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Figure 5.4 In vivo characterization of Per2-IL1Ra-t2a-Luc chronotherapy circuit. (A) Mouse
wheel-running actigraphy recorded to monitor circadian entrainment to the light cycle.
Yellow background is lights on; white background is lights off. (B) BLI of Per2-IL1Ra-t2aLuc pellets implanted in mice three days after implant (n=4 mice 16 pellets). (C) Serum IL1Ra concentration evaluated 4 hours post BLI peak and trough expression (n=4). Asterisks
denotes significance within each sample, between timepoints. (D) BLI of pellets post
entrainment to light/dark cycle (n=2 mice, 8 pellets). (E) Serum IL-1Ra concentration (n=2).
Asterisks denotes significance within each sample, between timepoints.
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5.5 Discussion
Going off the principles of chronotherapy, we used synthetic biology to develop cellbased chronogenetic therapies that are capable of delivering biologic drugs at prescribed times,
tracking with circadian rhythms. To our knowledge, this is the first approach to create a cell
therapy for timed drug delivery. While the notion of taking drugs in line with circadian rhythms
is gaining popularity, the inconvenient times and need to take the drugs at the same time each
day makes it difficult for patients to adhere to the chronotherapy approach. By harnessing the
power of stem cells and creating a cell-therapy, we created a mechanism to deliver drugs at
specific times without any burden on the patient that can also provide a more localized and
controlled delivery of the drug. This approach can be used for disease targeting where symptoms
or disease severity changes over the day and can be used for more effective delivery of growth
factors or drugs targeting tissue homeostasis.
By developing an in vitro system to characterize our chronogenetic circuits we can create
model systems to better understand the effect of chronotherapy on drug delivery and disease
targets. Although circadian rhythms, clock-controlled genes, and their therapeutic counterparts
are starting to be better understood, there are still many unknowns on the effect the core
circadian clock has on specific genes, and the importance of timed drug delivery. Therefore,
these synthetic circuits and in vitro characterization techniques can be used to better understand
important connections between circadian rhythms and disease progression. Additionally, these
systems can be used to deliver anabolic factors to cells to create better tissue engineered systems,
as well as can be used to create in vitro model systems that can accurately depict cyclic disease
states to better understand the effect of time.
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Here we show that our anti-inflammatory chronogenetic circuit was capable of delivering
the anti-inflammatory cytokine IL-1Ra in a timed and oscillating manner through different
concentrations of protein in the serum. This system can be expanded beyond applications in RA
and can be used for any inflammatory disease where there are inflammatory flares driven by the
circadian clock. Additionally, this type of system can be used to deliver different concentrations
of drugs at different times. Importantly, we also evaluated the ability of our tissue engineered
cell therapy to entrain to its host, as this is important when producing chronogenetic therapies
driven by the host circadian clock. Here we see that our tissue engineered constructs synchronize
to the host and can continue to entrain even with shifts in circadian rhythms. The ability of the
tissue engineered system to shift along with the mouse circadian clock is important in the ability
of our tissue engineered systems to maintain prescribed drug delivery synchronized to
personalized circadian rhythm even during perturbations or shifts in circadian rhythms that can
happen with shift work, circadian disorders, and other disease pathologies that can affect the
circadian clock.
Interestingly, we saw that our anti-inflammatory chronogenetic circuit was capable of
maintaining its circadian rhythm in the presence of inflammatory cytokine, IL-1. Previously, it
has been reported that inflammatory cytokines disrupt the circadian clock (33, 181) but that the
administration of anti-inflammatory agents could restore the circadian clock. Therefore, our
chronogenetic circuit is capable of being clock-preserving, which is important for its ability to
deliver anti-inflammatory biologics at prescribed times of day. Additionally, this type of clockpreservation can help elucidate the relationship between circadian rhythms and inflammation.
The creation of these chronogenetic therapies opens up a whole new field of cell-based
therapies and ways to enhance drug efficacy and mitigate side effects through the timed delivery
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of drugs personalized to the patient’s circadian rhythm. The chronogenetic circuits developed
here were all driven by core clock gene Per2, however other core clock genes and the thousands
of tissue-specific clock-controlled genes can be used for alternative timed delivery or for specific
inputs. Additionally, multiple circuits can be used with antiphase drivers to create a two-pronged
approach with one drug delivered at multiple peaks throughout the day or for two different drugs
to be delivered at different times, depending on the need in disease progression. Additionally,
mutations can be made in core clock genes to delay or advance the phase of the circadian clock,
to tailor this approach to any timing of delivery (195-197).
Using this type of circadian clock driven chronogenetic therapy approach we can deliver
drugs at specific times of day to enhance drug efficacy. This work can be directly used to
targeting the inflammatory flares associated with RA. However, these approaches can also be
expanded to create chronogenetic therapies for many different tissues and targeting different
diseases where there are therapeutic targets for clock-controlled genes. Together, this framework
for developing personalized chronogenetic therapies is a novel approach to establish a new
generation of cell therapies that provide precision and effective therapeutic drug delivery.
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5.6 Conclusions
We engineered cell therapies that are driven by the circadian clock component, Per2, to
produced therapeutics at prescribed times of day driven by circadian rhythms. Tissue engineered
cartilage pellets were used to deliver our chronogenetic therapies. In vitro, our Per2-IL1Ra-t2aLuc circuit was capable of protecting itself from inflammation mediated circadian disruption and
able to produce IL-1Ra at different concentrations throughout the day, tracking with Per2
expression. In vivo, our tissue engineered pellets were capable of entraining their circadian
rhythms to the host and were capable of producing IL-1Ra in the serum at different
concentrations related to peak Per2 expression and the trough of Per2 expression. This is the
first approach at creating temporally controlled synthetic cell circuits for cell-based
chronotherapy of therapeutic interventions.
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Chapter 6: Conclusions and Future
Directions
With recent strides in the fields of synthetic biology and genome engineering, the ability
to create cell-based therapies for disease treatment is more feasible than ever. We have applied
these tools to target repair of articular cartilage in the presence of arthritic diseases such as
osteoarthritis (OA) and rheumatoid arthritis (RA). In this way, we have created cell-based
therapies that can deliver biologics in a prescribed, localized, and long-term manner mitigating
many of the unwanted side-effects of systemic biologic delivery.
The work detailed in this dissertation establishes novel approaches for cell-based
therapies targeting arthritis. By considering important stimuli that drive arthritis or are unique to
articular cartilage, we first created synthetic circuits that can sense and respond to inflammation,
can sense mechanical stimuli and respond, and can preserve the cartilage circadian clock even in
the presence of desynchronizing stimuli such as inflammation. Finally, we build upon our
circuits to create a novel cell therapy based on the principles of chronotherapy.
In Chapter 2 we discuss the development of a synthetic gene circuit that can sense
activation of inflammatory signaling cascade NF-κB and produce an anti-inflammatory biologic
in response, creating a self-regulating circuit. In Chapter 3 we show the creation of two synthetic
circuits that are activated by mechanical loading, osmotic loading, or pharmacologic activation
of TRPV4, a mechanobiologic ion channel in chondrocytes. These circuits have controlled
production at different time scales in response to mechanical stimuli. In Chapter 4 we debut our
clock-preserving cell therapies that can maintain the cartilage circadian clock even in the
presence of inflammation. These cell-based therapies can be used to maintain the circadian clock
to mitigate disease associated with clock desynchrony and can be used to elucidate
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characteristics of the circadian clock that are not yet known. Finally, in Chapter 5 we introduce
our revolutionary approach to cell-based chronotherapy, with the timed delivery of an antiinflammatory agent driven by the circadian clock.
Although the main focus of these circuits was for use in tissue-engineered cartilage and
targeting arthritis, these principles can be used to create smart cell therapies in any tissue or any
field. Within cartilage, the therapeutic transgene can be replaced with a biologic to modulate
arthritis pain or promote anabolic pathways to promote tissue regeneration. Additionally, these
types of systems can be expanded to other musculoskeletal tissues. For example, we show in the
Appendix a system in muscle cells to be able to sense and inhibit muscle fibrosis. These systems
can be further expanded beyond musculoskeletal tissues and can be used in any diseases
involving inflammation, mechanical stimuli, maintenance of the circadian clock, and/or requiring
timed drug delivery. These systems will also further our understanding of important disease
processes and can elucidate unknowns in disease pathologies. Finally, this work adds to the
synthetic biology molecular toolkit of approaches to create better and more effective therapies to
treat disease.
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Appendix: Genome Engineered Muscle
Derived Stem Cells for Autoregulated AntiInflammatory and Anti-Fibrotic Activity
Partially adapted from Pferdehirt L., Guo P., Lu A., Huard M., Guilak F.*, & Huard, J.*
(2021). Genome engineered muscle derived stem cells for autoregulated anti-inflammatory and
anti-fibrotic activity. Orthopaedic Research Society 67th Annual Meeting.

A.1 Abstract
Traumatic muscle injury leads to chronic and uncontrolled fibrosis in skeletal muscles,
primarily driven through upregulation of transforming growth factor-β1 (TGF-β1). Cell-based
therapies such as injection of muscle derived stem cells (MDSCs) has shown promise in muscle
repair. However, these therapies remain challenging due to the harsh fibrotic environment within
the injured muscle. Here, we created a “smart” cell-based drug delivery system using CRISPRCas9 to gene edit MDSCs capable of sensing TGF-β1 and producing an anti-fibrotic biologic,
decorin. These gene edited smart cells, capable of inhibiting fibrosis in a dose-dependent and
autoregulating manner, show anti-inflammatory and anti-fibrotic properties. Additionally,
differentiation down a fibrotic lineage is eliminated in response to TGF-β1. Our results show that
gene editing can be used to successfully create smart stem cells capable of producing biologic
drugs in a controlled and localized manner. This autoregulating system provides a tool for cellbased drug delivery as the basis for a novel therapeutic approach for a variety of diseases.

136

A.2 Introduction
Muscle injuries commonly occur in teenagers and adults that participate in sports. While
muscle injuries generally have good repair capacity, traumatic injury to the skeletal muscle
usually causes fibrosis to develop, which leads to incomplete muscle repair and alters the
functionality of the muscle. Fibrotic scar tissue not only blocks the regeneration process, but also
predisposes the injured muscle to subsequent injuries (198-200). Muscle injury causes
upregulation of inflammatory cytokines and infiltrating neutrophils, which increases the
expression of transforming growth factor-b1 (TGF-b1), one of the main drivers of muscle
fibrosis (198, 199, 201-203). TGF-b1 causes activation of my0fibroblasts and drives fibrotic scar
tissue formation in the extracellular matrix (ECM) through upregulation of collagen 1 (201).
It has been shown that anti-fibrotic agents that inhibit TGF-b1, such as decorin, relaxin,
suramin, gamma-interferon, and losartan, can reduce muscle fibrosis, leading to an improvement
in muscle regeneration and repair (202-213). Decorin, a small leucine-rich proteoglycan, is a
component of the ECM (214) and is important in regulating the assembly of collagenous
matrices (215). Additionally, decorin interferes with muscle cell differentiation and migration,
regulating connective tissue formation in skeletal muscle (216-218). Decorin has been shown to
reduce muscle fibrosis by inhibiting TGF-b1 activity (204, 212, 219, 220). The delivery of
decorin through an adeno-associated virus (AAV) gene therapy not only showed reduced muscle
fibrosis, but also enhanced muscle regeneration (202).
In addition to anti-fibrotic agents, cell therapies have been shown to be effective in aiding
in muscle repair. Muscle derived stem cells (MDSCs) are cells taken from neonatal mouse
skeletal muscle and isolated through adhesion characteristics on collagen coated flasks (221,
222). Transplantation of MDSCs can improve muscle regeneration after injury (201, 202).
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However, under the influence of TGF-b1 from the muscle injury microenvironment, the MDSCs
themselves underwent differentiation down a fibrotic lineage and expressed TGF-b1, which
further exacerbated the fibrosis cascade and limited the regenerative effect of the MDSCs (201,
202, 223). Therefore, to effectively use MDSCs as cell therapies for muscle repair, the fibrotic
environment of the injured muscle must be inhibited. Combining losartan, an anti-fibrotic agent,
with MDSC transplantation significantly improved the potential of the MDSCs to aid in muscle
repair by inhibiting the differentiation of the MDSCs (212). However, systemic blockage of
TGF-b1 through losartan or other anti-fibrotic therapeutics can be undesirable since TGF-b1 is
important for the maintenance and repair of certain tissues (224-226). Additionally,
pharmacologic therapies are given in high and unregulated doses and can have undesirable side
effects, but new advances in cell therapies can overcome the disadvantages of pharmacologic
therapies.
Previously, we have used CRISPR-Cas9 gene editing to create stem cells that can
respond to inflammation in a feedback-controlled manner (60). Taking a similar approach, the
goal of this study is to develop an autoregulated cell system with MDSCs that can respond to
TGF-b1 by producing a biologic inhibitor of TGF-b1. In this way, we can create cell therapies
that reduce fibrosis in the muscle, helping in overall muscle repair and promoting the reparative
capabilities of MDSCs. To accomplish this goal, we first deconstructed the gene regulatory
networks (GRNs) and signaling pathways activated in MDSCs by TGF-b1 to determine an
optimal promoter to drive our gene circuit. We then used this promoter with CRISPR-Cas9 gene
editing to create MDSCs responsive to TGF-b1 that produce decorin, promoting muscle repair
by biologically inhibiting TGF-b1. Additionally, we incorporated luciferase within our circuit to
as a reporter system (Figure A.1). Here, we show that TGF-b1 stimulation of our edited cells
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elicits a dose-dependent and autoregulating response, reduces inflammatory and fibrotic markers,
and eliminates the differentiation of MDSCs down a fibrotic lineage. This type of gene edited
cell-based therapy could provide an effective method to inhibit muscle fibrosis after injury while
overcoming limitations of current therapeutics.

Figure A.1 Overview of design of CRISPR-Cas9 edited MDSCs. CRISPR-Cas9 was used to
incorporate luciferase and murine decorin downstream of the functional Smad7 gene using a 2A
component (MDSC-Dec). In the presence of TGF-β1, Smad7 is activated and the gene circuit
produces Smad7, luciferase, and decorin. The production of decorin prevents TGF-β1from binding
to the TGF-β1 receptor and inhibits activation of fibrotic cascades within the cell. A luciferase
control line was also created without decorin (MDSC-Luc).
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A.3 Materials and Methods
A.3.1 Isolation and Culture of MDSCs
MDSCs were isolated from C57BL/10J mice at 3 weeks of age by the pre-plate technique
as previously described (222). MDSCs were cultured on collagen type I (Sigma-Aldrich) coated
flasks in Dulbecco’s Modified Eagle’s Media-High Glucose (DMEM-HG, Gibco) containing
10% heat-inactivated fetal bovine serum (HI-FBS, Invitrogen), 10% horse serum (Invitrogen),
1% penicillin-streptomycin (P/S), and 0.5% chicken embryo extract (Gemini Bioproducts).

A.3.2 Gene Array Analysis
MDSCs were stimulated with 5ng/mL of TGF-b1 for 30 minutes. An untreated control
was cultured under identical conditions without the TGF-b1. After 30 minutes, cells were
collected and snap frozen in liquid nitrogen. Total RNA was extracted with Trizol reagent
(Invitrogen) and subjected to a gene array. Significantly differentially expressed genes (p<0.05)
were determined and fold changes in gene expression compared to untreated controls were
calculated.

A.3.3 Gene Editing of MDSCs
Based on the gene array data, Smad7 was determined as the target promoter to drive the
gene circuit. Two cell lines were created, a luciferase control line (MDSC-Luc) and a decorin
therapeutic line (MDSC-Dec). For the luciferase control line, targeting guides were produced in
which coding sequences for the luciferase transgene were integrated directly downstream of the
functional Smad7 transgene c-terminus with a t2a component incorporated. The therapeutic
decorin line was produced by integrating decorin downstream of luciferase in the luciferase
control line with a t2a component incorporated. Both lines are heterozygous edits. Cas9 and the
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determined gRNAs were transfected into the MDSCs using Lipofectamine CRISPRMAX
(Invitrogen) and clones were validated with junctional polymerase chain reaction (PCR) and
sanger sequencing.

A.3.4 Luminescence Assay
Luciferase activity from MDSC-Luc and MDSC-Dec cells was measured using Dluciferin (Sigma-Aldrich) and a Cytation5 plate reader (Biotek). Luciferase activity is reported as
a fold change of TGF-b1-stimulated cells over control cells cultured without TGF-b1 (n = 3).

A.3.5 Myogenic Differentiation Capacity
The myogenic differentiation capabilities of the MDSCs were assessed by switching the
culture media into fusion media composed of DMEM-HG containing 2% HI-FBS and 1% P/S.
After 3 days, the cells were strained for fast myosin heavy chain (MyHCf), which is a marker of
terminal myogenic differentiation and 4’,6-diamidino-2-phenylindole (DAPI). The level of
myogenic differentiation was quantified as the percentage of MyHCf-expressing nuclei/total
nuclei.

A.3.6 Decorin Gene Expression
Wild-type (WT), MDSC-Luc, and MDSC-Dec cells were stimulated with 0 ng/mL, 1
ng/mL, or 5 ng/mL TGF-b1 and collected for RNA isolation at 0, 0.5, 5, 12, and 24 hours (n =
3). RNA isolation was carried out following the manufacturer’s protocol (Norgen). Reverse
transcription was performed using Superscript VILO complementary DNA (cDNA) master mix
(Invitrogen). Quantitative, reverse transcription polymerase chain reaction (qRT-PCR) was
performed using Fast SyBR Green master mix (Applied Biosystems) following the
manufacturer’s protocol. Primer pairs were synthesized by Integrated DNA Technologies, Inc.
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Genes were normalized to r18s. Fold changes were calculated using the ΔΔCT method and are
shown relative to the 0 hour no cytokine, WT control samples. For samples with no
amplification, CT threshold was set to the cycle limit.

A.3.7 Anti-Inflammatory and Anti-Fibrotic Activity of Engineered MDSCs
PCR for inflammatory (interleukin 1, Il1 and interleukin 6, Il6) and fibrotic (fibronectin
1, Fn1 and actin alpha 2, Acta2) was performed using ThermoScientific DreamTaq Green PCR
Master Mix and the bands were imaged after agarose gel electrophoresis. The MDSC-Luc and
MDSC-Dec lines were stimulated with 5 ng/mL of TGF-β1 and cells were harvested, and total
RNA was extracted 12 hours post stimulation. Unstimulated control cells were harvested under
identical conditions. r18S was used as the housekeeping control gene and normalized the bands.
Additionally, immunochemical labeling was performed for alpha-smooth muscle actin
(α-SMA). Cultured cells were fixed in 5% formalin for 10 minutes and pre-incubated in 10%
donkey serum in phosphate buffered saline for 1 hour at room temperature (RT). The cells were
incubated for 3 hours at RT with primary antibodies for αSMA, Alexa 488-conjugated donkey
anti-mouse IgG was used as secondary antibodies and DAPI was used for the nucleus.

A.3.8 Statistical Analysis
Statistical analysis was performed with Prism. Luminescence and decorin gene
expression data were analyzed using analysis of variance (ANOVA) with Dunnet’s post hoc
testing using WT or unstimulated as the control (α = 0.05). Data are displayed as mean ± SEM.
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A.4 Results
A.4.1 Signaling pathways activated by TGF-β1 stimulation in MDSCs
MDSCs stimulated with 5 ng/mL of TGF-β1 showed 111 differentially expressed genes
compared to unstimulated controls. Of the genes significantly upregulated compared to controls,
four genes, Smad7, Vegfa, Tgif1, and Spsb1, showed the highest fold change in response to TGFβ1 by 30 minutes (Figure A.2) (p<0.05). Of the four genes, Smad7 had the largest increase with a
17-fold change compared to unstimulated controls. Therefore, due to the rapid response and
increased upregulation of Smad7, the Smad7 promoter was utilized to drive our gene circuit.
Additionally, due to the anti-fibrotic effects of Smad7 (227), CRISPR-Cas9 was used to
incorporate luciferase and murine decorin downstream of the functional Smad7 gene using a 2A
linker.
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Figure A.2 Signaling pathways
activated by TGF-β1 stimulation in
MDSCs. MDSCs were treated with
either 0 or 5 ng/mL of TGF-β1. 30
minutes after simulation, cells were
collected for microarray. Displayed
genes are scientifically differentially
expressed (p<0.05) compared to controls
(n=3-4).
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A.4.2 Myogenic differentiation and response of gene edited MDSCs to TGF-β1
Gene edited MDSC-Luc and MDSC-Dec cells were tested in their ability to respond to
TGF-β1 stimulation through luminescence output. MDSC-Luc and MDSC-Dec cells were
treated with 5 ng/mL of TGF-β1 and compared with cells without TGF-β1. By 12 hours, both
groups given TGF-β1 showed significant luminescence output compared to cells without
cytokine (Figure A.3A) (p<0.05). This increase in luminescence shows that the gene circuit can
sense and respond to TGF-β1 stimulation.

Figure A.3 Characterization of gene edited MDSCs to determine responsiveness to TGF-β1 and
ability to myogenically differentiate. (A) MDSC-Luc and MDSC-Dec cells were stimulated with 0 or
5 ng/mL of TGF-β1, and luminescence was measured at 0 and 12 hours. Data represents mean relative
luminescence (RLU) fold change ± SEM (n=3). Two-way ANOVA with Dunnett’s post-hoc was used
to determine significance. Asterisks represent significance (p<0.05) compared to 0-hour control. (B)
Wild type (WT) MDSCs and MDSC-Dec cells stained with fast myosin heavy chain (MyHCf), a
marker of terminal myogenic differentiation, and DAPI, a nuclear stain. Level of myogenic
differentiation is quantified as the percentage of MyHCf-expression nuclei/total nuclei ± SEM.
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To evaluate if the ability to myogenically differentiate was maintained after gene editing,
MDSC-Dec cells were stained for fast myosin heavy chain (MyHCf), a marker of terminal
myogenic differentiation. MDSC-Dec cells showed similar cell morphology and levels of
MyHCf stain compared to WT MDSCs (Figure A.3B), indicating that gene editing and decorin
expression in the cells does not affect the differentiation potential of the MDSCs.

A.4.3 Gene edited MDSC-Dec produce decorin in a dose-responsive and
autoregulated manner
Non-edited wild type (WT) MDSCs and MDSC-Dec cells were stimulated with 1 ng/mL
or 5 ng/mL of TGF-β1, and decorin expression was measured over time. Cells receiving no TGFβ1 were used as controls. At all timepoints, the MDSC-Dec groups at all doses of TGF-β1
showed significantly increased decorin expression compared to WT (Figure A.4) (p<0.001).
MDSC-Dec cells responded to TGF-β1 in a dose dependent manner, where both the 1 ng/mL and
5 ng/mL dose of TGF-β1 showed significant decorin expression compared to unstimulated
MDSC-Dec cells (p<0.05). The MDSC-Dec cells receiving 5 ng/mL showed increased decorin
expression compared to 1 ng/mL TGF-β1 except at 24 hours (Figure A.4). Additionally, decorin
expression in the MDSC-Dec cells was significantly decreased between 12 and 24 hours (Figure
A.4) (p<0.01). This decrease in decorin expression shows the ability of the MDSC-Dec cells to
produce enough decorin by 12 hours to inhibit TGF-β1 and turn the circuit off. Therefore, the
MDSC-dec cells respond to TGF-β1 in a dose-dependent manner and the gene edited circuit is
auto-regulating.
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Figure A.4 Gene expression of WT and MDSC-Dec given 0, 1, or 5 ng/mL TGF-β1. Fold changes
were determined relative to 0-hour WT cells without TGF-β1. Error bars represent means of fold
change ± SEM (n=3). Asterisks represent significance within MDSC-Dec groups compared to MDSCDec group given 0 ng/mL of TGF-β1 (p<0.05). Hashes represent significance relative to WT control
group (p<0.05). Ampersand represents significance within MDSC-Dec groups between 12 and 24
hours (p<0.05). Statistics analyzed with two-way ANOVA.

A.4.4 MDSC-Dec cells reduce inflammatory and fibrotic markers and
eliminate fibrotic differentiation of MDSCs
MDSC-Luc and MDSC-Dec cells were stimulated with 5 ng/mL of TGF-β1 and
compared to untreated MDSC-Luc and MDSC-Dec controls. Inflammatory cytokines Il6 and Il1
were downregulated in the MDSC-Dec cells in response to TGF-β1 compared to MDSC-Luc
cells (Figure A.5A). Additionally, pro-fibrotic gene Fn1 was also decreased in the MDSC-Dec
cells in response to TGF-β1 after 12 hours compared to MDSC-Luc cells (Figure A.5A). This
shows the anti-inflammatory and anti-fibrotic activity of the MDSC-Dec cells.
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Figure A.5 Assessment of MDSC-Dec ability to reduce inflammation, fibrosis, and fibrotic
differentiation. (A) Expression of inflammatory markers Il6 and Il1, fibrotic marker Fn1, and Acta2, a
gene encoding alpha smooth muscle actin (⍺-SMA) in MDSC-Dec and MDSC-Luc lines with and
without TGF-β1 stimulation after 12 hours. 18S rRNA used as housekeeping gene. (B) Staining for ⍺SMA (green) and DAPI (blue) in MDSC-Luc and MDSC-Dec cells treated with TGF-β1.

TGF-β1 stimulated MDSC-Dec cells also showed a decrease in Acta2, a gene encoding ⍺
smooth muscle actin (⍺-SMA) which is highly expressed in myofibroblasts, compared to MDSCLuc cells (Figure A.5A). This result was further supported by the inability to detect ⍺-SMA in
MDSC-Dec cells treated with TGF-β1 compared to MDSC-Luc (Figure A.5B). Together, these
results indicate that the TGF-β1 induced differentiation of MDSCs towards myofibroblasts,
which can further exacerbate fibrosis, was reduced or eliminated.

A.5 Discussion
A major challenge in muscle repair and regeneration after injury is the injury-associated
fibrotic microenvironment causing cell differentiation down a fibrotic lineage, further
exacerbating fibrosis. We developed a MDSC-based smart cell using CRISPR-Cas9 in which
cells sense and respond to fibrotic stimuli by producing anti-fibrotic biologic drugs. By utilizing
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MDSCs that have the ability to engraft onto muscle and aid in muscle regeneration (201, 202,
223), this system provides the potential to repair muscle, while providing site-specific and
autoregulated anti-fibrotic therapy. Our approach is based on the presence of TGF-β1, a main
driver of muscle fibrosis, and coopting endogenous signaling pathways within MDSCs to
produce anti-fibrotic biologic therapeutics. By deconstructing the differentially expressed genes
activated by TGF-β1, we rewired endogenous gene expression to drive production of decorin, an
anti-fibrotic, as a model system. Our results also demonstrate the use of this signaling pathway
for defining the timing and dose-response for the expression of therapeutic biologic drugs.
Additionally, we show the ability of the system to autoregulate itself. While we target a
treatment for skeletal muscle repair in traumatic injury, fibrosis occurs in many tissues and in
both acute and chronic diseases, suggesting a wide range of potential therapeutic applications for
anti-fibrotic cell therapies.
An important advance of this work is the use of MDSCs, which provide an attractive cell
source for muscle repair and regeneration because of their innate ability to differentiate into
functional muscle cells in vivo, as well as their ability to reduce fibrosis and aid in muscle repair
(201, 202, 223). Additionally, MDSCs have the ability to not only aid in skeletal muscle repair,
but other musculoskeletal cell types as well, expanding the potential use for these MDSC smart
cells (221, 222). Here, we show that our MDSC-Dec cells reduced pro-inflammatory and profibrotic markers in the presence of TGF-β1, mitigating fibrosis. This indicates the potential use
of this system for the repair of injured skeletal muscle and mitigation of fibrosis through a
soluble release of decorin. Importantly, MDSC-Dec cells had no presence of ⍺-SMA when given
TGF-β1. Previous limitations in MDSC cell therapies were due to the differentiation of MDSCs
into myofibroblasts in muscle injury microenvironment with high levels of TGF-β1, leading to
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enhanced fibrosis (201, 202, 223). With our MDSC-Dec smart cells and the lack of ⍺-SMA we
show the TGF-β1-induced differentiation into myofibroblasts is eliminated in our cells,
enhancing the ability of these MDSCs to maintain their regenerative capabilities.
Using CRSIPR-Cas9 gene editing, we engineered MDSC smart cells that produce
luciferase and decorin downstream of the functional Smad7 gene, creating a system that can
dynamically respond to and attenuate TGF-β1. MDSC-Dec cells rapidly responded to TGF-β1 in
a dose dependent manner, as cells given different doses of TGF-β1 had significant increases of
decorin expression by 5 hours and higher doses of TGF-β1 resulted in increased decorin
expression up to 12 hours. This dose response allows for controlled production of the therapeutic
drug in response to different levels of fibrosis. Importantly, MDSC-Dec cells produced
therapeutic levels of decorin so that TGF-β1 was inhibited and the gene circuit was shutting off
by 24 hours. While we designed the MDSC smart cells to respond to TGF-β1 by producing
decorin, there are many other drivers of fibrosis (228) as well as other anti-fibrotic agents that
can be utilized as biologic therapeutics (202-213). Additionally, this approach can be readily
expanded to other fibrotic diseases.
Current approaches for treatment of muscle fibrosis involve the use of anti-fibrotic agents
(202-213). However, systemic inhibition of TGF-β1 leads to unwanted side effects (224-226).
Additionally, for effective mitigation of fibrosis at the injured muscle, high doses of anti-fibrotic
agents must be given because only a small amount makes it to the injury site. These approaches
result in ineffective strategies to inhibit muscle fibrosis, calling for more effective and localized
therapies. Previous approaches to target delivery of anti-fibrotic agents have used non-integrating
viral vectors such as AAV (202). CRISPR-Cas9 editing techniques are advantageous for this
system due to its precision in editing the cell, as well as use of endogenous pathways within the
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cell, leading to prolonged life of the gene circuit and controlled activation of the circuit
compared to non-integrating systems or synthetic circuits that do not utilize the endogenous
pathways of the cell that can be subjected to silencing and random integration of the circuit.
Our gene edited cells have an autoregulating circuit that is capable of sensing and
responding to fibrosis with a therapeutic level of biologic drug. The ability to use CRISPR-Cas9
allows the tunability of biologic drug produced, as well as endogenous signaling cascade as the
input to the circuit. Similar approaches have been used to create CRISPR-based therapies for
inflammation (60), broadening the applicability of this type of gene circuit beyond muscle
injury-induced fibrosis. The continued development of designer circuits through gene switches
(114-116), microRNA classifiers (117, 229), synthetic transcription systems (119-121), and
lentiviral based cell-therapies (62, 63) provides a toolkit to engineer more complex circuits with
specialized control. This work adds to our long-term goal of developing a molecular toolbox
(122, 123) of biological building blocks for applications in mammalian cells for mitigating
chronic diseases.
It is important to note potential limitations and future directions of this work. The
microarray analysis offers us a look at the unique transcriptomic landscape in MDSCs in
response to TGF-β1 stimulation. However, with the advent of next-generation sequencing
technologies, performing a similar experiment and transcriptomic analysis would increase target
resolution and give us a more precise analysis of genes activated by TGF-β1 and help us identify
novel targets for future gene circuits. Additionally, although these cells have been tested in vitro,
subsequent in vivo experiments will be necessary to fully determine the anti-fibrotic and
reparative capabilities of the MDSC smart cells. Injecting the MDSCs into mice after muscle
injury will help determine the efficacy of the circuit to inhibit fibrosis in the context of multiple
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fibrotic inputs, in addition to TGF-β1 and determine the ability of MDSCs to maintain their
regenerative phenotype instead of differentiating down a pro-fibrotic lineage.
The autoregulatory capabilities of this system, along with the use of a localized cell-based
system, allows for applications in regenerative medicine or any chronic fibrotic disease.
Applying these cells not only allows for localized anti-fibrotic therapies, but also provides
regenerative potential to MDSCs. Together, this system allows for precise and localized delivery
of therapeutics and can be broadly applicable in developing autoregulating systems for drug
delivery in fibrotic diseases.
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A.6 Conclusion
We created gene edited smart cells in MDSCs that can sense TGF-β1 and, instead of
eliciting a fibrotic response and differentiation down a fibrotic lineage, produce decorin, a small
molecule that inhibits TGF-β1 and reduces fibrosis. These cells respond in an autoregulating and
dose-dependent manner to rapidly produce therapeutic levels of decorin. The anti-inflammatory
and anti-fibrotic properties, as well as reduced differentiation down a fibrotic lineage of the gene
edited MDSCs will allow for these cells to aid in muscle repair and regeneration, even in a
fibrotic microenvironment. Broadly, this approach may be applicable in developing
autoregulated biologic systems for drug delivery in fibrotic diseases.
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